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MALT  mucosa-associated lymphoid tissue 
MHC  major histocompatibility complex 
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napA  neutrophil-activating protein coding gene 
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NapA  neutrophil-activating protein 
NF-κB  nuclear factor κB 
NHPH  non-H. pylori Helicobacter 
NOD  nucleotide-binding oligomerization domain 
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OipA  outer inflammatory protein A 
OMP  outer membrane protein 
PAGE  polyacrylamide gel electrophoresis 
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S. aureus Staphylococcus aureus 
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s.s.  sensu stricto 
Th  T helper 
TNF  tumor necrosis factor 
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T4SS  type IV secretion system 
UreA/B urease subunit A/B 
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This thesis deals with Helicobacter suis, a microorganism that is highly prevalent in pigs and also 
causes gastric disease in humans. 
In the general introduction, first the nomenclature of gastric Helicobacter species is briefly 
discussed, including the background of the name “Helicobacter (H.) suis”. Then, prevalence, 
gastric pathology and clinical implications associated with H. suis infections in pigs are 
described. Additionally, the zoonotic significance of this microorganism is considered. The main 
aim of this general introduction, however, is to have a closer look at bacterium-host interactions 
with emphasis on bacterial virulence factors, the host immune response, and the effect of 
vaccination. Since information with regard to these subjects was very scarce for H. suis when we 
started our PhD studies, other gastric helicobacters and in particular H. pylori, are considered 
here as well. Finally, a brief overview of the literature regarding in vitro antimicrobial 
susceptibility of gastric helicobacters is presented. 
1. Helicobacter suis infections in pigs and humans 
1.1. Nomenclature of gastric non-Helicobacter pylori helicobacters 
In 1984, Marshall and Warren reported for the first time that gastritis and stomach ulcers in 
humans can be caused by a Gram-negative bacterium (Marshall and Warren, 1984). This slightly 
curved bacterium was named “Helicobacter pylori” (Goodwin et al., 1989), and is nowadays 
known as the most prevalent Helicobacter species in the human stomach, causing gastritis, peptic 
ulcer disease, gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) 
lymphoma (Stolte et al., 1993; Kusters et al., 2006). Human gastric biopsy samples, however, 
harbor bacteria which are morphologically different from H. pylori (Heilmann and Borchard, 
1991; Debognie et al., 1995). These long spiral-shaped non-H. pylori helicobacters (NHPH) are 
primary associated with animals but infect humans as well (Haesebrouck et al., 2009). Frequent 
changes in nomenclature of NHPH colonizing the stomach of humans have caused difficulties in 
reaching international agreement on this complex group of microorganisms. The initial name, 
“Gastrospirillum hominis” (McNulty et al., 1989) was replaced by “Helicobacter heilmannii” 
(Heilmann and Borchard, 1991). However, subsequent analyses of the 16S ribosomal RNA 
(rRNA)- and 23S rRNA-encoding genes revealed two different types of “H. heilmannii” in the 
human stomach: “H. heilmannii” type 1 and “H. heilmannii” type 2. “H. heilmannii” type 1 is 
both morphologically and genetically identical to a bacterium colonizing the stomach of pigs (De 
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Groote et al., 1999; O’Rourke et al., 2004). “H. heilmannii” type 2, however, does not represent a 
single Helicobacter species, but a group of species, all known to colonize the gastric mucosa of 
cats and dogs: H. felis, H. bizzozeronii, H. salomonis, H. cynogastricus, H. baculiformis and the 
recently in vitro cultivated H. heilmannii sensu stricto (H. heilmannii s.s.) (Haesebrouck et al., 
2009; 2011). 
In 1990, for the first time, large spiral-shaped microorganisms were described in the stomach of 
pigs with chronic gastritis (Queiroz et al., 1990). These microorganisms were provisionally 
named “Gastrospirillum suis” (Mendes et al., 1990). Based on 16S rRNA sequences, fluorescent 
in situ hybridization (FISH) and electron microscopy, this bacterium was described to be a 
member of the genus Helicobacter. Because at that time this species could not be characterized 
thoroughly due to the lack of pure in vitro isolates, the organism was given the name “Candidatus 
Helicobacter suis” (De Groote et al., 1999). Several research groups tried to cultivate these tightly 
coiled bacteria present in the stomach of pigs, however all attempts failed (Mendes et al., 1991; 
Grasso et al., 1996; Cantet et al., 1999; Park et al., 2000; Roosendaal et al., 2000). Only in 2008, 
the first pure in vitro isolate was obtained, which finally led to the description of H. suis as a 
formal species name. Nowadays, the name H. suis is worldwide accepted as a new gastric 
Helicobacter taxon corresponding to the above mentioned “H. heilmannii” type 1 (Baele et al., 
2008). 
1.2. Helicobacter suis infections in pigs 
1.2.1. Prevalence of H. suis infections in pigs 
H. suis colonizes the stomach of pigs worldwide. Prevalence rates range from 8% to 95%, 
although most studies report 60% or higher at slaughter age (Barbosa et al., 1995; Grasso et al., 
1996; Cantet et al., 1999; Roosendaal et al., 2000; Choi et al., 2001; Hellemans et al., 2007a; 
Kopta et al., 2010). Though, in younger animals the frequency of H. suis infection is much lower. 
Hellemans et al. (2007a) observed a prevalence of only 2% in suckling piglets, which increased 
rapidly after weaning with a prevalence of 90% in adult boars and sows. This suggests a possible 
maternal protection due to the protective effect of milk. For H. pylori, passive immunity acquired 
from immunized dams protects young mice against colonization until weaning (Corthésy-Theulaz 
et al., 2003). Also, a recent study in infants fed on breast milk showed that H. pylori-specific 
immunoglobulin (Ig) A antibodies may play an important role in preventing acquisition of 
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infection (Bhuiyan et al., 2010). In porcine milk, next to antibodies, other proteins have been 
shown to inhibit H. pylori colonization in mice by specific H. pylori-binding epitopes 
(Gustafsson et al., 2006). The high prevalence of infection in adult pigs suggests that H. suis 
persists in adult pigs, indicating that the natural immune response against H. suis does not lead to 
its clearance from the stomach. Indeed, it is assumed that once Helicobacter infection is 
established, it persists throughout life (Rhen et al., 2003). The immunological basis of this 
persistence will be further described in section 3 of this introduction. 
1.2.2. Role of H. suis in porcine gastric pathology 
H. suis infections in pigs have been associated with two main gastric pathologies, being 
ulcerations of the non-glandular part of the stomach and gastritis. Numerous studies, in both 
naturally and experimentally infected pigs showed that H. suis infections cause chronic gastritis, 
which is mainly located in the antrum (Mendes et al., 1991; Queiroz et al., 1996; Park et al., 
2000; Hellemans et al., 2007b, De Bruyne et al., 2012). 
In pigs, gastric ulcers appear in the non-glandular part of the stomach, called pars oesphagea. 
This rectangular area around the oesophageal opening is covered with stratified squamous 
epithelium and does not secrete mucus. Consequently, this epithelial layer offers limited 
protection against low pH in the lumen and gastric enzymes (Friendship, 2006). Factors 
impairing blood supply to the mucosa or increasing the exposure of the mucosa of the pars 
oesophagea to acidic conditions could lead to epithelial insults, followed by hyperkeratosis, 
erosion and finally ulceration. It is now recognized that gastric ulcer disease in pigs is a 
multifactorial condition, arising from one or more of the following predisposing factors: particle 
size of feed (pelleting and fine grinding of feed), the presence of short chain fatty acids in the 
stomach, concurrent diseases leading to decreased food intake, stress and H. suis infections 
(Hessing et al., 1992; Ayles et al., 1996; Amory et al., 2006; Argenzio and Eisemann, 1996; 
Robertson et al., 2002; Millet et al., 2012). The exact role of H. suis in the development of 
porcine gastric ulcers is not clear. Some studies indeed reported an association of H. suis with 
gastric ulcers (Barbosa et al., 1995; Queiroz et al., 1996; Roosendaal et al., 2000; Choi et al., 
2001; Appino et al., 2006; Krakowka and Ellis, 2006; Proietti et al., 2010), while others did not 
find this association (Grasso et al., 1996; Melnichouk et al., 1999; Park et al., 2000; Szeredi et al., 
2005). These contradictory results could be due to different diagnostic tools used for 
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demonstrating H. suis, differences in sampling, but also differences in virulence between H. suis 
strains. 
The pathogenesis of H. suis-associated gastric ulcers is still unclear. One research group 
suggested that H. suis can increase the number of endocrine gastrin-producing cells, and decrease 
the number of somatostatin-producing cells, resulting in increased production of hydrochloric 
acid (HCl) (Sapierzyński et al., 2007). Additionally, H. suis was found in close contact with 
parietal cells of the fundic region of experimentally H. suis infected pigs, which might indicate 
that the bacterium may have an impact on these HCl-producing cells (Hellemans et al., 2007b). 
The secretion of excessive amounts of gastric acid may lead to increased contact of the non-
glandular part of the stomach with HCl. Consequently, this chronic insult of the pars oesophagea 
may result in the development of ulcers. Finally, it is also possible that H. suis is not the primary 
cause of ulcers, but instead causes a delay in healing leading to more severe lesions. 
Regarding the clinical outcome of H. suis infections in pigs, De Bruyne et al. (2012) showed that 
an experimental H. suis infection causes a decreased daily weight gain of approximately 10% in 
pigs over an average period of 5 weeks, which may be important from an economical point of 
view. Also, H. suis infections might be a source of welfare concern in pig populations worldwide 
due to pain and stress induced by gastritis and gastric ulcers (Friendship, 2006; De Bruyne et al., 
2012). 
1.3. Zoonotic significance of H. suis 
H. pylori is considered to be the major cause of chronic atrophic gastritis, peptic ulceration as 
well as gastric carcinoma and MALT lymphoma in humans (Marshall and Warren, 1984; 
Parsonnet et al., 1991; Lehours and Mégraud, 2005; Kusters et al., 2006). However, in 0.1% to 
8% of the gastric biopsies, large spiral-shaped NHPH are detected (Stolte et al., 1994; Holck et 
al., 1997; Yali et al., 1998; Yang et al., 1998; Boyanova et al., 2003; Joo et al., 2007; Yakoob et 
al., 2012). Infections with these bacteria have been associated with gastritis (Debognie et al., 
1995; Stolte et al., 1997; Joo et al., 2007), gastric ulcers (Debognie et al., 1998; Sykora et al., 
2003) and gastric cancer (Morgner et al., 1995, 2000) in humans. Compared to H. pylori-
associated gastritis, gastritis associated with NHPH is mostly less active (Stolte et al., 1997; Joo 
et al., 2007). Histological examination reveals an inflammation that is generally characterized by 
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infiltration with lymphocytes and plasma cells (Morgner et al., 1995; Stolte et al., 1997; Sykora et 
al., 2003). 
Interestingly, patients with NHPH gastritis develop more frequently MALT lymphoma than those 
with H. pylori gastritis (1.48% and 0.66%, respectively) (Stolte et al., 1997; 2002). Recently, 
Flahou et al. (2010) demonstrated that H. suis causes MALT lymphoma-like lesions at 8 months 
post-infection in a Mongolian gerbil model. 
Coinfections with both H. pylori and NHPH have been described in human patients (De Groote et 
al., 2005; Van den Bulck et al., 2005a; Ojano et al., 2012; Yakoob et al., 2012). These infections 
mainly result in aspecific gastro-intestinal symptoms, such as vomiting, epigastric pain and 
dyspepsia (Ojano et al., 2012; Yakoob et al., 2012). The significance of coinfections in terms of 
disease development and severity, however, needs to be determined. 
H. suis comprises 13.9% to 78.5% of gastric NHPH infections in humans (Trebesius et al., 2001; 
De Groote et al., 2005; Van den Bulck et al., 2005a). The prevalence of other NHPH in humans 
(with cats and dogs as natural host) is lower (Trebesius et al., 2001; Van den Bulck et al., 2005a), 
making H. suis the most prevalent NHPH species colonizing the stomach of humans. 
Results of multilocus sequencing typing (MLST) revealed that a human H. suis strain was closely 
related to porcine H. suis strains, further supporting the hypothesis that H. suis infections in 
humans originate from pigs (Liang et al., 2013). Probably, transmission of H. suis from pigs to 
humans occurs by contact. Indeed, a questionnaire-based study illustrated that individuals having 
close contact with pigs have a higher risk for contracting “H. heilmannii” infections (Meining et 
al., 1998). Further, a recent study reported that a pig veterinarian suffering from reflux 
oesophagitis and general dyspeptic symptoms was colonized with H. suis (Joosten et al., 2013). 
MLST analysis of 7 housekeeping genes of H. suis revealed a very close relationship with 
porcine H. suis strains, suggesting that the patient contracted the infection through close contact 
with pigs (Joosten et al., 2013; Liang et al., 2013). Besides contact with pigs, the consumption of 
raw or undercooked pork might be of importance. Recently, it has been shown that H. suis can 
survive for at least 48 hours (h) in raw minced pork (De Cooman et al., unpublished data). In the 
same study, in 2 out of 50 commercial minced pork samples, DNA of viable H. suis bacteria was 
detected (De Cooman et al., unpublished data). This might indicate that raw or undercooked pork 
might occasionally constitute a source of H. suis infection for humans. 
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2. Virulence factors of gastric Helicobacter species 
Before the start of this thesis, little was known about genes associated with colonization and 
virulence of H. suis or other gastric NHPH. Indeed, most of the research regarding virulence 
factors of gastric Helicobacter species has been done with H. pylori. As a consequence, this 
section is focused on this microorganism. 
Figure 1 shows an overview of the main virulence factors of H. pylori involved in gastric 
colonization and pathology. These factors, together with other virulence-associated genes will be 
described in the following paragraphs. 
2.1. Virulence factors and their genes involved in gastric colonization and persistence 
A successful gastric colonization of Helicobacter depends on many factors including flagella-
driven motility in the stomach mucus layer, acid neutralization via urease, oxidative stress 
resistance and adhesion to gastric epithelial cells mediated by several adhesion factors. A review 
of the involvement of these factors is given in the following paragraphs. 
Acid resistance 
Gastric helicobacters have adapted to the acid gastric environment for survival and colonization. 
The main component of Helicobacter acid resistance is the urease enzyme, which converts urea 
into ammonia and carbon dioxide (Burne and Chen, 2000). The ammonia production generated 
by this reaction increases the pH. The H. pylori urease gene cluster consists of an operon 
containing ureA and ureB, encoding the structural subunits of the enzyme, urease subunit A 
(UreA) and urease subunit B (UreB), respectively, followed by a downstream operon comprising 
the ureI and the urease accessory genes ureE, ureF, ureG and ureH (Akada et al., 2000). Urease 
is a cytoplasmic protein, which is also associated with the surface of viable bacteria after 
autolysis of surrounding bacteria, so-called “altruistic autolysis” (Dunn and Phadnis, 1998; 
Marcus and Scott, 2001). Urease activity is essential for H. pylori colonization, as urease 
negative mutants are unable to colonize mice (Eaton et al., 1991; Tsuda et al., 1994; Karita et al., 
1995). This activity is regulated by different parameters including the pH, the availability of its 
substrate, urea, and of its co-factor, nickel. UreI, encoded by the ureI gene, is a proton-gated urea 
channel which controls the intracellular urea concentration and pH and thus assures cytoplasmic 
urease activity (Scott et al., 2000; Bury-Moné et al., 2001). It has been demonstrated that UreI is 
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essential for in vivo gastric colonization by H. pylori (Skouloubris et al., 1998; Mollenhauer-
Rektorschek et al., 2002). The ureEFGH genes are involved in the Ni
2+
 incorporation into the 
urease apoenzyme (Cussac et al., 1992). Apart from genes of the urease complex, the 
hydrogenase accessory proteins HypA (encoded by hypA) and HypB (encoded by hypB), are 
important for a normal urease activity. Inactivation of hypA and hypB reduces H. pylori urease 
activity 40- and 200-fold, respectively (Olson et al., 2001). H. pylori urease has also been 
implicated in damage of gastric epithelial cells through the production of ammonia (Smoot et al., 
1990; Sommi et al., 1996). Additionally, the urease protein directly causes cell damage by 
stimulating macrophage inducible nitric oxide (Gobert et al., 2002). Besides urease, other H. 
pylori-ammonia-producing enzymes facilitating gastric H. pylori survival have been described. 
These include amidase (AmiE), (Skouloubris et al., 1997), formamidase (AmiF) (Skouloubris et 
al., 2001) and aspartase (AspA), encoded by amiE, amiF and aspA, respectively. 
Oxidative stress resistance 
Additional to acid neutralization factors, H. pylori possesses genes coding for enzymes involved 
in oxidative stress resistance. Genes encoding H. pylori catalase and superoxide dismutase show 
a high homology to those of intracellular pathogens (Odenbreit et al., 1996; Spiegelhalder et al., 
1993), suggesting their role in resistance against killing by polymorphonuclear cells. In addition 
to catalase and superoxide dismutase, H. pylori depends on a family of peroxiredoxins that 
detoxify organic peroxides. For instance, mutant H. pylori cells defective in the alkyl 
hydroperoxide reductase, AhpC, were more sensitive to in vitro oxidative stress conditions, 
resulting in more DNA fragmentation and coccoid or lysed forms compared to wild-type bacteria 
(Wang et al., 2004). More recently described are the antioxidant proteins, including the 
nicotinamide adenine dinucleotide phosphate (NADPH) quinine reductase (MdaB), and an iron 
sequestering protein, also known as the H. pylori neutrophil-activating protein, HP-NAP. The 
latter has a dual role in inducing and combating oxidative stress resistance. Indeed, Wang et al. 
(2006) demonstrated in a mouse model that HP-NAP, although able to induce oxygen radicals’ 
release (see paragraph 2.2.), protects H. pylori from iron-mediated oxidative DNA damage. 
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Chemotaxis and motility 
Helicobacter species are motile by the presence of flagella, whose filaments consist of two 
flagellins, flagellin A (FlaA) (encoded by the flaA gene) and flagellin B (FlaB) (encoded by the 
flaB gene). Experiments in different animal models with H. pylori, H. felis and H. mustelae, the 
gastric pathogen of ferrets, illustrated that flagellar motility is essential for gastric Helicobacter 
species to colonize (Eaton et al., 1992; Josenhans et al., 1999; Ottemann and Lowenthal, 2002). 
Many other proteins are known to be essential in flagellar structure and motility of Helicobacter. 
For instance, mutations in the flgE and fliD genes, encoding the flagellar hook and flagellar cap 
proteins, respectively, result in nonmotile bacteria (O’Toole et al., 1994; Kim et al., 1999). H. 
pylori shows taxis (directed motility) towards urea, bicarbonate, cholesterol, arginine and several 
other amino acids, and moves away from low pH (Lertsethtakarn et al., 2011). In addition to 
motility, several in vivo studies indicated that chemotaxis is required for colonization of H. pylori 
(Foynes et al., 2000; McGee et al., 2005; Terry et al., 2005). Indeed, screening for in vivo 
essential genes in an infection model of H. pylori in the Mogolian gerbil yielded an abundance of 
motility and chemotaxis genes, indicating that in vivo both features are prime factors in 
colonization (Kavermann et al., 2003). For example, the chemotaxis receptor TlpB is required for 
pH taxis, and tlpB mutants are defective for mouse colonization (Croxen et al., 2006). 
Adhesins and outer membrane proteins 
Many bacterial factors mediate the adhesion of H. pylori to the gastric epithelium. H. pylori 
exhibits five families of outer membrane proteins (OMPs): the major OMP family consisting of 
Hop and Hor proteins, the Hof protein family, the Hom protein family, the iron-regulated OMPs 
and the efflux pump OMPs. Given the multitude of OMPs and adhesins, it is extremely difficult 
to test for the contribution of each individual adhesin. Therefore, in this overview only adhesins 
for which sufficient data about their putative role in the pathogenesis of Helicobacter infection 
are available, will be described. 
In 1998, Ilver et al. detected a 78- kilo Dalton (kDa) adhesin on the H. pylori outer membrane 
that recognizes Lewis b (Le
b
) ABO blood group antigen on the surface of gastric epithelium, and 
designated it as “blood group antigen-binding adhesin” (BabA) (HopS). Two corresponding 
babA genes encode BabA: babA1 and babA2, but only BabA2 has Le
b
 binding ability (Yamaoka, 
2008). Several studies suggested a correlation between babA2
+
 H. pylori genotype and increased 
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risk of developing gastric diseases (Gerhard et al., 1999; Yu et al., 2002; Olfat et al., 2005). In 
2002, Mahdavi et al. observed that inactivated babA1A2 mutants could not bind human ABO/Le
b
 
blood group antigens, but still bound to the gastric epithelium. They identified the sialic acid-
binding adhesin (SabA) (HopP) as another putative adhesin of H. pylori, which adheres to the 
sialylated Le
x
 (sLe
x
) antigen on the surface of epithelial cells. The SabA is encoded by the sabA 
gene. Besides sLe
x
, SabA can also mediate the adherence of H. pylori to laminin (Walz et al., 
2005). Both, the babA and sabA expressing profile can be modulated according to alternations in 
host environment by switching “on” and “off” gene expression (Mahdavi et al., 2002; Solnick et 
al., 2004; Goodwin et al., 2008). The capacity of rapidly switching “on” and “off” BabA and 
SabA expression allows a continued adaptation of H. pylori binding properties to the glycan 
profile modifications on host epithelial cells that occur during the inflammation process and 
contributes to the establishment of an infection. 
The outer inflammatory protein A (OipA), encoded by the oipA gene, is another member of the 
Hop protein family (HopH) that may serve as an adhesin. It was originally identified as a pro-
inflammatory response-inducing protein (Yamaoka et al., 2000). Like for babA and sabA, the 
expression of the oipA gene can be switched “on” and “off” by a slipped-strand repair mechanism 
within a cytosine-thymine dinucleotide repeat motif (Saunders et al., 1998; Yamaoka et al., 
2000). A functional OipA status is strongly associated with increased interleukin (IL)-8 secretion 
of epithelial cells in vitro and heightens gastric inflammation in vivo (Yamaoka et al., 2000; 
2002a; b). Aside from OipA, HomB is another OMP involved in the host inflammatory response. 
Indeed, H. pylori homB knockout mutant strains have reduced ability to induce IL-8 secretion by 
human gastric epithelial cells, as well as reduced capacity to bind these cells (Oleastro et al., 
2008). 
The H. pylori adhesin A (HpaA) is a surface-located lipoprotein that was initially described as a 
putative N-acetyl-neuraminyllactose-binding hemagglutinin (Evans et al., 1988; O’Toole et al., 
1995). Several studies have tried to elucidate the function of HpaA in in vitro adhesion studies, 
but the results are not conclusive. For instance, in vitro bacterial binding to gastric cell lines was 
not affected by an inactivated hpaA gene (O’Toole et al., 1995; Jones et al., 1997). On the other 
hand, Carlsohn et al. (2006) described that a hpaA mutant H. pylori strain is not able to establish 
colonization in mice, indicating that HpaA is essential for colonization of H. pylori in mice. 
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Other adhesins that have been identified on H. pylori are AlpA and AlpB (Odenbreit et al., 1999; 
Peck et al., 1999). Inactivation of the respective genes, alpA and alpB results in decreased 
adherence to gastric epithelial cells and absence of colonization in a guinea pig model (Odenbreit 
et al., 1999; 2002; de Jonge et al., 2004). More recently, Snelling and co-authors (2007) found 
that HorB also is a gastric epithelial cell adhesin. They observed that disruption of the horB gene 
reduced H. pylori adhesion to gastric epithelial cells by more than twofold. Additionally, 
insertional mutagenesis in the horB gene of a mouse-adapted H. pylori strain reduced mouse 
stomach colonization threefold, indicating its role in gastric colonization. 
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Figure 1. Schematic represention of the stomach colonized with H. pylori, showing the main H. pylori 
virulence factors involved in colonization and gastric pathology. (1) The H. pylori urease allows survival 
in the acid environment by hydrolyzing urea into ammonia and carbon dioxide. The ammonia molecules 
buffer cytosolic and periplasmic pH as well as the surface layer around the bacterium. Flagella propel the 
bacterium into the mucus layer, and this in a directed way, so-called chemotaxis. For example, H. pylori 
moves away from low pH (2). Once H. pylori reaches the apical domain of gastric epithelial cells, it 
attaches to the cells using specialized adhesins (3). BabA and SabA adhere to blood group antigen 
receptors, whereas the receptors of OipA, AlpA/B and HopZ are not known. The secreted vacuolating 
cytotoxin, VacA, induces the formation of large vacuoles in epithelial cells and mitochondrial-mediated 
apoptosis (4). The neutrophil-activating protein, HP-NAP (yellow sphere), after crossing the epithelial 
lining and endothelium, recruits neutrophils and monocytes, which extravasate and cause tissue damage 
by releasing reactive oxygen species (ROS). H. pylori can inject a cytotoxin-associated protein, CagA (red 
sphere), into host cells by a specialized type IV secretion system, encoded by the cag PAI (6). Injected 
CagA causes alterations of the cytoskeleton, can induce apoptosis in vitro and signals the nucleus to 
induce nuclear factor (NF)-κB. The H. pylori γ-glutamyl transpeptidase, GGT (green sphere), is involved 
in mitochondrial-mediated apoptosis and induces NF-κB. Finally, both VacA, CagA and HP-NAP can 
induce production of pro-inflammatory cytokines by lymphocytes and/or polymorphonuclear cells (8). 
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2.2. Virulence factors and their genes involved in induction of gastric lesions 
Cytotoxin-associated gene pathogenicity island 
In 1990, a strain-specific H. pylori gene, cytotoxin-associated gene A (cagA), was identified 
(Cover et al., 1990), which is now recognized as a major virulence factor of H. pylori. No 
homologs are known for cagA in other Helicobacter species. cagA is a marker for the H. pylori 
cytotoxin-associated gene pathogenicity island (cag PAI), which is present in virulent strains but 
missing in avirulent H. pylori isolates (Akopyants et al., 1998). The cag PAI consists of about 30 
genes (Akopyants et al., 1998) and encodes a type IV secretion system (T4SS) which mediates 
the injection of cytotoxin-associated effector protein (CagA) into epithelial cells, both in vitro 
(Segal et al., 1999; Odenbreit et al., 2000) and in vivo (Yamazaki et al., 2003). In contrast with 
other bacterial T4SS, the cag PAI exhibits specific cag genes, of which only a few encode 
proteins with clear sequence similarities to known T4SS VirB and VirD proteins (Fischer et al., 
2010). Once within the cytoplasm of the eukaryotic cell, CagA protein is phosphorylated at 
tyrosine residues at its five amino-acid Glu-Pro-Ile-Tyr-Ala (EPIYA) repeat region (Backert et 
al., 2001) by the host cell Src kinases (Stein et al., 2002). Phosphorylated CagA interacts with the 
Src homology 2 (SH2) domains of the tyrosine phosphatase SHP-2 (Higashi et al., 2002), which 
affects migration, spreading and adhesion of epithelial cells (Yamazaki et al., 2003). This 
phenomenon of cytoskeleton rearrangements, inducing dramatic elongation and spreading of 
epithelial cells has been called “hummingbird” phenotype and depends on the phosphorylation of 
CagA (Segal et al., 1999). CagA also interacts with Grb2, which results in activation of the 
Ras→Mek→Erk pathway, leading to the activation of pro-inflammatory nuclear factor (NF)-κB 
(Brandt et al., 2005), cytoskeletal rearrangements and proliferation of cells in vitro (Mimuro et 
al., 2002). Conflicting reports exist about the effect of CagA on apoptosis in human epithelial 
cells. One study described that CagA promotes the expression of anti-apoptotic myeloid cell 
leukemia sequence 1 and prosurvival factor phospho-Erk in vivo (Mimuro et al., 2007). In 
contrast, Tsutsumi et al. (2003) demonstrated that CagA increases apoptosis of human gastric 
adenocarcinoma cell line (AGS) in vitro. Human infections with cagA-positive H. pylori strains 
mainly show overexpression of pro-apoptotic proteins. However, to a lesser extent anti-apoptotic 
proteins are also overexpressed (Cabral et al., 2006). It has been suggested that the anti-apoptotic 
effects of CagA may aid persistence by maintaining the turnover of the epithelial cells to which 
H. pylori bacteria are attached (Mimuro et al., 2007). In any case, the cagA
+
 status of H. pylori 
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strains has been identified as possible virulence marker for disease outcome as it is associated 
with increased risk for peptic ulcer disease (Nomura et al., 2002) and gastric cancer (Blaser et al, 
1995; Wen and Moss, 2009). 
Vacuolating cytotoxin 
Another major virulence factor of H. pylori, is the vacuolating cytotoxin (VacA). This protein is 
delivered to the host cell’s cytoplasm by releasing outer membrane vesicles. The first 
documented effect of VacA was its ability to induce gastric epithelial cell vacuolization (Cover 
and Blaser, 1992). The vacuolization is dependent on the formation of membrane channels by the 
toxin as it is completely abrogated by chloride channel inhibitor 5-nitro-2-(3-phenylpropylamino) 
benzoic acid (NPPB) (Szabò et al., 1999). VacA also causes alterations in mitochondria, such as 
reduction of the mitochondrial transmembrane potential and release of the mitochondrial 
cytochrome c, which could lead to apoptosis or impaired cell cycle of host cells (Kimura et al., 
1999; Willhite and Blanke, 2004). Indeed, several studies showed that in vitro exposure of AGS 
cells to VacA leads to apoptosis of these cells (Kuck et al., 2001; Cover et al., 2003). The toxicity 
of VacA is dependent on variations of the signal (s) and middle (m) regions of its encoding gene, 
vacA. The s1/m1 allele has been shown to be the most virulent form of the vacA gene whereas the 
s2/m2 genotype did not show any vacuolating activity (Atherton et al., 1995). Interestingly, the 
s1/m1 type of vacA is clearly linked with cagA
+
 genotype, indicating that vacA alone could not be 
considered as a virulence marker for disease outcome. Yamaoka et al. (1999) indeed observed 
that the vacA type alone is a poor predictive marker for disease severity. 
VacA is also able to execute either pro-inflammatory or immune suppressive effects. On the one 
hand, VacA stimulates the expression of cyclooxygenase 2 (COX-2) in neutrophils and 
macrophages and activates lymphocytes and mast cells to produce pro-inflammatory cytokines 
(Supajatura et al., 2002; de Bernard et al., 2005). On the other hand, VacA is able to inhibit the 
activation of nuclear factor of activated T cells (NFAT), and consequently the production of IL-2, 
required for T cell proliferation (Boncristiano et al., 2003; Gebert et al., 2003). 
In H. felis, H. bizzozeronii, H. heilmannii s.s. and H. mustelae, no vacA orthologs has been found 
yet (O’Toole et al., 2010; Arnold et al., 2011; Schott et al., 2011; Smet et al., 2013). 
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Neutrophil-activating protein 
Another H. pylori virulence factor with pro-inflammatory capacities is HP-NAP. HP-NAP, 
encoded by the napA gene, was first identified to stimulate the production of toxic reactive 
oxygen species (ROS) in neutrophils and promote adhesion of neutrophils to endothelial cells 
(Evans et al., 1995). Purified recombinant HP-NAP was found to be chemotactic for human 
neutrophils and monocytes in vitro (Satin et al., 2000). Moreover, using intravital microscopy, it 
has been demonstrated that in rats HP-NAP is able to cross the endothelia efficiently and to 
promote rapid neutrophil adhesion in vivo (Polenghi et al., 2007). After crossing the epithelial 
monolayer, HP-NAP is able to activate the underlying mast cells (Montemurro et al., 2002), 
monocytes (Montemurro et al., 2001; Amedei et al., 2006), and neutrophils (Polenghi et al., 
2007) to release pro-inflammatory cytokines. It has been suggested that the presence of a large 
number of positively charged residues on the surface of HP-NAP might account for its unique 
ability in activating human leucocytes (Zanotti et al., 2002). A recent study added evidence that 
HP-NAP further contributes to inflammation by increasing the lifespan of monocytes and 
neutrophils (Cappon et al., 2010). This study showed that in vitro exposure of monocytes to HP-
NAP induced anti-apoptotic proteins, and reported that HP-NAP promotes survival of neutrophils 
in a monocyte-dependent manner (Cappon et al., 2010). 
HP-NAP is a Toll-like receptor (TLR)2 agonist with immune modulatory capacities, able to 
induce the expression of IL-12 and IL-23 by human neutrophils and monocytes. In fact, HP-NAP 
has the potential to shift antigen-specific T cell responses from a predominant T helper (Th)2 to a 
polarized Th1 cytotoxic phenotype, characterized by high levels of interferon (IFN)-γ and tumor 
necrosis factor (TNF)-α production (Amedei et al., 2006; D’Elios et al., 2007). Homologs of the 
HP-NAP coding gene, napA, have also been found in the genome of H. felis, H. bizzozeronii, H. 
mustelae and H. heilmannii s.s. (O’Toole et al., 2010; Arnold et al., 2011; Schott et al., 2011; 
Smet et al., 2013). 
γ-glutamyl transpeptidase 
In 1999, Chevalier and co-authors identified a catalytically active enzyme, γ-glutamyl 
transpeptidase (GGT), as essential for colonization of mice. GGT activity is found in all gastric 
Helicobacter species and is constitutively expressed in vivo and in vitro (Haesebrouck et al., 
2009; Wachino et al., 2010). Additionally, Rossi et al., (2012) recently showed evidence that 
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GGT has a conserved function in the Helicobacter genus. The role of GGT as virulence factor of 
gastric Helicobacter species has only been investigated for H. pylori and recently for H. suis. In 
H. pylori, GGT induces apoptosis of AGS cells in a dose-dependent manner (Shibayama et al., 
2003). Later, the authors showed that H. pylori GGT very efficiently utilizes both glutamine and 
glutathione from epithelial cells as a source of glutamate. As glutamine and glutathione are 
important nutrients for maintenance of healthy gastrointestinal tissue, their depletion by the GGT 
enzyme was hypothesized to account for the damaging of gastric epithelial cells (Shibayama et 
al., 2007). A later study confirmed that H. pylori GGT causes apoptosis of AGS cells and 
demonstrated that the H. pylori GGT-induced apoptosis of AGS cells occurs via a mitochondria-
mediated pathway (Kim et al., 2007). More recent work of the same research group showed that 
recombinant H. pylori GGT inhibits growth of AGS cells by inducing cell cycle arrest in the G1-
S transition phase (Kim et al., 2010). Aside from apoptosis, H. pylori GGT also upregulates 
expression of COX-2 and epidermal growth factor (EGF)-related peptides in human gastric cells, 
suggesting a possible role in H. pylori-associated gastric carcinogenesis (Busiello et al., 2004). A 
better understanding of the clinical importance of GGT has been recently obtained from a study 
of Gong et al. (2010). They observed significantly higher GGT activity in H. pylori isolates 
obtained from patients with peptic ulcer disease than isolates from patients with nonulcer 
dyspepsia. In the same study, purified native H. pylori GGT caused an increase of oxidative DNA 
damage and generated H2O2 in primary gastric epithelial and AGS cells, resulting in the 
activation of NF- κB, that in turn lead to upregulation of pro-inflammatory IL-8. 
The role of H. suis GGT in gastric pathology has recently been examined by Flahou et al. (2011). 
Incubation of AGS cells with purified native or recombinant H. suis GGT showed that also the H. 
suis GGT induces apoptosis of AGS cells (Flahou et al., 2011). Additionally, they demonstrated 
that the induction of epithelial cell death caused by H. suis and H. pylori GGT is mainly 
glutathione degradation-dependent. The degradation products, including cysteinyl glycine, induce 
an increase of H2O2, which in turns results in oxidative cell damage (Flahou et al., 2011). 
H. pylori, but also the enterohepatic H. bilis GGT has immune modulatory capacities, playing a 
role in suppression of the host immune response (Gerhard et al., 2005; Schmees et al., 2007; 
Rossi et al., 2012). This will be further described in paragraph 3.3. 
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Other virulence factors 
Besides the extensively studied major H. pylori virulence genes, cagA, vacA, and the more 
recently discovered virulence factors GGT and HP-NAP, H. pylori harbors other virulence-
associated candidates. The role and association with pathology of these candidates, including the 
duodenal ulcer promoting gene A (dupA), H. pylori flavodoxin protein (FldA), iceA (“induced by 
contact with epithelium”), the high temperature requirement A (HtrA) and plasminogen-binding 
proteins A and B (PgbA and PgbB) are described in Table 1. To our knowledge, dupA and iceA 
have only been found in the H. pylori genome, whereas htrA, fldA and pgbA/B were also found in 
the genome of other gastric Helicobacter species (O’Toole et al., 2010; Arnold et al., 2011; 
Schott et al., 2011; Smet et al., 2013). 
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Table 1. H. pylori less documented virulence-associated factors and their association with H. 
pylori-related disease 
Protein/gene Predicted role Association with H. pylori-related 
disease/effects 
References 
DupA/dupA dupA encodes for a VirB4 
ATPase homolog. There 
are two alleles: dupA1 and 
its truncated version dupA2 
 Gastric and duodenal ulcers 
 Gastric cancer, but this association is 
not universal 
 dupA1 increases IL-12p40, IL-12p70 
and IL-23 expression by mononuclear 
cells 
Lu et al., 2005; 
Hussein, 2010; 
Hussein et al., 2010 
IceA/iceA iceA1 allele encodes a 
CATG-recognizing 
restriction endonuclease 
 IceA1: associated with peptic ulcers, 
but this association is not universal  
Peek et al., 1998; 
Yamaoka et al., 
1999; Donahue et 
al., 2000; Kidd et 
al., 2001; Xu et al., 
2002  
FldA/fldA Electron acceptor of the 
pyruvate oxidoreductase 
enzyme complex 
 Antibodies against FldA are associated 
with gastric MALT lymphoma in 
humans 
Chang et al., 1999 
HtrA/htrA Cleaving ectodomain of E-
cadherin, a mammalian 
cell-adhesion protein 
 In vivo and in vitro disruption of 
gastric epithelial barrier junctions, 
facilitating intercellular entry of H. 
pylori 
Hoy et al., 2010; 
Löwer et al., 2011 
PgbA, PgbB/ 
pgbA, pgbB 
Binds host plasminogen  Could enhance tissue damage by 
proteolysis 
 May obstruct natural healing process 
of gastric ulcers 
Ljung et al., 2000; 
Jönssen et al., 2004 
 
dupA: duodenal ulcer promoting gene, iceA: “induced by contact with epithelium” coding gene, fldA: H. 
pylori flavodoxin coding gene, MALT: mucosa-associated lymphoid tissue, htrA:
 “
high-temperature 
requirement A” coding gene, pgbA and pgbB: plasminogen-binding protein coding gene A and B. 
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3. Host immune response against gastric Helicobacter infections 
In contrast to the scarce literature available on host immune responses against NHPH, numerous 
studies evaluated the host immune response against H. pylori. This section is therefore focused 
on H. pylori. Where possible, recent insights in H. suis-induced immune responses will also be 
discussed. 
In humans, H. pylori often elicits a distinct host immune response, which is however inefficient 
for bacterial clearance without treatment (Blaser and Atherton, 2004). The underlying mechanism 
for persistence of H. pylori in the human stomach remains incompletely understood. Insights in 
the complex immunobiology of chronic H. pylori infections are helpful for the development of an 
effective vaccine. 
The following section reviews how H. pylori establishes and maintains persistent infection, 
mainly in mouse models, complemented with results from in vitro experiments and studies in H. 
pylori-infected humans. Both innate and acquired host immune responses to H. pylori are 
described, followed by the role of H. pylori virulence factors in evasion of the host immune 
response. 
3.1. Innate immune response to H. pylori 
Since H. pylori is a predominantly extracellular bacterium (Dubois and Borén, 2007), innate 
immune cells, including dendritic cells (DCs) and marcophages as well as gastric epithelial cells, 
form a first barrier to infection. They detect invading pathogens via conserved microbial 
structures, the so-called pathogen-associated molecular patterns (PAMPs). PAMPs are 
recognized by pattern recognition receptors (PRRs) located either on cytoplasmic and endosomal 
membranes or in the cytosol of host cells. The surface-expressed PRRs, Toll-like receptors 
(TLRs), play an important role in mucosal host defense against H. pylori. In particular, TLR4, -5 
and -9 have been detected on gastric epithelial cells of humans suffering from H. pylori-gastritis 
as well as in patients with a non-inflamed gastric mucosa (Schmausser et al., 2004). Interestingly, 
H. pylori differs from other gastrointestinal pathogens in that it has evolved to largely avoid 
recognition of its PAMPs. First, although lipopolysaccharide (LPS) is the classical bacterial 
ligand for TLR4, H. pylori-derived LPS has a weak affinity for this receptor and mainly acts via 
TLR2 (Bäckhed et al., 2003; Ferrero, 2005; Cullen et al., 2011). Second, Helicobacter flagellin 
has been shown to evade the TLR5-mediated innate immunity (Gewirtz et al., 2004; Lee et al., 
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2003). This is possibly due to the ability of H. pylori to modify its flagellar TLR recognition site, 
rendering the flagellin protein unable to activate TLR5 (Andersen-Nissen et al., 2005). Besides 
TLRs, another family of PRRs, the cytosolic nucleotide-binding oligomerization domain (NOD) 
proteins, appear to play a central role in mediating innate immunity against H. pylori. NOD1 is 
involved in the intracellular recognition of bacterial muropeptides derived from bacterial 
peptidoglycan. Viala et al. (2004) found that H. pylori activates NOD1 in gastric epithelial cells 
by introducing its peptidoglycan into the cytoplasma of epithelial cells through its T4SS. This H. 
pylori-mediated NOD1 signaling resulted in the activation of NF-κB and a subsequent production 
of pro-inflammatory cytokines, including CXCL-8 (IL-8), CXCL-2 (a murine IL-8 homolog) 
(Viala et al., 2004) and type 1 IFN (Watanabe et al., 2011). H. pylori is also able to avoid 
detection by NOD1. Indeed, Chaput et al. (2006) demonstrated that transformation of H. pylori to 
coccoid forms, which are still able to infect (Wang et al., 1997), results in modification of cell 
wall peptidoglycan, which in turns allows coccoid forms to escape detection by NOD1. 
The production of chemokines by gastric epithelial cells after H. pylori infection facilitates a 
second stage in the innate immune response: the recruitment of innate immune cells such as 
neutrophils, macrophages and DCs. Phagocytosis is an important anti-bacterial innate immune 
mechanism, and a substantial phagocytic cell infiltrate (macrophages and neutrophils) can be 
found in H. pylori-infected gastric mucosa. However, H. pylori partially evades phagocyte-
mediated killing. Indeed, a large proportion of bacteria seems to survive inside phagosomes 
which may provide a protected intracellular niche contributing to the persistence of infection 
(Allen et al., 2000; Allen, 2001). Additionally, H. pylori induces the generation and extracellular 
release of ROS, but is capable of surviving this response through neutralization by its catalase 
activity (Ramarao et al., 2000). 
In response to H. pylori antigens, macrophages and DCs are stimulated leading to recruitment, 
differentiation and activation of CD4
+
 Th cells, which organize the adaptive immune response 
(Wilson and Crabtree, 2007). 
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3.2. Acquired immune response to H. pylori 
The predominant T cell response in the gastric mucosa of H. pylori-infected humans includes an 
IFN-γ-producing CD4+ T cell phenotype (D’Elios et al., 1997; Bamford et al., 1998). This Th1 
cell response is associated with reduced bacterial colonization density in humans (Holck et al., 
2003) and in mouse models (Lucas et al., 2001; Stoicov et al., 2004) (Figure 2). Additionally, the 
development of H. pylori-induced gastric pathology largely depends on Th1 cell-mediated 
responses and Th1 cytokines (Mohammadi et al., 1996; Smythies et al., 2000; Sommer et al., 
2001). This has been confirmed in animal models, using for instance IL-4
-/-
 and IFN-γ-/- mice 
(Smythies et al., 2000), IFN-γ neutralization in a H. felis mouse model (Mohammadi et al., 1996), 
and mice deficient in Th1 cell development (Sommer et al., 2001). A number of H. pylori 
virulence factors have been reported to promote Th1 responses. For example, HP-NAP promotes 
the expansion of IFN-γ-producing cells (i.e. the Th1 phenotype) in antigen-stimulated cell 
cultures, while decreasing the number of IL-4-secreting cells (i.e. the Th2 phenotype) (Amedei et 
al., 2006). In addition, the cag PAI is associated with increased IL-12 and IL-18 responses (Wang 
et al., 2007; Yamauchi et al., 2008; Takeshima et al., 2009), and OipA stimulates IL-18, which in 
turns results in a Th1 response (Yamauchi et al., 2008).  
In addition to Th1 cells, a Th2 phenotype has been observed in H. pylori-infected gastric mucosa 
(Serrano et al., 2007; Robinson and Atherton, 2010). In contrast to Th1 cells, the Th2 cell 
response suppresses H. pylori-induced inflammation and is associated with increased H. pylori 
colonization (Fox et al., 2000; Smythies et al., 2000) (Figure 2). 
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Figure 2. Effect of CD4
+
 cell subsets on gastric H. pylori colonization in mice and/or humans, 
pathological outcome of infection and vaccination in mice. In addition, the innate factors that influence 
their differentiation from naive T cells and the cytokines they secrete are shown. IL-10 down-regulates 
both Th1 and Th17 responses. Th: T helper cell, Treg: regulatory T cell. IFN-γ: interferon γ, IL: 
interleukin, LT: lymphotoxin, TNF-α: tumor necrosis factor α, TGF-β: transforming growth factor β. 
 
IL-17-secreting T cells, Th17 cells, have also been identified in the stomach of H. pylori infected 
humans and play a role in inducing IL-8 secretion by gastric epithelial cells and recruitment of 
neutrophils to the site of infection (Luzza et al., 2000; Mizuno et al., 2005). Numerous studies 
demonstrated that IL-17 is a pro-inflammatory cytokine and that the Th17/IL-17 pathway plays 
an important role in the inflammatory response to H. pylori infection (Shiomi et al., 2008; Shi et 
al., 2010; Hitzler et al., 2012; Ragavan and Quiding-Järbrink, 2012). For instance, Shiomi et al. 
(2008) observed that IL-17
-/-
 mice showed decreased gastric inflammation and neutrophil 
infiltration compared to wild-type mice. This has been confirmed in another study in which 
gastric inflammation was decreased when IL-17 activity was blocked in vivo (Shi et al., 2010). 
Further, mice infected with H. pylori showed a mixed Th17/Th1 response, with the Th17/IL-17 
pathway preceding and modulating the Th1 response. Recently, Hitzler et al. (2012) 
demonstrated that H. pylori-associated gastritis is reduced in the absence of Th17-polarizing 
cytokine IL-23. 
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The study of Serelli-Lee et al. (2012) strengthens the importance of IL-17 in H. pylori-induced 
chronic inflammation. They found that persistent H. pylori-specific Th17 responses, associated 
with elevated gastric IL-1β, occurred in humans with past H. pylori infection. This suggests that 
the persistent inflammation, induced by IL-17 and IL-1 β, might contribute to the development of 
gastric cancer. Finally, most studies reveal a negative correlation between a Th17 response and 
H. pylori colonization (Scott Algood et al., 2009; Kao et al., 2010), although some authors 
suggest the opposite (Shi et al., 2010). 
H. pylori uses a variety of mechanisms to inhibit the T cell response and to persist in the gastric 
mucosa. Regulatory T cells (Tregs) are mainly CD4
+
 T cells expressing high levels of CD25, 
and inhibit the effector function of other immune cells by producing anti-inflammatory cytokines 
such as IL-10 and transforming growth factor (TGF)-β (Raghavan and Quiding-Järbrink, 2012). 
Many studies reported that H. pylori may induce a Treg response, leading to H. pylori persistence 
(Lundgren et al., 2003; Raghavan et al., 2003; 2004; Rad et al., 2006; Nedrud et al., 2012). 
Indeed, DCs exposed in vitro to H. pylori antigens have been shown to skew T cell response from 
Th17/Th1 towards Treg differentiation, which reduces effector responses (IFN-γ and IL-17) and 
in turn clearance of the infection (Kao et al., 2010). Robinson et al. (2008) suggested that low 
numbers of IL-10-secreting Tregs results in an increased Th1 response, leading to more severe 
gastritis. This has been confirmed by Harris et al. (2008), who showed that gastric Treg responses 
down-regulate the inflammation and ulceration by H. pylori in children. The influence of CD4
+
 T 
cell subsets upon outcome of H. pylori infection, complemented with their role in H. pylori 
vaccine-mediated immunity is summarized in Figure 2. 
In summary, a H. pylori infection mainly leads to specific Th17/Th1 immune responses. 
Additionally, the induction of IL-10-secreting Tregs could result in evasion of the host immune 
system and control of immunopathology caused by Th1 and Th17 responses (Robinson and 
Atherton, 2010). 
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A H. pylori infection stimulates the production of mucosal and systemic anti- H. pylori IgA and 
IgG antibodies (Ferrero et al., 1998; Meining et al., 2002), but the effect of antibody responses on 
bacterial colonization remains controversial. One study reported that the intragastric 
administration of specific monoclonal IgA mediated protection against H. felis infection in mice 
(Czinn et al., 1993). In contrast, others showed that specific IgA and IgG in mice actually 
promote bacterial colonization and impair the host resistance against H. pylori infection (Akhiani 
et al., 2004; 2005). The role of antibodies in limiting H. pylori infection is further discussed in 
section 4. 
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3.3. Role of H. pylori virulence factors in host immune evasion 
H. pylori has virulence factors that allow the bacterium to suppress CD4
+
 T cell-mediated 
immunity. VacA has been shown to inhibit T cell proliferation by interfering with the T cell 
receptor/IL-2 signaling pathway at the level of calcineurin, i.e. the Ca
2+
-calmodulin-dependent 
phosphatase (Boncristiano et al., 2003; Gebert et al., 2003). Additionally, one study demonstrated 
that VacA may interrupt phagosome maturation in macrophages, allowing H. pylori strains 
expressing VacA to evade the innate host immune response (Zheng and Jones, 2003). 
Gerhard and co-workers (2005) showed that a H. pylori secreted low-molecular weight protein, 
distinct from VacA, arrests antigen-activated T cells in the G1 phase of the cell cycle by 
interfering with G1 cyclin-dependent kinase activity. The authors demonstrated later through a 
biochemical approach that the secreted γ-glutamyl transpeptidase of H. pylori (GGT) is the 
responsible factor for inhibition of T cell proliferation (Schmees et al., 2007). Indeed, 
mutagenesis of GGT abrogated the inhibitory effect of the bacteria and recombinantly expressed 
GGT showed anti-proliferative activity (Schmees et al., 2007). 
3.4. Host immune response against H. suis 
Little is known about the immune response against H. suis infections, because isolation of H. suis 
and in vitro cultivation of this bacterium have only been possible since 2008. 
Some studies described the immune response after inoculation of rodents with gastric tissue 
suspensions containing H. suis. One study observed that an infection with “H. heilmannii” type 1, 
originating from a pig stomach and which in fact is H. suis, leads to increased messenger 
(m)RNA expression of IFN-γ and IL-10 in the mouse stomach, indicating that both a Th1 
response and Th2 response are associated with “H. heilmannii” type 1 infection (Park et al., 
2008). Cinque et al. (2006) observed that “H. heilmannii” type 1-infected IFN-γ-/-  mice did not 
show gastric follicular gastritis, whereas wild-type and IL4-deficient infected mice developed this 
pathology. The authors concluded that IFN-γ plays an essential role in the pathogenesis of gastric 
lymphoid follicles formation in “H. heilmannii” type 1-infected mice. In two other studies, 
mRNA expression levels of IFN-γ were upregulated in the gastric mucosa of C57BL/6 mice at 3 
to 6 months after inoculation with a gastric tissue homogenate containing H. suis, indicating a 
Th1 response (Nobutani et al., 2010; Mimura et al., 2011). 
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On the other hand, Flahou et al. (2012) observed in the gastric mucosa of both BALB/c and 
C57BL/6 mice, experimentally infected with H. suis a mild upregulation of the Th2 signature 
cytokine, IL-4, but no upregulation of IFN-γ mRNA expression. It has to be emphasized that only 
in the study of Flahou et al. (2012) pure cultures of H. suis were used, whereas in all other studies 
animals were inoculated with homogenates of gastric tissue not only containing H. suis, but also 
other bacteria. This might explain these discrepancies. Differences in H. suis strains and animal 
models might also play a role. 
While literature describes a Th1 or Th2 response, all studies agree on the presence of a Th17 
response in H. suis-infected rodent models. Gastric expression levels of both IL-17 and IL-6 
(promoting Th17 response) mRNA were negatively correlated with H. suis colonization in mice 
(Flahou et al., 2012) and IL-17 mRNA was also upregulated in Mongolian gerbils infected with 
H. suis (unpublished data). Despite a fully functional Th17 response, with subsequent infiltration 
of neutrophils, H. suis colonization has been shown to persist in mice and gerbils. 
 
In summary, in the stomach of mice inoculated with pure cultures of H. suis, a predominant Th17 
response is induced, accompanied by a less pronounced Th2 response (Flahou et al., 2012). This 
contrasts with the Th17/Th1 response and the absence of Th2 response induced by H. pylori 
infection in these rodent models (Robinson and Atherton, 2010). These discrepancies could 
possibly explain the different pathologies induced by both Helicobacter species, i.e. more 
lymphoid lesions in case of H. suis, and predominant metaplastic/dysplastic changes in case of H. 
pylori infections (Wiedemann et al., 2009; Flahou et al., 2010). 
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4. Prophylactic and therapeutic control of gastric Helicobacter infections 
Human gastric infections with H. pylori occur in one-half of the world’s population. Similarly in 
pigs, infections with H. suis show a very high prevalence worldwide (Haesebrouck et al., 2009). 
Although combined antimicrobial and anti-acid therapy can successfully eradicate H. pylori in 
most patients, increasing antimicrobial resistance in the bacterium remains a serious problem 
(Selgrad and Malfertheiner, 2008). Additionally and from an epidemiological point-of-view, 
Helicobacter infections are so widespread that antimicrobial treatment is an impractical approach 
for controlling Helicobacter infections. As described previously in section 3, gastric Helicobacter 
infections are not readily cleared by the host inflammatory and immune responses, and may 
persist for life. Vaccination approaches eliciting a protective immune response have therefore 
been studied extensively for H. pylori since the early nineties. This section will mainly focus on 
vaccination experiments against gastric Helicobacter infections. Additionally, as part of a 
therapeutic perspective, the in vitro antimicrobial susceptibility of gastric Helicobacter species 
will be described. 
4.1. Vaccination against gastric Helicobacter infections 
In this paragraph, a brief overview of approaches to discover candidate protective antigens will 
be given. Next, the in vivo validation of candidate protective antigens in vaccination experiments 
against gastric Helicobacter infections will be discussed. Finally, the aspects of the immune 
response induced by vaccination and their link with protective immunity will be given. 
4.1.1. Selection of candidate protective antigens for subunit vaccines 
For 20 years, a number of researchers have been pursuing the objective of developing vaccines 
against H. pylori. Initial, but also recent attempts, have made use of inactivated whole-cell 
vaccines. However, the use of whole-cell preparations for vaccination implies potential 
drawbacks. First, whole-cell lysates could contain LPS fractions, which may induce undesirable 
side-effects (Moran et al., 2002). Second, whole-cell vaccines consist of a complex mixture of 
many antigens, including both protective antigens, and antigens suppressing protection 
(Haesebrouck et al., 2004). Therefore, many laboratories began investigating specific purified or 
recombinant proteins, with less potential for side-effects, as candidates for subunit vaccination in 
General introduction 
31 
mice. The discovery of candidate protective antigens could be based on different approaches, 
including the pregenomic approach, the genomic approach, and the proteomic approach. 
Most Helicobacter antigens, considered as potential vaccine candidates, were identified in the 
pregenomic era (Del Guidice et al., 2001). This approach is based on the involvement of the 
protein in virulence and/or colonization of Helicobacter and/or on its abundance. In this way, the 
urease enzyme, CagA, VacA and others have been selected as candidates for subunit vaccines. 
Since the first description of the H. pylori genome (Tomb et al., 1997), the genomic based 
approach for selecting potential antigens has gained interest. The complete genome sequencing of 
a bacterium represents a large reservoir of genes encoding potential antigens that can be selected 
and tested as vaccine candidates. Potential vaccine candidates, including membrane- or surface-
associated proteins, can be identified in a reverse manner, based on in silico predictions. This 
approach has been used for many bacterial species and has been termed “reverse vaccinology” 
(Rappuoli, 2001; Serruto et al., 2009; Sette and Rappuoli, 2010). Since H. pylori isolates are 
genetically diverse (Alm et al., 1999; Salama et al., 2000), and vaccines should preferably contain 
antigens that are highly conserved among different strains, the availability of complete genome 
sequences of independent strains may enable to select conserved antigens. There are, however, 
also some limitations related to the genome-based selection of vaccine candidates. For instance, 
this approach does not provide information about the translation and synthesis of the gene 
products, nor whether the deduced proteins are actually functional. 
Common molecular techniques, e.g. DNA microarray technology and (immuno)proteomics, 
allow analyzing sets of genes and/or proteins expressed in vivo as well as screening of in vivo 
immunoreactive antigens. Screening sera from vaccinated mice against a H. pylori expression 
library has identified urease, the heat-shock protein (Hsp) B, putative membrane proteins and 
lipoprotein 20 (Lpp20) as candidate vaccine antigens (Hocking et al., 1999). Immunoproteomics 
is a strategy combining standard proteomics with immunological screening. Mostly, two-
dimensional (2D) gel electrophoresis of Helicobacter proteins is performed, followed by 
immunoblotting with sera from Helicobacter-infected patients exhibiting different pathologies. 
Immunogenic proteins could further be characterized by mass spectrometry and sequence 
analysis. This technique is currently the method of choice for identifying new antigens of 
diagnostic and protective values (Adamczyk-Poplawska et al., 2011). It has been proposed that 
highly immunogenic, conserved, abundant and surface-located proteins could be used as efficient 
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anti-Helicobacter vaccine candidates (McAtee et al., 1998; Bumann et al., 2004). For instance the 
well-known Helicobacter proteins UreB, FlaA, HP-NAP and HspB have been identified as 
potential vaccine candidates of H. pylori. In almost each study, also new immunogenic proteins 
with potential protective value have been found. Some of them, including a putative neuraminyl-
lactose binding hemagglutinin homolog (HpaA homolog) and HP0231 (disulfide bond A and C 
homolog) induced a protective response in the murine infection model (Sabarth et al., 2002). 
Before the start of this thesis, no genomic nor (immuno)proteomic information was available for 
H. suis. 
4.1.2. In vivo vaccination trials 
Most in vivo vaccination experiments against gastric Helicobacter infections have been 
performed in the mouse model. It has only been possible to reliably infect mice with H. pylori 
since the mid-nineties. Therefore, in early immunization experiments, challenge was often done 
with H. felis (Nedrud, 2001). Consequently, this section is mainly focused on the effectiveness of 
vaccine antigens against H. pylori and H. felis in the mouse model, complemented with 
immunization studies against other gastric Helicobacter species. 
As mentioned previously, initial attempts for developing a H. pylori vaccine were performed 
using inactivated or killed whole-cell preparations (Chen et al., 1993; Czinn et al., 1993). The 
antigen preparations were delivered intragastrically to mice in the presence of a mucosal 
adjuvant, cholera toxin (CT), and were highly effective in inducing protection against gastric H. 
felis infection (Chen et al., 1993; Czinn et al., 1993; Lee and Chen, 1994). Until today, 
prophylactic mucosal and parenteral immunization of mice with Helicobacter whole-cell lysates 
showed to be effective against H. pylori infections (Garhart et al., 2003b; Sutton et al., 2007; 
Flahou et al., 2009; Harbour et al., 2008; Raghavan et al., 2010). Also therapeutic immunization 
with whole-cell lysate may provide strong protection against both experimental H. pylori 
infection and later reinfection (Raghavan et al., 2002a; b; Nyström et al., 2006). In several of 
these studies a strong reduction of bacterial load was observed, even leading to complete 
protection in some animals. 
In addition to whole-cell preparations, studies with subunit vaccines consisting of purified or 
recombinant proteins were carried out. Of the various candidate antigens, the most promising is 
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the urease protein, which activity is critical for the survival of H. pylori (Eaton et al., 1991; 
Tsuda et al., 1994; Karita et al., 1995). The urease subunit B (UreB) is a 65-kDa protein encoded 
by a 1.7-kilo base pair (kbp) gene, which frequently elicits an antibody response in patients with 
gastric diseases (Futagami et al., 1998; Kimmel et al., 2000). It has been suggested that the UreB 
seems to be more important in terms of immunogenicity and protection than the urease subunit A 
(UreA) (Ferrero et al., 1994; Michetti et al., 1994; Bégué et al., 2007; 2010). Table 2 provides an 
overview of vaccination experiments using H. pylori urease or its subunits, alone, or in 
combination with other antigens. As noted, not only the antigen, but also administration route and 
adjuvant or vector influence the outcome of vaccine-induced protection and immunity. Before the 
present PhD research, vaccination studies with H. suis urease had not yet been done. 
 
  
 
Table 2. Vaccination experiments in mice against H. pylori or H. felis with urease or its subunits alone or in combination with other 
antigens 
Antigen Adjuvant/ 
vector 
Delivery 
route  
Conclusions
a
 Reference 
rUrease  
 
CT 
Freund’s 
oral, IG 
SC 
 All: protection against H. felis challenge 
 Protection correlated with gastric secretory anti-urease IgA 
Lee et al., 1995 
rUrease CT oral Protection against H. felis challenge Pappo et al., 1995 
UreA+UreB S.typhimurium IN  Protection against H. pylori challenge 
 Th1- and Th2 responses were generated 
Corthésy-Theulaz et 
al., 1998 
UreB Lactobacillus IG Protection against H. felis challenge Corthesy et al., 2005 
rUreB + rHspA CT oral Combination of two proteins has a synergistic effect against H. felis challenge 
(UreB alone: 80% protection, whereas in combination 100%) 
Ferrero et al., 1995 
rUrease LT 
Alum, Bay
b
 
IN 
SC 
 Both: protection against H. pylori challenge 
 Correlation between protection and density of MHC class II T cells 
 Antibodies not required for protection 
Ermak et al., 1998 
rUrease LT 
Bay, Saponin 
oral 
SC 
 
 Both: protection against H. pylori challenge 
 Using an adjuvant inducing both Th1 and Th2 responses elicit better protection 
than using an adjuvant with a predominant Th2 response  
Guy et al., 1998 
UreB Poliovirus oral Prophylactic as well as therapeutic protection against H. pylori Smythies et al., 2005 
Urease LT oral, IN, 
rectal 
Protection against H. pylori challenge 
 
Kleanthous et al., 
1998 
Urease 
Urease 
Urease+ CagA 
LT oral 
rectal 
rectal 
Protection against H. pylori challenge 
Protection against H. pylori challenge + clearance 
Protection against H. pylori challenge + clearance 
Kleanthous et al., 
2001 
UreB DNA IN Protection against H. pylori challenge Hatzifoti et al., 2006 
UreB CpG/DNA IN, oral, 
rectal, 
IM 
No protection against H. pylori challenge Zavala-Spinetti et al., 
2006 
  
 
 
 
 
 
 
 
  
 
a 
Conclusions: Protection against H. pylori/H. felis challenge: a significant decrease of H. pylori/H. felis colonization in immunized and challenged 
groups compared to unimmunized and challenged groups. Clearance: At least some individuals are present in the immunized and challenged group with 
undetectable numbers of bacteria. 
b
 Bay: a glycosylamide adjuvant.
 c
 UreB138: a 138 amino acids long segment of subunit B of urease corresponding to 
the most important region of the enzymatic activity of H. pylori urease. Abbreviations: r: recombinant; UreA and UreB: urease subunit A and B, 
respecitively; rHspA: recombinant heat-shock protein A; rHpaAtrunc: truncated form of recombinant H. pylori adhesin A; CagA: cytotoxin-associated 
protein A; VacA: vacuolating cytotoxin; MHC: major histocompatibility complex; Alum: aluminium hydroxide; S.: Salmonella; CT: cholera toxin; 
LT: heat-labile enterotoxin of E. coli; SC: subcutaneous; SL: sublingual; IG: intragastric; IM: intramuscular; IN: intranasal. 
UreB138
c
 Freund’s SC  Protection against H. pylori challenge 
 IgA in stomach of immunized mice were significant higher than in 
unimmunized mice 
 Severe gastritis in immunized mice 
 
Morihara et al., 2007 
UreB rLactococcus 
lactis 
oral  Protection against H. pylori challenge 
 Significant serum anti-UreB IgG and UreB-specific fecal IgA in immunized 
group 
Gu et al., 2009 
rUreB + rHpaAtrunc CT 
 
SL/IG  Gastric IL-17 correlated with protection 
 SL delivery induces stronger protection than IG delivery 
 Combination of two proteins has a synergistic effect against H. pylori infection 
Flach et al., 2011a 
rUreB CpG 
Freund’s 
Alum 
IN 
SC 
IM 
Neither immunogenic, nor protective against H. pylori challenge 
Immunogenic and highly protective against H. pylori challenge 
Immunogenic and modestly protective against H. pylori challenge 
Bégué et al., 2010 
rUreB CT 
 
IN 
 
 Protection against H. pylori challenge, which is correlated with increased 
specific rUreB Th17 response 
Zhang et al., 2011 
UreB+CagA+VacA attenuated 
S.typhimurium  
oral  Protection against H. pylori challenge, clearance rate of 62.5% 
 Protection correlated with specific Th1 response (IFN-γ), serum IgG and 
mucosal IgA responses 
Liu et al., 2011 
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Immunization with recombinant (r)CagA and rVacA administered intragastrically together with a 
detoxified mutant of the heat-labile enterotoxin of E. coli (LT) eradicated an existing H. pylori 
infection in mice (Ghiari et al., 1997). However, a large number of H. pylori strains do not 
express CagA and VacA, thus limiting their potential as vaccine candidates if used alone. They 
can, however, be included in a vaccine that also contains other antigens common to all strains 
(see further). Another virulence factor used in immunization experiments is HP-NAP. 
Prophylactic intragastric immunization of mice with HP-NAP has been shown to induce a similar 
partial protection compared to vaccination with CagA and H. pylori lysate (Satin et al., 2000). 
Rossi et al. (2004) described successful therapeutic vaccination against H. pylori in beagle dogs 
with a multivalent subunit vaccine consisting of VacA, HP-NAP and CagA. Interestingly, these 
virulence factors have also recently been used in a Phase I study in humans (Malfertheiner et al., 
2008). This study evaluated the safety and immunogenicity of a vaccine consisting of 
recombinant VacA, CagA, and HP-NAP given intramuscularly with an aluminium hydroxide 
adjuvant to H. pylori-negative healthy individuals. Vaccination elicited no adverse reactions and 
generated a humoral and T cell response and cytokine production, indicating that this is a 
promising candidate vaccine for further clinical studies (Malfertheiner et al., 2008). 
The HpaA protein, which is an immunogenic adhesin of H. pylori (Voland et al., 2003), has also 
been reported to induce protection in a mouse model. Prophylactic intragastric immunization with 
rHpaA (+ CT) induced a reduction in bacterial colonization in some mouse strains (inbred 
BALB/c and outbred QS mice), but was ineffective in others (inbred C57BL/6 mice), 
demonstrating the importance of the host genetic background. By contrast, therapeutic 
immunization was effective in all three mice strains, but immunization with lysate was shown to 
be more effective (Sutton et al., 2007). Purification of this lipoprotein requires detergents, which 
might confer toxicity. Therefore, in a subsequent study, a truncated form of rHpaA (rHpaAtrunc), 
which purification does not require detergents, was created and evaluated in a mouse model 
(Flach et al., 2011a). The authors concluded that rHpaAtrunc was equally protective as rHpaA, but 
immunization in combination with rUreB induced significantly better protection than 
immunization with rHpaAtrunc alone. It was suggested that HpaA (and its truncated form 
rHpaAtrunc) is a promising antigen for inclusion in a mucosal vaccine against H. pylori (Sutton et 
al., 2007; Flach et al., 2011a), however most likely as a component of a multiantigenic vaccine. 
Recently, Anderl et al. (2009) published an abstract describing immunization against H. pylori 
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with a combination of HpaA and GGT. As described earlier, GGT can inhibit T cell 
proliferation, and thus helps to evade the host immune response. The authors found that by 
vaccination of mice with GGT, strong anti-GGT antibody responses block the enzymatic activity 
of the protein, and thereby counteract the immunosuppressive activity of GGT. As GGT is a 
secreted protein, GGT-specific T cells can hardly target the pathogen. Therefore, the OMP HpaA 
was also included in the vaccine used in this study. 
Other antigens used in H. pylori/H. felis mouse vaccination studies include catalase (Radcliff, 
1997), superoxide dismutase (Every et al., 2011), Lpp20 (Keenan et al., 2000), flagellar sheath 
proteins (Skene et al., 2007) and heat-shock proteins. The latter have been shown to induce a 
partial protection against H. felis or H. pylori colonization in mice (Ferrero et al., 1995; 
Yamaguchi et al., 2003). Heat-shock proteins could be candidates for vaccination against H. 
pylori, however like for HpaA, most probably as a component of a multiantigenic vaccine. 
Indeed, immunization of mice with both HspA and UreB induced a 100% protection from 
challenge with H. felis, whereas immunization with HspA alone only induced 80% reduction of 
bacterial load (Ferrero et al., 1995). 
So far, the majority of subunit vaccines contain one or two antigens. However, some studies 
indicate that including more antigens might increase vaccine efficacy against Helicobacter 
infections. Wu et al. (2008) observed that a multivalent vaccine delivered either orally or 
intramuscularly and consisting of UreB, HspA and the surface-located protein HpaA induced a 
better protection against H. pylori in Mongolian gerbils than single-or double-antigen vaccines. 
Apart from H. felis, only a few studies dealt with vaccination against NHPH species. Dieterich et 
al. (1999) showed that intranasal (+ CT) immunization of mice with recombinant H. heilmannii 
s.s. UreB or H. pylori urease protects mice against a H. heilmannii s.s. infection (prophylactic) 
and could also reduce the bacterial load of a preexisting infection (therapeutic). Only two studies 
reported immunization against H. suis (Hellemans et al., 2006; Flahou et al., 2009). Hellemans et 
al., (2006) found that intranasal (+ CT) and subcutaneous (+ saponin formulation) immunization 
with heterologous H. pylori and H. felis whole bacterial antigens only induced a partial protection 
against challenge with the at that moment unculturable “Candidatus H. suis”. Flahou et al. (2009) 
demonstrated that subcutaneous immunization of mice with whole bacterial cell lysates of H. 
suis, H. cynogastricus and H. bizzozeronii was not protective against a H. suis challenge. 
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However, prophylactic intranasal immunization of mice using a homologous (H. suis) or 
heterologous (H. cynogastricus and H. bizzozeronii) whole-cell lysate induced a protective 
response against H. suis, since several animals were negative in both a H. suis-specific PCR and 
urease activity test. This standardized intranasal mouse model can be used for future vaccination 
experiments against H. suis. 
4.1.3.  Mechanism of vaccine-induced Helicobacter immunity 
Literature generally acknowledges an enhanced Th1/Th17 response to be most important in 
vaccine-induced protection against H. pylori, accompanied with innate mediators and a decreased 
Treg response. In addition, a role for antibody- and Th2 responses have been proposed 
(Blanchard and Nedrud, 2010). 
The role of local and systemic antibodies in protection against gastric Helicobacter infections 
remains ambiguous. Initial and recent H. pylori vaccine studies showed that local IgA and IgG in 
the stomach were associated with protection in mice (Blanchard et a., 1995; Lee et al., 1995; 
Ferrero et al., 1997; Goto et al., 1999; Nyström et al., 2006; Morihara et al., 2007), and that 
passive immunization with IgA and IgG offered protection against H. felis and H. pylori infection 
(Czinn et al., 1993; Blanchard et al., 1995; Gorrell and Robins-Browne, 2009; Bhuiyan et al., 
2010). In contrast to the positive evidence for antibody-mediated vaccine-induced protection 
against H. pylori infection, numerous other authors did not find a clear correlation between 
antibody responses and protection. Indeed, studies in B cell- or antibody- deficient mice indicated 
that both prophylactic and therapeutic vaccinations mediate immune protection in a B cell- and 
antibody-independent manner (Ermak et al., 1998; Blanchard et al., 1999; Gottwein et al., 2001; 
Garhart et al., 2003b; Akhiani et al., 2004). 
Studies in major histocompatibility complex (MHC)-knockout mice showed that vaccine efficacy 
mainly depends on the presence of a MHC class II-restricted CD4
+ 
T cell population (Ermak et 
al., 1998; Pappo et al., 1999). The role of different CD4
+
 T cell subsets in vaccination is 
illustrated in Figure 2. However, conflicting reports about the polarization of CD4
+
 T cell 
population can be found in literature. Some authors demonstrated that a Th2 or a balanced 
Th2/Th1 response confers protection against H. pylori infection (Saldinger et al., 1998; Gottwein 
et al., 2001), whereas most studies showed that Th2 responses are not required for protective 
immunity against H. pylori infection (Garhart et al., 2003b; Nyström and Svennerholm, 2007; 
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Taylor et al., 2008). Nowadays, Th1 polarized responses are considered to be more important 
than Th2 responses in vaccine-mediated protection (Figure 2). The role of the signature Th1 
cytokine, IFN-γ, remains controversial. Several studies have reported that IFN-γ is critical for 
protective immunity in mice (Akhiani et al., 2002; Rahn et al., 2004; Sayi et al., 2009), whereas 
others found it to be less important (Sawai et al., 1999; Garhart et al., 2003a; Flach et al., 2011b). 
The relative importance of different cytokines in vaccine-mediated protection was compared by 
Flach and coworkers (2011b). Significant inverse correlations were found between bacterial 
colonization and gastric expression of TNF-α, IL-12p40, IFN-γ and IL-17. In vivo neutralization 
of these cytokines during the effector phase of immune response revealed a significant role of the 
Th17 signature cytokine IL-17, but not of TNF-α and IFN-γ in vaccine-induced protection, 
indicating that mainly Th17 effector mechanisms are of critical importance for protection. 
Indeed, recent studies demonstrated that Th17 cells are correlated with protection against H. 
pylori infection (DeLyria et al., 2009; Raghavan et al., 2010; Zhang et al., 2011). DeLyria et al. 
(2009) demonstrated that Th17 mediates protection in a mouse model of H. pylori infection, as 
did Velin et al. (2009) using H. pylori and H. felis. In the latter study, neutralizing IL-17 
significantly reduced vaccine efficacy. As mentioned in paragraph 3.2., H. pylori infection may 
activate a Treg response in the gastric mucosa, which down-regulates both inflammation and 
immune response (i.e. Th1 and Th17 responses) leading to persistence of infection (Zhang et al., 
2008; Kao et al., 2010). Indeed, H. pylori-specific-Th1 responses and protective immunity can be 
enhanced by depletion of Treg (Zhang et al., 2008). It has been shown that T cell activation at 
lymph nodes due to immunization could possibly circumvent this Treg-mediated suppression of 
immunity (Blanchard et al., 2004). 
Finally, also innate immune mediators have been shown to play an important role in protective 
immunity against H. pylori infections. Mast cells have been shown to collaborate with CD4
+
 Th 
cells to mediate bacterial clearance (Velin et al., 2005), while others showed that neutrophils 
were essential for induction of Th17 responses (DeLyria et al., 2009). A study of Ding et al. 
(2009) suggested that these findings can be reconciled, as mast cells contributed to protection but 
did so by amplifying neutrophil recruitment and effects of IL-17. Interestingly, also DCs have 
been suggested to play a critical role in the development of a successful H. pylori vaccine (Zhang 
et al., 2008). 
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Apart from H. felis, nothing is known about vaccine-mediated immune response against gastric 
NHPH species. 
Enhanced gastritis has been often observed after H. pylori challenge in prophylactic vaccination 
studies in mice. This enhanced gastritis is termed “post-immunization” gastritis and has mainly 
been found when using whole-cell lysate (Goto et al., 1999; Garhart et al., 2002; Morihara et al., 
2007). Although this phenomenon represents a major concern in H. pylori vaccination trials in 
mice, it has been shown that the enhanced inflammation in vaccinated mice can resolve over time 
to background or to levels no higher than observed in infected mice (Sutton et al., 2001; Garhart 
et al., 2002). The mechanism of post-immunization gastritis is not fully understood. It has been 
shown that the severity of post-immunization gastritis is often associated with the degree of 
protection (Goto et al., 1999; Garhart et al., 2002; Morihara et al., 2007; Becher et al., 2010). 
Indeed, Becher et al. (2010) demonstrated that the vaccine-induced protection is correlated with 
increased properties of CD4
+
 T cells and neutrophils, and reduced numbers of Treg cells in the 
gastric mucosa (Becher et al., 2010). 
4.2. In vitro antimicrobial susceptibility of gastric Helicobacter species 
A considerable amount of work has been conducted over the last years assessing many issues 
around H. pylori eradication therapy. These studies were mainly focused on the efficacy of the 
current standard therapy, the investigation of antimicrobial resistance rates, and the development 
of rescue therapies required when treatment fails. As part of this thesis, the present overview will 
deal with in vitro antimicrobial susceptibility of H. pylori, complemented with that of other 
gastric helicobacters. 
The current first choice treatment for a H. pylori infection consists of a proton-pump inhibitor 
and two antimicrobials (e.g. clartithromycin, amoxicillin, metronidazole, tetracycline or 
fluoroquinolones) for 7 days (Malfertheiner et al., 2007). H. pylori can acquire resistance to the 
antimicrobial agents used to treat the infection. Therefore, susceptibility testing is important in 
the management of the infection. The Clinical and Laboratory Standards Institute (CLSI) 
recognizes only the agar dilution susceptibility testing method for H. pylori (CLSI, 2010). This 
method requires a H. pylori cell suspension equivalent to a 2.0 McFarland standard, Mueller-
Hinton plates containing 5% aged sheep blood, and incubation for 72h in a microaerobic 
atmosphere at 35°C +/- 2°C. Currently, the CLSI has only established a breakpoint for 
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clarithromycin in the case of H. pylori susceptibility testing (resistant breakpoint ≥ 1 µg/ml) 
(CLSI, 2010). Other breakpoints to define resistance have only been suggested in literature for 
tetracycline (≥ 2 µg/ml), ciprofloxacin (≥ 1 µg/ml), metronidazole and amoxicillin (both ≥ 8 
µg/ml) (Mendonça et al., 2000; Mégraud and Lehours, 2007). H. pylori is intrinsically resistant to 
some compounds, including glycopeptides, cefsulodin, nystatin, polymyxins, nalidixic acid, 
trimethoprim, sulfonamides, cycloheximide and amphotericin B. Some of these are therefore 
used as selective agents in isolation media. A variety of other methods have been examined for 
their suitability for testing antimicrobial susceptibility of H. pylori. They include the broth 
dilution method (Hachem et al., 1996), the Epsilonmeter testing method (Etest) (Glupczynski et 
al., 2002) and the disk diffusion method (Falsafi et al., 2004). These traditional methods of 
susceptibility testing all require prior isolation and cultivation of H. pylori. Because isolation of 
H. pylori from a gastric biopsy may take several days, empiric therapy is often initiated before 
antimicrobial susceptibility results are available. To circumvent this problem, rapid molecular 
methods, including quantitative real-time PCR (qPCR) and FISH, have been developed to guide 
the therapy based on the presence of specific resistance determinants. Molecular rapid tests have 
already been developed for detection of resistance to fluoroquinolones (Glocker and Kist, 2004), 
tetracycline (Lawson et al., 2005) and clarithromycin (Chisholm et al., 2001; Lottspeich et al., 
2007) using DNA from gastric biopsy, gastric juice or stool samples. H. pylori resistance is 
essentially due to chromosomal mutations, and for the most part, a limited number of punctual 
mutations are present. Genes involved in resistance to antimicrobial agents in H. pylori are 
summarized in Table 3. 
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Table 3. Genes involved by mutation or other genetic events leading to antimicrobial resistance 
in H. pylori 
Antibiotics Concerned 
gene(s) 
Target Location of action Reference 
Macrolides  rrn 23S  23S RNA Point mutations at position 
2142 and 2143 of 23S 
Versalovic et al., 
1996 
Tetracyclines rrn 16S  16S RNA Change of nucleotide triplet 
AGA925-928→TTC 
Trieber and 
Taylor, 2002 
Quinolones gyrA DNA gyrase A AA substitution in QRDQ 
mainly at 87 and 91 
Moore et al., 1995 
Amoxicillin pbp-1a Penicillin-binding protein AA substitution Ser-
414→Arg 
Gerrits et al., 2002 
Metronidazole rdxA, frxA Oxygen-insenstive 
nitroreductase, flavin 
oxidoreductase 
Different mutations in rdxA 
and/or frxA 
Goodwin et al., 
1998; Jeong et al., 
2000 
Rifampicins rpoB DNA-dependent RNA 
polymerase subunit B 
Mutations at positions 524, 
525, 585 of rpoB 
Heep et al., 1999 
 
AA: amino acid, QRDR: quinolone-resistance determining region. 
 
There are no standard treatment schemes for eradication of gastric NHPH. Therefore, infections 
with NHPH in humans have been empirically treated with similar therapeutic regimens as used 
for H. pylori (Solnick, 2003). Triple therapy using combinations of a proton pump inhibitor and 
two antimicrobial agents (clarithromycin, amoxicillin, metronidazole or tetracycline) for 7 to 14 
days have been shown to be effective (Goddard et al., 1997; Ojano et al., 2012; Joosten et al., 
2013). However, also these species may acquire antimicrobial resistance. Indeed, an eradication 
therapy regimen containing lanzoprazole (proton pump inhibitor), tetracycline, and metronidazole 
was not successful in a patient infected with H. bizzozeronii, as shown by histology and positive 
culture. In vitro susceptibility testing before and after treatment revealed high minimal inhibitory 
concentrations (MICs) for metronidazole (Kivistö et al., 2010).  
To date, in vitro susceptibility studies have only been performed for H. bizzozeronii, H. 
salomonis and H. felis, three natural inhabitants of the gastric mucosa of cats and dogs (Van den 
Buck et al., 2005b). MICs were determined using a slightly modified method (that is horse blood 
instead of sheep blood) from that recommended for H. pylori and Campylobacter jejuni. All 
strains showed to be highly susceptible to ampicillin, clarithromycin, tetracycline, tylosin, 
enrofloxacin, gentamicin and neomycin. Acquired resistance was only detected to metronidazole 
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in one H. bizzozeronii and two H. felis strains, showing a MIC of 16 µg/ml (Van den Buck et al., 
2005b). Only since a few years, a successful in vitro cultivation method has been developed for 
H. suis (Baele et al., 2008). Hence, before the present PhD thesis, in vitro antimicrobial 
susceptibility studies for this species had not been performed. 
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Worldwide, Helicobacter (H.) suis causes chronic gastritis and decreased daily weight gain in 
pigs. This microorganism has also been associated with ulcers of the pars oesphagea of the 
porcine stomach. In addition, it is the most frequent non-H. pylori Helicobacter species in 
humans suffering from gastric disorders. For a long time, the lack of pure H. suis in vitro isolates 
hampered the progress of research on this bacterium. Only in 2008, a successful in vitro culture 
method was developed, creating new opportunities to investigate the pathogenesis of H. suis 
infections and to develop control strategies. 
 
In contrast to H. pylori, little is known about the pathogenesis of H. suis infections, especially 
from a molecular perspective. Therefore, the genome of H. suis was sequenced with the aim to 
identify genes possibly involved in gastric colonization, persistence and pathogenicity of this 
microorganism (first aim of this thesis, Chapter 1). 
 
Measures to control H. suis infections in pigs may not only decrease the number of pigs suffering 
from gastric disease, but are also important from a public health point of view. When we started 
our studies, the few vaccination trials that had been carried out for H. suis only focused on the 
protective efficacy of whole-cell preparations. However, it was not known which bacterial 
proteins are important for induction of protective immunity against H. suis infections. Therefore, 
the second aim of this thesis was to obtain better insights into this matter. First, it was 
determined which H. suis proteins are recognized by sera from protected animals and not by sera 
from non-protected animals. Subsequently, the protective efficacy of a limited number of 
candidate antigens was evaluated and compared with that of H. suis whole-cell lysate in a 
standardized mouse model (Chapters 2 and 3). 
 
Currently, H. suis infections in human patients suffering from severe gastric pathology are treated 
in the same way as H. pylori infections. However, little is known about intrinsic and acquired 
antimicrobial resistance of H. suis isolates. Therefore, the third aim of this PhD thesis was to 
develop an in vitro assay allowing the determination of the antimicrobial susceptibility of H. suis 
isolates (Chapter 4). 
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Abstract 
Helicobacter (H.) suis has been associated with chronic gastritis and ulcers of the pars 
oesophagea in pigs, and with gastritis, peptic ulcer disease and gastric mucosa-associated 
lymphoid tissue lymphoma in humans. In order to obtain better insight into the genes involved in 
pathogenicity and in the specific adaptation to the gastric environment of H. suis, a genome 
analysis was performed of two H. suis strains isolated from the gastric mucosa of swine. 
Homologs of the vast majority of genes shown to be important for gastric colonization of the 
human pathogen H. pylori were detected in the H. suis genome. H. suis encodes several putative 
outer membrane proteins, of which two similar to the H. pylori adhesins HpaA and HorB. H. suis 
harbours an almost complete comB type IV secretion system and members of the type IV 
secretion system 3, but lacks most of the genes present in the cag pathogenicity island of H. 
pylori. Homologs of genes encoding the H. pylori neutrophil-activating protein and γ-glutamyl 
transpeptidase were identified in H. suis. H. suis also possesses several other presumptive 
virulence-associated genes, including homologs for mviN, the H. pylori flavodoxin gene, and a 
homolog of the H. pylori vacuolating cytotoxin A gene. It was concluded that although genes 
coding for some important virulence factors in H. pylori, such as the cytotoxin-associated protein 
(CagA), are not detected in the H. suis genome, homologs of other genes associated with 
colonization and virulence of H. pylori and other bacteria are present. 
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Introduction 
Helicobacter (H.) suis is a very fastidious, spiral-shaped, Gram-negative bacterium requiring a 
biphasic culture medium at pH 5 enriched with fetal calf serum, and a microaerobic atmosphere 
for in vitro growth (Baele et al., 2008). H. suis colonizes the stomach of more than 60% of 
slaughter pigs (Baele et al., 2008; Hellemans et al., 2007b). Although the exact role of H. suis in 
gastric disease in pigs is still unclear, it has been associated with chronic gastritis (Mendes et al., 
1991; Hellemans et al., 2007a) and ulcers of the pars oesophagea of the stomach (Queiroz et al., 
1996; Roosendaal et al., 2000; Haesebrouck et al., 2009). This may result in significant economic 
losses due to sudden death, decreased feed intake and reduced daily weight gain (Ayles et al. 
1996). A reduction of approximately 20 g/day in weight gain was observed in animals 
experimentally infected with H. suis, compared to the non-infected control animals (Kumar et al., 
2010a). 
Bacterial gastric disorders in humans are mainly caused by Helicobacter pylori (Cover and 
Blaser, 2009). However, non-Helicobacter pylori helicobacters (NHPH) have also been 
associated with human gastric disease with a prevalence ranging between 0.2 and 6% 
(Haesebrouck et al., 2009). H. suis is the most frequent NHPH species found in humans, where it 
was originally named “H. heilmannii” type 1 (O’Rourke et al., 2004). There are strong 
indications that pigs may serve as a source of infection for humans (Meining et al., 1998; 
Haesebrouck et al., 2009). In the human host, H. suis has been associated with peptic ulcer 
disease (Debognie et al., 1998), gastric mucosa-associated lymphoid tissue (MALT) lymphoma 
(Morgner et al., 1995) and chronic gastritis (Debognie et al., 1995). In rodent models of human 
gastric disease, the bacterium causes severe inflammation and MALT lymphoma-like lesions 
(Flahou et al., 2010). 
Up to now, little is known about the pathogenesis of H. suis infections. To improve 
understanding in the genes playing a role in pathogenicity, gastric colonization and persistence of 
H. suis, a genome-wide comparison with the well-investigated H. pylori genome was performed. 
Some virulence factors may indeed be similar for both bacteria. As there may also be differences, 
ab initio annotations of the H. suis genome were performed as well. 
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Materials and methods 
Genome sequencing 
A pyrosequencing (454 Life Sciences Corporation, Branford, CT, USA) assay was applied to the 
genome of the type strain of H. suis (HS1
T
 = LMG 23995
T
 = DSM 19735
T
) and H. suis strain 5 
(HS5), isolated from the gastric mucosa of two different swine, according to the method 
described by Baele et al. (2008). Quality filtered sequences were assembled into contigs using a 
454 Newbler assembler (Roche, Branford, CT, USA). 
Functional annotation 
In order to maximize the number of quality gene annotations, two different annotating 
approaches were followed: cross-mapping with three Helicobacter pylori strains (26695, Shi470, 
and G27 with NCBI accession numbers NC_000915, NC_010698, and NC_011333, 
respectively), and ab initio annotation. 
Cross-mapping annotation 
A custom BLAST (Altschul et al., 1997) database was created from the HS1
T
 and HS5 genomic 
contigs. The H. pylori proteome and non-coding RNAs were aligned (tblastn program of the 
BLAST suite, e threshold set to 10
-3
) to the H. suis database. For each BLAST hit the following 
additional information was analysed: 1) (secretion) signal peptide cleavage site if present, as 
assessed by the SignalP 3.0 program (Nielsen et al., 1997; Bendtsen et al., 2004); 2) 
specifications of transmembrane helices (number, start and end positions, presumed topology 
with regard to the cytoplasmic membrane) if present, as assessed by the TMHMM program 
(Krogh et al., 2001); 3) an estimate of the ribosome binding strength of the mRNA region 
preceding the most probable start codon. Ribosome binding strength was estimated by applying 
two established facts: i) on an mRNA strand, usually within 20 nucleotides before the actual start 
codon, the reverse complement of 5 to 7 nucleotides near the 16S rRNA 3’ end acts as an 
attractor and positioner for the ribosomal small subunit; this region is known as the Shine-
Dalgarno sequence (Shine and Dalgarno, 1974; Mikkowen et al., 1994); ii) in Gram-negative 
bacteria an AU-rich mRNA region some 16 nucleotides long and immediately preceding the 
Shine-Dalgarno sequence may also attract and position ribosomes to help initiate translation of 
the correct, biologically active gene product (Boni et al., 1991; Komarova et al., 2005). For H. 
suis, the Shine-Dalgarno sequence was determined to be a subsequence of AGGAGGU (which is 
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the reverse complement of the 3’ end of the 16S rRNA), and the minimum AU-richness 
(equivalent to ribosome binding capacity) of the preceding region was arbitrarily set to 10/16. For 
each theoretical ORF a range of possible start codons was scored; the higher the similarity to the 
ideal Shine-Dalgarno sequence, or the AU-richer the preceding region, or the better a 
combination of both, the more likely the potential start codon is to be the actual start codon. 
Ab initio annotation 
For ab initio annotation, theoretical open reading frames (ORFs) were first determined using the 
EMBOSS getorf tool (with minimum ORF length set to 90 nucleotides, and taking all alternative 
start codons into account) (Rice et al., 2000). All ORFs were translated subsequently, and 
BLAST (blastp program) was performed with an e threshold of 10
-15
 against the Uniprot-KB 
universal protein database. The generalist algorithm of getorf yielded roughly a tenfold of the 
expected natural ORFs, reducing the risk of false negatives. In order to keep the false positive 
rate low, extra parameters were considered: 1) percentage alignment between query and hit 
ORFs; 2) percentage similarity or conservation between aligned portions of query and hit ORFs; 
3) ribosome binding strength (for more details see above). To determine the presence of one or 
more conserved domains a rpsblast search (with default parameter values) was carried out for 
every single theoretical ORF against the compiled Conserved Domain Database which holds 
protein domain alignments from several other database sources (Marchler-Bauer et al., 2009). 
 
Results 
General features of the H. suis genome 
In the HS1
T
 genome a total of 1 635 292 base pairs and in the HS5 genome 1 669 960 bp were 
sequenced, both with an average GC content of 40%. In contrast to H. pylori, only one copy of 
both the 16S and 23S rRNA genes was detected, but like H. pylori, H. suis has three copies of the 
5S rRNA gene. Thirty-eight transfer RNAs were identified. On the whole, 1266 ORFs from HS1
T
 
and 1257 from HS5 were detected, of which 194 and 191 encoded hypothetical proteins 
respectively. In 98 and 92 ORFs a signal peptide cleavage site was detected, demonstrating 
predicted secreted proteins of HS1
T
 and HS5 respectively. The TMHMM program predicted 210 
and 206 proteins with at least one transmembrane helix for HS1
T
 and HS5 respectively. The 
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sequence fraction identical for HS1
T
 and HS5 is henceforward described together as the “H. suis 
genome”. 
Genes possibly involved in gastric colonization and persistence  
Homologs of H. pylori genes involved in acid acclimation, chemotaxis, adhesion to gastric 
epithelial cells, oxidative stress resistance (Table 1), and motility were detected in the H. suis 
genome. The latter were identified as a flagellar biosystem similar to that of H. pylori (Tomb et 
al., 1997). Moreover, H. suis contains a fibrinonectin/fibrinogen-binding protein coding gene, but 
the corresponding protein lacks a transmembrane helix or signal peptide cleavage site according 
to the bioinformatics tools mentioned earlier. Homologs coding for CMP-N-acetylneuraminic 
acid synthetase (NeuA) (HSUHS1_0474, HSUHS5_0481), sialic acid synthase (NeuB) 
(HSUHS1_0477, HSUHS5_0478), and UDP-N-acetylglucosamine-2-epimerase (WecB) 
(HSUHS1_1107, HSUHS5_0784) were observed as well. 
Genes encoding putative outer membrane proteins (OMPs) in relation to H. pylori OMPs are 
presented in Additional file 1. Genes coding for members of major H. pylori OMP families (Hop, 
Hor, Hof proteins, iron-regulated and efflux pump OMPs) could be aligned with the H. pylori 
genome. Both H. suis strains contain the hof genes hofA, C, E, F, the hop genes hopE, G-2 and H, 
and the hor genes horB, C, D, and J. Additionally, HS1
T
 contains homologs of the hopW protein 
precursor and horE, whereas HS5 possesses additional homologs of horA, horF, and horL. No 
members of the Helicobacter outer membrane (hom) family were detected in H. suis. Besides the 
major H. pylori OMP family proteins, the H. suis genome contains some predicted OMPs based 
on their N-terminal pattern of alternating hydrophobic amino acids similar to porins, 
encompassing omp29 for HS1
T
 and omp11 and omp29 for HS5. A 491 amino acids membrane-
associated homolog of the virulence factor MviN, aligned for 92% with the MviN homolog of H. 
acinonychis (Hac_1250), was also present in H. suis. 
Type IV secretion systems in H. suis  
Of the H. pylori type IV secretion systems (T4SS), only two members of the cag pathogenicity 
island (cagPAI) were identified in the H. suis genome (cag23/E and cagX). Most members of the 
comB transport apparatus were present. These include comB2, B3, B6, B8 and a number of 
additional genes not classified as comB: recA, comE, comL and dprA. H. suis possesses genes 
encoding VirB- and VirD-type ATPases (virB4, B8, B9, B10, B11, and virD2, D4), all designated 
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members of the H. pylori type IV secretion system 3 (tfs3). The HS1
T
 and HS5 T4SS are 
presented in Table 2. 
Genes possibly involved in induction of gastric lesions 
Homologs of H. pylori genes involved in induction of gastric lesions in the H. suis genome are 
summarized in Table 3. Homology searches with the H. pylori vacuolating cytotoxin A gene 
(vacA) identified HSUHS1_0989 in HS1
T
. The corresponding protein, which is exceptional in 
that it is one of the longest in the world of prokaryotes, possesses three small conserved VacA 
regions (residues 490-545, 941-995, and 1043-1351), followed by an autotransporter region 
(residues 2730-2983). The amino acid sequence of the HS5 homolog (HSUHS5_0761) could be 
aligned for 22% with the H. pylori strain HPAG1 sequence, and possesses only one conserved 
VacA region (residues 242-298), followed by an autotransporter region (1258-1510). In both 
vacA homologs, no signal sequence was determined. Additionally, an ulcer-associated adenine-
specific DNA methyltransferase (HSUHS1_0375, HSUHS5_0957) coding sequence was 
identified, whereas a molecular homolog of the ulcer-associated restriction endonuclease (iceA) 
could not be discovered in H. suis. H. suis contains homologs of pgbA and pgbB encoding 
plasminogen-binding proteins, though both lacking a transmembrane helix or signal peptide 
cleavage site according to the bioinformatics tools mentioned earlier. H. suis harbours homologs 
of genes coding for the H. pylori neutrophil-activating protein (HP-NAP) and γ-glutamyl 
transpeptidase (HP-GGT). Homologs encoding the H. pylori flavodoxin fldA and the pyruvate-
oxidoreductase complex (POR) members porA, porB, porC, and porD were also identified in H. 
suis. 
 
Discussion 
Genes possibly involved in gastric colonization and persistence 
The results of the present study demonstrate that several H. pylori genes involved in acid 
acclimation, chemotaxis and motility, have counterparts in the H. suis genome. These genes are 
known to be essential for colonization of the human gastric mucosa (Eaton et al., 1991; Tomb et 
al., 1997; Skouloubris et al., 1997; 2001; Wen et al., 2003). 
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Several OMP coding sequences were identified by comparative analyses with H. pylori and other 
bacterial species. H. suis contains some similar members of the major OMP families described in 
H. pylori (Alm et al., 2000). Some of these OMPs have been described to be involved in adhesion 
of H. pylori to the gastric mucosa, which is widely assumed to play an important role in the initial 
colonization and long-term persistence in the human stomach. These include the gastric epithelial 
cell adhesin HorB (Snelling et al., 2007) and the surface lipoprotein, H. pylori adhesin A (HpaA). 
HpaA, also annotated as neuraminyllactose-binding hemagglutinin, is found exclusively in 
Helicobacter and binds to sialic acid-rich macromolecules present on the gastric epithelium 
(Carlsohn et al., 2006). On the other hand, H. suis lacks homologs of several other H. pylori 
adhesion factors, including genes coding for the blood group antigen-binding adhesins babA 
(hopS) and babB (hopT), the sialic acid-binding adhesins sabA (hopP) and sabB (hopO), and the 
adherence-associated lipoproteins alpA (hopC) and alpB (hopB) (Odenbreit et al., 2009). 
H. suis contains a fibrinonectin/fibrinogen-binding protein coding gene, which may enhance its 
adherence to injured gastric tissue. Damage to host epithelial cells may indeed expose fibronectin 
and other extracellular matrix components. Strong homology was found with fibronectin-binding 
proteins of H. felis (YP_004072974), H. canadensis (ZP_048703091) and Wolinella 
succinogenes (NP_907753). To our knowledge, no exact function has been given to these 
proteins in these species. In Campylobacter jejuni, however, fibronectin-binding proteins CadF 
and FlpA have been shown to be involved in adherence to and/or invasion of host’s intestinal 
epithelial cells (Monteville et al., 2003; Konkel et al., 2010). According to the bioinformatics 
tools used here, the H. suis fibronectin-binding protein lacks a transmembrane helix or signal 
peptidase cleavage site, indicating that it is not surface exposed or secreted. Its real role in 
colonization therefore remains to be elucidated. 
Three genes involved in sialic acid biosynthesis (neuA, neuB, and wecB) were annotated in the H. 
suis genome, indicating that this bacterium may decorate its surface with sialic acid. The 
presence of surface sialylation has been studied extensively in pathogenic bacteria, where it 
contributes to evasion of the host complement defense system (Severi et al., 2007). 
Additionally, H. suis possesses genes encoding enzymes involved in oxidative-stress resistance 
(napA, sodB, katA, mutS, mdaB, and peroxiredoxin coding sequence). This indicates that H. suis 
may harbour a defense mechanism against the host inflammatory response, contributing to the 
ability of chronic gastric colonization by this bacterium (Wang et al., 2006). 
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Type IV secretion systems in H. suis 
Two partial T4SS were predicted in the H. suis genome, namely the comB cluster and the tfs3 
system. The H. suis comB system probably plays a role in genetic transformation (Hofreuter et 
al., 2001; Karnholz et al., 2006). Transformation of DNA can be responsible for the high degree 
of diversity among H. suis strains as has been recently demonstrated by multilocus sequence 
typing of available H. suis strains (Kumar et al., 2010b). The role of the H. pylori tfs3 secretion 
system in pathogenesis is not exactly known. Seven genes of the tfs3 cluster are homologs of 
genes involved in type IV secretion: virB4, virB11, and virD4 code for ATPases which move 
substrates to and through the pore. The latter is coded by transmembrane pore genes virB7, virB8, 
virB9, and virB10 (Kersulyte et al., 2003). All these genes, except virB7 were identified in H. 
suis, indicating that the H. suis tfs3 can be important in transmembrane transport of substrates in 
H. suis. 
The H. pylori cag pathogenicity island (cagPAI) region encodes a T4SS allowing H. pylori to 
insert the cytotoxin-associated antigen A (CagA) into the host cell. This process results in altered 
host cell structure, an increased inflammatory response, and a higher risk for gastric 
adenocarcinoma (Backert and Selbach, 2008). Although H. suis possesses two members of the H. 
pylori cagPAI (cag23/E and cagX), the majority of genes, including the gene coding for 
pathology-causing protein (CagA), were not identified. This indicates that HS1
T
 and HS5 lack a 
functional cag protein transporter secretion system. 
Genes possibly involved in induction of gastric lesions 
Genomic comparison of H. suis with H. pylori resulted in the identification of additional genes 
possibly associated with virulence in H. suis. A H. suis homolog of the H. pylori vacA was 
detected. VacA is both a cytotoxin of the gastric epithelial cell layer, and an immunomodulatory 
toxin of H. pylori (Gebert et al., 2004). H. pylori contains either a functional or non-functional 
vacA. The H. suis vacA homolog exhibits no vacA signal sequence, indicating that it might 
encode a non-functional cytotoxin (Atherton et al., 1995). In vitro and in vivo studies with a 
knockout mutant of the H. suis vacA could clarify the functionality of the vacA homolog in this 
Helicobacter species. 
Strong homology was found with two H. pylori virulence-associated genes namely napA, 
encoding the HP-NAP and ggt, encoding HP-GGT. The H. pylori GGT has been identified as an 
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apoptosis-inducing protein (Shibayama et al., 2003; Kim et al., 2007). The HP-NAP protein is 
designated as a proinflammatory and immunodominant protein by stimulating production of 
oxygen radicals and IL-12 from neutrophils and recruiting leukocytes in vivo (Brisslert et al., 
2005; Wang et al., 2008). Moreover, HP-NAP also plays a role in protecting H. pylori from 
oxidative stress by binding free iron (Cooksley et al., 2003). H. suis contains homologs of two H. 
pylori genes coding for plasminogen-binding proteins, pgbA and pgbB. The corresponding 
proteins, PgbA and PgbB bind host plasminogen, which subsequently can be activated to plasmin 
and may contribute to obstructing the natural healing process of gastric ulcers (Ljung, 2000; 
Jönsson et al., 2004). The biological role of the H. suis pgbA and B homologs in chronicity of 
gastric ulceration is uncertain, as no exact membrane association was found in the corresponding 
proteins. 
The risk to develop MALT lymphomas in H. suis infected human patients is higher than after 
infection with H. pylori (Morgner et al., 1995; Haesebrouck et al., 2009). Homologs encoding the 
H. pylori flavodoxin (fldA) and its electron donor, the POR enzyme complex (porA to D) were 
found in H. suis. The H. pylori flavodoxin protein (FldA) has been proposed to play a role in the 
pathogenesis of H. pylori-associated MALT lymphoma, as antibodies against the H. pylori FldA 
protein were more prevalent in patients with MALT lymphomas compared to patients with other 
H. pylori-related diseases (Chang et al., 1999). Besides, insertion mutagenesis of the fldA and the 
por complex has shown that these genes are essential for the survival of H. pylori (Freigang et al., 
2001). These observations indicate that fldA and its por complex may play a role in gastric 
colonization of H. suis and MALT lymphoma development in H. suis infected people. 
Recently, the genomes of the carcinogenic H. pylori strain B38 and the carcinogenic and 
ulcerogenic Helicobacter mustelae have been sequenced (O’Toole et al., 2010; Thiberge et al., 
2010). Both helicobacters lack homologs of major H. pylori virulence genes (e.g. cagA, babA/B, 
sabA/B), which are also absent in the H. suis genome. Additionally, H. mustelae lacks a vacA 
homolog. Despite this absence, infection with H. pylori strain B38 and H. mustelae has been 
associated with gastric MALT lymphomas and other gastric disorders. Whole genome 
sequencing data are also available from H. acinonychis strain Sheeba, a gastric pathogen of large 
felines. Similar to H. suis, H. acinonychis lacks a cagPAI as well as genes encoding BabA/B and 
SabA/B. Both species contain a vacA homolog, which for H. acinonychis has been described to 
be fragmented (Dailidiene et al., 2004; Eppinger et al., 2006). 
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H. suis contains a mviN homolog. This gene has been described to be a virulence factor of several 
bacterial species, such as Burkholderia pseudomallei and Vibrio alginolyticus (Ling et al., 2006; 
Cao et al., 2010). In addition to virulence, MviN has been described to be essential for in vitro 
growth of these and other bacteria (Ling et al., 2006; Inoue et al., 2008; Cao et al.,2010). The 
biological significance of mviN in the Helicobacter genus, however, remains to be elucidated. 
Conclusion 
Although H. suis lacks homologs of some major H. pylori virulence genes, other candidate 
virulence factors, such as napA, ggt, mviN, and fldA were detected. H. suis also possesses genes 
known to be essential for gastric colonization. Future in vitro and in vivo research of the currently 
presented genes of this porcine and human gastric pathogen should elucidate their precise role in 
colonization and virulence. 
Nucleotide sequence accession numbers 
The genome sequences have been deposited at GenBank/EMBL/DDBJ under the accession 
ADGY00000000 for HS1
T
 and ADHO00000000 for HS5. The versions described in this paper 
are the first versions, ADGY1000000 and ADHO1000000. 
 
Acknowledgements 
This work was supported by the Research Fund of Ghent University, Belgium (project no. 
01G00408), and by the Agency for Innovation by Science and Technology in Flandres (IWT) 
(grant no. SB-091002). We thank Mrs Sofie De Bruyckere and Mrs Marleen Foubert for her 
technical support. 
 
  
 
Table 1. Genes associated with pH homeostasis, chemotaxis, adhesion to epithelial cells, and oxidative stress resistance in the genome 
of H. suis type strain 1 (HS1
T
) and H. suis strain 5 (HS5) 
Group Gene detected 
in HS1
T
 
Gene detected 
in HS5 
Description of homolog Percentage of 
sequence aligned (of 
which % conserved) 
with described 
homolog
1
 
pH 
homeostasis 
HSUHS1_0708 
HSUHS1_0707 
HSUHS1_0706 
HSUHS1_0705 
HSUHS1_0704 
HSUHS1_0702 
HSUHS1_0703 
HSUHS1_0133 
HSUHS1_0615 
HSUHS1_0616 
HSUHS1_0617 
HSUHS5_0286 
HSUHS5_0285 
HSUHS5_0284 
HSUHS5_0283 
HSUHS5_0282 
HSUHS5_0280 
HSUHS5_0281 
HSUHS5_0547 
HSUHS5_0817 
HSUHS5_0816 
HSUHS5_0815 
Urease subunit alfa (ureA) of H. heilmannii 
Urease subunit beta (ureB) of H. heilmannii 
Urease transporter (ureI) of H. felis 
Urease accessory protein (ureE) of H. bizzozeronnii 
Urease accessory protein (ureF) of H. bizzozeronnii 
Urease accessory protein (ureH) of H. bizzozeronnii 
Urease accessory protein (ureG) of H. bizzozeronnii 
Hydrogenase expression/formation protein (hypA) of H. pylori 
Hydrogenase expression/formation protein (hypB) of H. pylori 
Hydrogenase expression/formation protein (hypC) of H. pylori 
Hydrogenase expression/formation protein (hypD) of H. achinonychis 
100 (94) 
100 (94) 
100 (89) 
100 (84) 
100 (84) 
96 (84) 
100 (95) 
98 (83) 
99 (91) 
98 (89) 
98 (80) 
 HSUHS1_0081 
HSUHS1_0230 
HSUHS1_0888 
HSUHS1_0680 
HSUHS1_0161 
HSUHS1_0391 
HSUHS5_1197 
HSUHS5_1130 
HSUHS5_0231 
HSUHS5_0265 
HSUHS5_1077 
HSUHS5_0874 
l-Asparaginase II (ansB) of H. pylori 
Arginase (rocF) of H. pylori 
Acylamide amidohydrolase (amiE) of H. pylori 
Formamidase (amiF) of H. pylori 
α-Carbonic anhydrase of H. pylori 
Aspartase (aspA) of H. acinonychis 
98 (64) 
99 (75) 
100 (93) 
100 (98) 
92 (69) 
100 (89) 
 
  
 
 
1
 Resulting from tblastn-based cross-mapping of the H. pylori proteome to the H. suis HS1
T
 and HS5 genomes and blastp-based ab initio analyses of the translated 
H. suis HS1
T
 and HS5 ORFs against the Uniprot-KB universal protein database. Differences between HS1
T
 and HS5 homologs ≤ 1%.  2 Lacking in other 
Helicobacter genomes available at GenBank.  
3
 Member of the 2-Cys peroxiredoxin superfamily.  
Chemotaxis  HSUHS1_1004 
HSUHS1_1003 
HSUHS1_1002 
HSUHS1_0538 
HSUHS1_0846 
HSUHS1_0299 
HSUHS1_1001 
HSUHS1_0286 
HSUHS1_0479 
HSUHS1_0196 
HSUHS1_0141 
HSUHS1_0763 
HSUHS1_0944 
HSUHS5_0649 
- 
HSUHS5_0775 
HSUHS5_0706 
HSUHS5_0081 
HSUHS5_0250 
HSUHS5_0774 
HSUHS5_0256 
HSUHS5_0476 
HSUHS5_0122 
HSUHS5_0641 
- 
HSUHS5_0990 
CheA-MCP interaction modulator of H. pylori 
Bifunctional chemotaxis protein (cheF) of H. pylori 
Purine-binding chemotaxis portein (cheW) of H. pylori 
Chemotaxis protein (cheV) of H. pylori 
Putative chemotaxis protein of H. pylori 
Chemotaxis protein (cheY) of H. pylori 
Methyl-accepting chemotaxis protein (tlpA) of H. pylori 
Methyl-accepting chemotaxis protein ( tlpB) of H. pylori 
Methyl- accepting chemotaxis protein of H. acinonychis 
Methyl- accepting chemotaxis protein of Campylobacter upsaliensis
 2 
Methyl- accepting chemotaxis protein of Campylobacter fetus subsp. fetus
 2 
Methyl- accepting chemotaxis protein of Methylibium petroleiphilum 
2 
Methyl-accepting chemotaxis sensory transducer Marinomonas sp.
2
 
99 (79) 
82 (86) 
98 (91) 
100 (92) 
100 (79) 
100 (95) 
100 (60) 
98 (63) 
100 (66) 
99 (53) 
99 (64) 
83 (52) 
57 (59) 
Adhesion HSUHS1_0666 
HSUHS1_0354 
HSUHS5_1053 
HSUHS5_0398 
Outer membrane protein (horB) of H. pylori 
Neuraminyllactose-binding hemagglutinin (hpaA) of H. acinonychis 
100 (63) 
94 (77) 
Oxidative 
stress 
resistance 
HSUHS1_1147 
HSUHS1_0549 
HSUHS1_0163 
HSUHS1_1186 
HSUHS1_0683 
HSUHS1_0689 
HSUHS5_0608 
HSUHS5_1206 
HSUHS5_0495 
HSUHS5_0005 
HSUHS5_0262 
HSUHS5_0268 
Catalase (katA) of H. acinonychis 
Mismatch repair ATPase (mutS) of H. hepaticus 
Superoxide dismutase (sodB) of H. pylori 
Bacterioferritin co-migratory protein of H. hepaticus 
NAD(P)H quinone reductase (mdaB) of Campylobacter fetus subsp. fetus 
Peroxiredoxin of H. pylori 
3
 
95 (82) 
99 (60) 
100 (90) 
99 (72) 
97 (68) 
100 (92) 
  
Table 2. H. suis strain 1 (HS1
T
) and strain 5 (HS5) homologs of H. pylori and other Helicobacter sp. type IV secretion system genes 
 
1
 Resulting from tblastn-based cross-mapping of the H. pylori proteome to the H. suis HS1
T
 and HS5 genomes and blastp-based ab initio analyses of the translated H. 
suis HS1
T
 and HS5 ORFs against the Uniprot-KB universal protein database. Differences between HS1
T
 and HS5 homologs ≤ 1%. 
Homolog Gene detected in 
HS1
T
 
Gene detected in 
HS5 
Description of corresponding 
protein 
Percentage of sequence 
fraction aligned (of which 
% conserved) with 
Helicobacter homolog
1
 
cag pathogenicity island 
   cag23/E of H. pylori  
   cagX of H. pylori 
 
HSUHS1_0731 
HSUHS1_0964 
 
HSUHS5_1234 
HSUHS5_0688 
 
DNA transfer protein 
Conjugal plasmid transfer protein  
 
81 (42) 
92 (71) 
comB system 
   comB2 of H. acinonychis 
   comB3 of H. acinonychis 
   comB6 of H. pylori 
   comB8 of H. pylori 
   trbL of H. pylori 
   comE of H. acinonychis 
   comL of H. pylori 
   dprA of H. acinonychis 
   recA of H. hepaticus 
 
HSUHS1_1181 
HSUHS1_1182 
HSUHS1_0337 
HSUHS1_0747 
HSUHS1_0755 
HSUHS1_0314 
HSUHS1_0722 
HSUHS1_0096 
HSUHS1_0672 
 
HSUHS5_0010 
HSUHS5_0009 
- 
Overlap with virB8 
HSUHS5_0054 
HSUHS5_0381 
HSUHS5_0300 
HSUHS5_0824 
HSUHS5_1058 
 
ComB2 protein 
ComB3 competence protein 
NADH-ubiquinone 
oxidoreductase 
comB8 competence protein 
TrbL protein 
Competence locus E 
Competence protein 
DNA processing protein 
Recombinase A 
 
96 (64) 
95 (77) 
70 (85) 
93 (66) 
99 (77) 
94 (55)  
99 (84) 
99 (70) 
97 (84) 
virB –homologs 
   virB4 of H. pylori 
   virB8 of H. pylori 
   virB9 of H. cetorum 
   virB10 of H. cetorum 
   putative virB9 of H. pylori 
   putative virB10 of H. pylori 
   virB11 of H. pylori 
   virB11 of H. cetorum 
   virB11-like of H.pylori (HPSH_04565) 
   virB11-like of H.pylori (HPSH_07250) 
 
HSUHS1_0960 
HSUHS1_0963 
HSUHS1_0319 
HSUHS1_0320 
- 
- 
HSUHS1_0750 
HSUHS1_0965 
- 
HSUHS1_0036 
 
HSUHS5_0692 
HSUHS5_0689 
- 
- 
HSUHS5_0372 
HSUHS5_0371 
HSUHS5_0368 
- 
HSUHS5_0686 
HSUHS5_0600 
 
DNA transfer protein 
DNA transfer protein 
VirB9 protein 
VirB10 protein 
Putative VirB9 protein 
Putative VirB10 protein 
VirB11 protein  
VirB11 protein 
VirB11-like protein  
Type IV ATPase  
 
98 (68) 
91 (61) 
76 (69) 
90 (77) 
100 (86) 
97 (87) 
100 (98) 
95 (71) 
98 (72) 
100 (75) 
virD – homologs 
   virD2 of H. cetorum 
   virD4 of H.pylori 
 
HSUHS1_0752 
HSUHS1_0870 
 
HSUHS5_0414 
HSUHS5_0257 
 
VirD2 protein (relaxase) 
VirD4 protein (conjugation protein) 
 
100 (90) 
82 (78) 
  
Table 3. Homologs of H. pylori genes involved in induction of gastric lesions in the H. suis type strain 1 (HS1
T
) and strain 5 (HS5) 
genome 
 
1
 Resulting from tblastn-based cross-mapping of the H. pylori proteome to the H. suis HS1
T
 and HS5 genomes. 
Gene detected in 
HS1
T
 
Gene detected in 
HS5 
Gene 
name 
Protein annotation/function  
in H. pylori 
Sequence fraction 
HS1
T
/HS5 aligned with 
H. pylori homolog (%)
1
 
Aligned sequence 
fraction HS1
T
/HS5 
conserved with H. 
pylori homolog (%)
1
 
References 
HSUHS1_0989 HSUHS5_0761 vacA Vacuolating cytotoxin A: host 
cell vacuolation, apoptosis-
inducing, immunosuppresive 
63/22 45/72 (Gebert et al., 2004) 
HSUHS1_0265 HSUHS5_0449 ggt γ-glutamyl transpeptidase: 
apoptosis-inducing, 
immunosuppresive 
99/99 86/86 (Shibayama et al., 
2003; Kim et al., 2007; 
Schmees et al., 2007) 
HSUHS1_1177 HSUHS5_0014 napA Neutrophil-activating protein A: 
proinflammatory 
99/99 83/83 (Brisslert et al., 2005; 
Wang et al., 2008) 
HSUHS1_1067 HSUHS5_1177 fldA Electron acceptor of the 
pyruvate oxidoreductase enzyme 
complex, associated with gastric 
MALT lymphoma in humans 
96/98 84/83 (Chang et al., 1999; 
Freigang et al., 2001) 
HSUHS1_0403 HSUHS5_0887 pgbA Plasminogen-binding protein 60/60 72/72 (Ljung, 2000;  
Jönssen et al., 2004) 
HSUHS1_1192 HSUHS5_0523 pgbB Plasminogen-binding protein 70/70 72/72 (Ljung, 2000;  
Jönssen et al., 2004) 
  
Additional file 
Additional file 1. Classification of H. suis strain 1 (HS1
T
) and strain 5 (HS5) outer membrane proteins (OMPs) in relation to H. pylori OMPs 
OMP family Gene detected in 
HS1
T
 
Gene detected in 
HS5 
Percentage of sequence fraction aligned (of which 
% conserved) with H. pylori homolog
1
 
1. Hop-related OMPs 
   HopE 
   HopG-2 
   HopH
2
 
   HopW protein precursor 
 
HSUHS1_0015 
HSUHS1_0180 
HSUHS1_0340 
HSUHS1_1105 
 
HSUHS5_0838 
HSUHS5_1092 
HSUHS5_0513 
- 
 
99 (57) 
92 (79) 
83 (49) 
90 (71) 
2. Hor-related OMPs 
   HorA 
   HorB 
   HorC 
   HorD 
   HorE 
   HorF 
   HorJ 
   HorL 
 
- 
HSUHS1_0666 
HSUHS1_0472 
HSUHS1_0202 
HSUHS1_1144 
- 
HSUHS1_0188 
- 
 
HSUHS5_1252 
HSUHS5_1053 
HSUHS5_0483 
HSUHS5_0115 
- 
HSUHS5_0133 
HSUHS5_0782 
HSUHS5_0611 
 
100 (52) 
100 (63) 
99 (63) 
91 (77) 
96 (64) 
85 (76) 
99 (53) 
93 (67) 
3. Hof-related OMPs 
   HofA 
   HofC 
   HofE 
   HofF 
   Hof-family OMP 
 
HSUHS1_0120 
HSUHS1_0181 
HSUHS1_0179 
HSUHS1_0178 
HSUHS1_0182 
 
HSUHS5_0671 
HSUHS5_1091 
HSUHS5_1093 
HSUHS5_1094 
HSUHS5_1090 
 
93 (74) 
99 (73) 
98 (61) 
95 (85) 
95 (84) 
4. Iron-regulated OMPs 
   Iron(III) dicitrate transport protein (FecA) 
   Iron(III) dicitrate transport protein (FecA) 
   Iron-regulated OMP (FrpB) 
 
HSUHS1_0092 
HSUHS1_1124 
HSUHS1_1106 
 
HSUHS5_0819 
HSUHS5_1010 
HSUHS5_0783 
 
100 (89) 
96 (76) 
99 (79) 
5. Efflux pump OMPs 
   Omp of the hefABC efflux system (HefA)    
   Membrane fusion protein of the hefABC efflux system (HefB) 
   Cytoplasmic pump protein of the hefABC efflux system 
(HefC) 
 
HSUHS1_0643 
HSUHS1_0644 
 
HSUHS1_0645 
 
HSUHS5_1029 
HSUHS5_1030 
 
HSUHS5_1031 
 
82 (77) 
92 (79) 
 
100 (78) 
  
6. Unclassified OMPs3 
   Omp11 of H. pylori 
   Omp29 of H. pylori 
   Putative Omp of H. pylori (HPSH_03820) 
   Putative Omp of H. pylori (HP_1525) 
   Putative Omp of H.pylori (HPSH_03230) 
   Putative Omp of H. pylori (jhp_0368) 
   Putative Omp of H. pylori (jhp_0370) 
   Putative Omp of H. pylori (HP_1056) 
   Putative Omp of H. pylori (HPSH_02040) 
   Putative Omp of H. pylori (HPSH_02045) 
 
- 
HSUHS1_0008 
HSUHS1_0646 
HSUHS1_1135 
HSUHS1_0446 
HSUHS1_0585 
HSUHS1_0583 
HSUHS1_0584 
- 
- 
 
HSUHS5_1235 
HSUHS5_1251 
HSUHS5_1032 
HSUHS5_0620 
HSUHS5_0930 
- 
- 
- 
HSUHS5_0158 
HSUHS5_0156 
 
99 (68) 
94 (46) 
100 (58) 
94 (72) 
96 (56) 
100 (67) 
95 (84) 
74 (69) 
75 (66) 
95 (59) 
 
1
 Resulting from tblastn-based cross-mapping of the H. pylori proteome to the H. suis HS1
T
 and HS5 genomes and blastp-based ab initio analyses of the translated H. 
suis HS1
T
 and HS5 ORFs against the Uniprot-KB universal protein database. Differences between HS1
T
 and HS5 homologs ≤ 1%. 2 99 amino acid HopH of H. pylori 
strain Shi 470 (HPSH_03675). 
3
 Predicted OMPs based on their N-terminal pattern of alternating hydrophobic amino acids similar to porins.
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Abstract 
Helicobacter (H.) suis is a porcine and human gastric pathogen. Previous studies in mice showed 
that a H. suis infection does not result in protective immunity, whereas immunization with H. suis 
whole-cell lysate (lysate) protects against a subsequent experimental infection. Therefore, two-
dimensional gel electrophoresis of H. suis proteins was performed followed by immunoblotting 
with pooled sera from H. suis- infected mice or mice immunized with lysate. Weak reactivity 
against H. suis proteins was observed in post-infection sera. Sera from lysate-immunized mice, 
however, showed immunoreactivity against a total of 19 protein spots which were identified 
using LC-MS/MS. The H. suis urease subunit B (UreB) showed most pronounced reactivity 
against sera from lysate-immunized mice and was not detected with sera from infected mice. 
None of the pooled sera detected H. suis neutrophil-activating protein A (NapA). The protective 
efficacy of intranasal vaccination of BALB/c mice with H. suis UreB and NapA, both 
recombinantly expressed in Escherichia coli (rUreB and rNapA, respectively), was compared 
with that of H. suis lysate. All vaccines contained choleratoxin as adjuvant. Immunization of 
mice with rUreB and lysate induced a significant reduction of H. suis colonization compared to 
non-vaccinated H. suis-infected controls, whereas rNapA had no significant protective effect. 
Probably, a combination of local Th1 and Th17 responses, complemented by antibody responses 
play a role in the protective immunity against H. suis infections. 
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Introduction 
Helicobacter (H.) suis is a world-wide spread pathogen, mainly colonizing pigs. An infection 
with this Gram-negative bacterium has been associated with ulcers of the gastric non-glandular 
mucosa (Roosendaal et al., 2000; Haesebrouck et al., 2009) and causes gastritis and decreased 
daily weight gain (De Bruyne et al., 2012) in pigs. H. suis is also the most prevalent non-
Helicobacter pylori Helicobacter species in humans suffering from gastric disorders 
(Haesebrouck et al., 2009)  and pigs may serve as a source of H. suis infections for humans 
(Meining et al., 1998; Haesebrouck et al., 2009). Control of H. suis infections by antibiotic-based 
therapy is not recommended partly due to an increased risk of developing acquired antimicrobial 
resistance in H. suis strains and in bacteria belonging to the normal porcine microbiota 
(Vermoote et al., 2011b). Immunization against H. suis may therefore represent a valuable 
alternative. Up to now, however, few studies have dealt with vaccination against this porcine and 
zoonotic pathogen. 
Previous studies in a mouse model showed that a H. suis infection does not result in protective 
immunity, whereas vaccination based on homologous (H. suis) or heterologous (H. bizzozeronii 
or H. cynogastricus) whole-cell lysate induced a reduction or even complete clearance of gastric 
colonization with H. suis (Flahou et al., 2009). However, the use of this type of vaccines has 
drawbacks, including the laborious in vitro culture of H. suis, which results in difficulties to 
produce sufficient antigen. Also, whole-cell lysates may contain both protective antigens and 
antigens suppressing protection (Haesebrouck et al., 2004). An effective subunit vaccine might be 
a useful alternative for control of H. suis infections. Immunoproteomics is an appropriate 
approach for rapid identification of candidate proteins for vaccination and has been applied to 
study and develop subunit vaccines for a wide range of pathogens (Adamczyk-Poplawska et al., 
2011). 
It was the aim of the present study to select H. suis proteins which might induce protective 
immunity against H. suis infection. Therefore, H. suis proteins recognized by sera of mice 
immunized with H. suis whole-cell lysate and protected against infection were identified by using 
two-dimensional (2D) gel electrophoresis followed by immunoblotting and LC-MS/MS. Sera of 
H. suis- infected mice were also included, since an infection does not result in protection. Based 
on this analysis, the immunoreactive H. suis urease subunit B (UreB) was selected for further in 
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vivo testing. As a control we included the H. suis neutrophil-activating protein A (NapA), which 
has been previously described as a possible virulence factor (Vermoote et al., 2011a) but was not 
recognized by sera of mice immunized with whole-cell lysate. Subsequently, the protective 
efficacy against a H. suis infection of both subunit vaccines was evaluated and compared with 
that of H. suis lysate in a standardized mouse model. 
 
Materials and methods 
Bacterial strain 
In all experiments, H. suis strain 5 (HS5, GenBank: ADHO00000000) was used. This strain was 
isolated from the gastric mucosa of a pig according to the method described by Baele et al. 
(2008). 
Animals 
One week prior to the initiation of the experiments, five-week-old specific-pathogen-free female 
BALB/c mice were obtained from an authorized breeder (HARLAN, Horst, The Netherlands). 
The animals were housed on sterilized wood shavings in filter top cages. They were fed with an 
autoclaved commercial diet (TEKLAD 2018S, HARLAN) and received autoclaved water ad 
libitum. All laboratory animal experiments were approved by the Animal Care and Ethics 
Committee of the Faculty of Veterinary Medicine, Ghent University. 
Immunoproteomics of H. suis 
Two-dimensional gel electrophoresis (2D-PAGE) 
HS5 was grown as described previously (Flahou et al., 2010). Bacteria were harvested by 
centrifugation (5000 g, 4 °C for 10 min) and washed four times with Hank’s balanced salt 
solution (HBSS). Total proteins (both soluble and insoluble proteins) were extracted in two steps 
using the ReadyPrep™ Sequential Extraction Kit (Bio-Rad, Hercules, CA, USA) according to 
manufacturer’s instructions. In order to obtain good 2D-PAGE results, the homogenates were 
treated with proper additives (5 mg protease inhibitor cocktail, 1 µL DNAse I, 1 µL RNAse A, 
10 µL phosphatase inhibitors PP2 and PP3 (Sigma-Aldrich, Steinheim, Germany)). Finally, the 
protein concentration was determined using the RC DC Protein Assay (Bio-Rad) and proteins 
were stored at -70 °C till further use. A total of 100 µg of HS5 proteins were rehydrated in 
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200 µL rehydration buffer (7M ureum, 2M thioureum, 2% CHAPS, 0.2% carrier ampholyte pH3-
4, 100mM dithiothreitol (DTT) and bromophenol blue). Samples were passively absorbed into a 
ReadyStrip (11 cm, pH3 to pH10, Bio-Rad) and iso-electric focusing was carried out in a Protean 
IEF Chamber (Bio-Rad) as previously described (Van Steendam et al., 2010). After iso-electric 
focusing, the strips were equilibrated for 15 min in 1.5% DTT in equilibration buffer (50mM 
TrisHCl, pH 8.8 6M urea, 20% glycerol, 2% SDS) followed by another equilibration in 4% 
iodoacetamide in equilibration buffer. Gel electrophoresis was carried out on a 10% TrisHCl 
SDS-PAGE using 150V for 30 min, followed by 200V for 1 h. Two gels were run in parallel: one 
was stained with Sypro
®
 Ruby Protein Gel staining (Bio-Rad) while the other was used for 
immunoblotting (see Western blotting described below). Prior to staining, gels were fixed in 10% 
MeOH, 7% acetic acid. After staining, H. suis proteins were visualized using the VersaDoc 
Imaging System (Bio-Rad). 
Serum pools 
Three pools of mouse sera were used in this study: 
 Sera from mice immunized with H. suis whole-cell lysate (hereafter referred to as “lysate-
immunized mice”) (n = 10). These animals were inoculated intranasally twice with three 
weeks interval with 100 µg HS5 lysate + 5 µg cholera toxin (CT) (List Biological 
Laboratories Inc., Madison, NJ, USA). HS5 lysate was prepared as described previously 
but without final filtration of the supernatant (Flahou et al., 2009). Three weeks after the 
last immunization, blood was collected and sera were pooled. This immunization protocol 
has been shown to be (partially) protective against H. suis challenge (Flahou et al., 2009) 
and the protective effect was confirmed here in a preliminary experiment (data not 
shown). 
 Sera from H. suis-infected mice (hereafter referred to as “infected mice”) (n = 10). These 
animals were inoculated intragastrically with 200 µL Brucella broth at pH 5, containing 
10
8
 freshly prepared H. suis bacteria (Flahou et al., 2010). Four weeks after infection, 
blood was collected and sera were pooled. 
 Sera from negative control mice (n = 10). These animals received HBSS intranasally 
twice with a three weeks interval followed by intragastric inoculation with 200 µL 
Brucella broth at pH5 (4 weeks after last sham immunization). After four weeks, blood 
was collected and sera were pooled. 
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All sera were stored at -70 °C until further use. 
Western blotting 
Proteins were electrotransferred from gels onto nitrocellulose membranes (Bio-Rad) as described 
elsewhere (Van Steendam et al., 2010). Membranes were blocked in 5% skimmed milk in 
phosphate buffered saline (PBS) (blocking buffer), incubated overnight (ON) with diluted mouse 
sera (1/100 in blocking buffer) at room temperature (RT), rinsed in PBS with 0.3% Tween-20 
(wash buffer) and incubated for 1 h at RT with stabilized goat anti-mouse immunoglobulin G 
(IgG) horseradish-peroxidase (HRP)-conjugated (1/1000 in blocking buffer, Pierce, Rockford, IL, 
USA). After a wash step in wash buffer, immunodetection of proteins was performed by 
enhanced chemiluminescence detection using Supersignal West Dura Extended Duration 
Substrate (Pierce). Protein patterns were scanned and digitized using the VersaDoc Imaging 
System. All experiments were performed in triplicate. 
In-gel protein digestion and identification by mass spectrometry 
In-gel digestion of proteins was performed as described by Cheung et al. (2009). Prior to mass 
spectrometry the isolated peptides were separated on a U3000 nano-high-performance liquid 
chromatography (HPLC) (Dionex, Sunnyvale, CA, USA) as previously described (Van Steendam 
et al., 2012). 
Identification of the peptides was performed using an electrospray ionization quadrupole time-of-
flight mass spectrometry (ESI-Q-TOF) Ultima (Waters, Milford, MA, USA) as described 
previously (Van Steendam et al., 2012). Data analysis was performed against the Helicobacter 
protein database from NCBI (146 612 entries) using the in-house search engine Mascot Daemon 
(2.3, Matrix Science, London, UK). An error tolerant search was performed with 
carbamidomethyl (C) as fixed modification. Carbamidomethyl (N-terminal) and oxidation (M) 
were set as variable modifications. Peptide mass tolerance and fragment mass tolerance was set at 
0.35 Da and 0.45 Da, respectively. Maximum two miscleavages were allowed. Proteins were 
only considered to be correctly annotated when the significance was below 0.05 (p < 0.05) and at 
least one peptide passed the required bold red criteria from Mascot Daemon, indicating that at 
least one peptide had rank 1 and a significance below 0.05. 
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One-dimensional gel electrophoresis (1D-PAGE) and Western blotting of rUreB  
1D-PAGE of 10 µg recombinant H. suis urease subunit B (rUreB) was performed as described by 
Van Steendam et al. (2010). Sera preparation and Western blot analyses were performed as 
described above. 
Protective efficacy of recombinant H. suis proteins in a mouse model 
Preparation of recombinant UreB 
A fragment encoding the H. suis UreB sequence (GenBank locus tag HSUHS5_0285) was 
amplified by PCR using a Pwo polymerase with proofreading activity (Roche, Mannheim, 
Germany) from the DNA of HS5 (forward primer: 5’- ATG AAA AAA ATC TCT AGG AAA 
GAA TAT G -3’; reverse primer: 5’- CTA GTG ATG GTG ATG GTG ATG GAA CAA GTT 
GTA GAG TTG AGC -3’) and cloned into the protein expression vector pET-24d. The rUreB 
was expressed in E. coli strain BL21 (DE3). The cells were lyzed by sonication (5 times for 30 s) 
in buffer containing 50mM Na.PO4 pH7, 0.5M NaCl, 1M DTT, 1% Triton X-100 and 1mM 
PMSF. After centrifugation (4 °C, 20 000 g for 30 min), rUreB was purified from the soluble 
fraction using Ni-affinity chromatography in buffer consisting of 1M NaCl, 50mM PBS, 1% 
Triton X-100, 250mM imidazole and 10% glycerol (His GraviTrap, GE Healthcare Bio-Sciences 
AB, Uppsala, Sweden) followed by gel filtration on a Superdex™ 200 HR 16/60 column (GE 
Healthcare Bio-Sciences AB). After purification, rUreB was analyzed using SDS-PAGE and 
Western blot analysis using anti-hexahistidine-tag mouse monoclonal antibody (Icosagen Cell 
Factory, Tartu, Estonia). The detergent Triton X-100 was removed from the purified rUreB by 
using Pierce Detergent Removal Spin columns (Pierce) following manufacturer’s instructions. 
Protein concentration was determined with the RC DC protein Assay (Bio-Rad). 
Preparation of recombinant NapA 
The protein was expressed in the E. coli Expression System with Gateway
®
 Technology 
(Invitrogen, Carlsbad, CA, USA) as follows. A fragment encoding the H. suis neutrophil-
activating protein A (NapA) sequence (GenBank locus tag HSUHS5_0014) was amplified by 
PCR using a Pwo polymerase with proofreading activity (Roche) from the DNA of HS5 (forward 
primer: 5’- CACCATG AAAGCAAAAACAGTTGATGTACTC -3’; reverse primer: 5’- 
TTAAGCCAAACTTGCCTTAAGCATCC -3’) and cloned into the pENTR™/TEV/D-TOPO® 
vector and transferred into the pDEST17™ destination vector. The selected pDEST17-NapA 
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plasmid was transformed to the BL21-AI™ E. coli and subsequently grown at 37 °C to an OD600 
of 0.6-1.0 in Luria Broth supplemented with 50 µg/mL carbenicillin. Recombinant H. suis NapA 
(rNapA) expression was induced by adding 0.2% L- arabinose. After 4 h incubation at 37 °C, the 
cells were harvested and resuspended in lysis buffer: 50mM TrisHCl, 100mM NaCl, 1% Triton 
X-100, 0.2 mg/mL lysozyme, 20 µg/mL DNAse, 1mM protease inhibitor (Sigma), and 1mM 
MgCl2. The cells were lyzed by sonication (5 times for 30 s). Cell debris and inclusion bodies 
were isolated by centrifugation at 4 °C (20 000 g for 30 min). The inclusion bodies were 
subsequently washed twice based on the following protocol: the pellet was resuspended in cold 
lysis buffer, sonicated 5 times for 30 s followed by centrifugation (4 °C, 20 000 g for 30 min). 
The washed inclusion bodies were solubilized in binding buffer, pH8 (6M guanidium HCl, 
20mM TrisHCl, 0.5M NaCl, 5mM imidazole, 1mM β-mercaptomethanol) by gentle rotation for 
1 h at RT. Insoluble material was removed by high speed centrifugation at 4 °C (100 000 g for 
30 min). rNapA was purified from the clarified supernatant onto a Ni-sepharose column (His 
GraviTrap, GE Healthcare Bio-Sciences AB) according to the manufacturer’s instructions. 
rNapA was eluted with elution buffer, pH8 (8M urea, 20mM TrisHCl, 0.5M NaCl, 0.5M 
imidazole, and 1mM β-mercaptoethanol) and ON dialyzed against PBS at 4 °C. Afterwards, 
rNapA was analyzed using SDS-PAGE and protein concentration was determined using RC DC 
Protein Assay (Bio-Rad). 
Immunization and infection experiments 
The experimental design is summarized in Figure 1. Five groups of 10 mice were intranasally 
inoculated twice with 3 weeks interval, each time with 17.5 µL inoculum. In groups 1, 2 and 3 
the inoculum consisted of HBSS with 5 µg CT, containing 30 µg rUreB, 30 µg rNapA and 
100 µg HS5 lysate, respectively. Groups 4 (sham-immunized group) and 5 (negative control 
group) were inoculated with HBSS. Three weeks after the second intranasal immunization, blood 
was collected by tail bleeding from five animals per group and one week later, all animals, except 
the negative control group, were inoculated intragastrically with 200 µL Brucella broth at pH 5 
containing 10
8
 viable H. suis bacteria (Flahou et al., 2010). The negative control group was 
inoculated intragastrically with 200 µL Brucella broth at pH5. Four weeks after the intragastric 
inoculation, mice were euthanized by cervical dislocation following isoflurane anaesthesia 
(IsoFlo; Abbott, IL, USA). From the euthanized animals, blood was collected by sterile cardiac 
puncture, centrifuged (1000 g, 4 °C, 10 min) and serum was frozen at -70 °C until further use. 
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Stomachs were excised and dissected along the greater curvature. One-half of the stomachs, 
including antrum and fundus, was immediately placed into 1 mL RNA Later (Ambion, Austin, 
TE, USA) and stored at -70 °C for further RNA- and DNA-extraction. A longitudinal strip of the 
gastric tissue was cut from the oesophagus to the duodenum along the greater curvature for 
histopathological examination. 
 
Figure 1. Experimental design of vaccination study. Per group 10 mice were intranasally immunized 
twice with 3 weeks interval, each time with 30 µg rUreB + 5 µg cholera toxin (CT); 30 µg rNapA + 5 µg 
CT, and 100 µg HS5 lysate + 5 µg CT (groups 1, 2 and 3, respectively). Groups 4 (sham-immunized 
group) and 5 (negative control group) were intranasally inoculated with HBSS. Three weeks after the 
second immunization, blood was collected from 5 mice per group and one week later mice of groups 1, 2, 
3 and 4 were intragastrically inoculated with 10
8
 viable H. suis bacteria. Group 5 was intragastrically 
inoculated with 200 µL Brucella broth at pH5. Four weeks after intragastric challenge, mice were 
euthanized. 
 
Quantification of H. suis in the stomach 
After thawing, stomach tissues were homogenized (MagNAlyser, Roche, Mannheim, Germany) 
in 1 mL Tri Reagent
®
 RT (MRC, Brunschwig Chemie, Amsterdam, The Netherlands) and DNA 
was extracted from the inter- and organic phase according to Tri Reagent
®
 RT manufacturer’s 
instructions. The bacterial load in the stomach was determined using the previously described H. 
suis specific quantitative real-time PCR (qPCR) (Vermoote et al., 2011b). 
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Analysis of stomach cytokine response 
The expression levels of IFN-γ, IL-4, IL-10, IL-17 and TNF-α were assessed by qPCR using 
cDNA synthesized from stomach tissue as described previously (Flahou et al., 2012). The 
threshold cycle (Ct) values were normalized to the geometric mean of the Ct-values from the 
reference genes after which normalized mRNA levels were calculated using the 2
-∆ΔCt 
method 
(Livak and Schmittgen, 2001). 
Measurement of serum antibody responses by enzyme-linked immunosorbent assay (ELISA) 
The Protein Detector™ ELISA Kit (KPL, Gaithersburg, MD, USA) was used to evaluate rUreB-, 
rNapA-, and HS5 lysate specific IgG in serum. In brief, 96 well flat bottom plates (Nunc 
MaxiSorp, Nalge Nunc Int., Rochester, NY, USA) were coated with 2 µg/well of purified rNapA, 
1 µg/well of purified rUreB, or 1 µg/well of H. suis whole cell proteins diluted in 100 µL coating 
buffer (24 h, 4 °C). After blocking with 1% bovine serum albumin in PBS, 100 µL of 1/400 
diluted serum was added to each well. After further washing, 100 µL of HRP-labeled anti-mouse 
IgG (H+L) in a final concentration of 50 ng per well was added. Five minutes after adding 2,2'-
azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) peroxidase substrate solution, 
absorbance was read at 405nm (OD405nm). 
Histopathological examination 
The longitudinal gastric tissue strips were fixed in 4% phosphate buffered formaldehyde, 
processed by standard procedures and embedded in paraffin. For evaluation of gastritis, 
haematoxylin - eosin (HE) stained sections of 5 µm were blindly scored based on the degree of 
infiltrating lymphocytes, plasma cells and neutrophils, using a visual analog scale similar to the 
Updated Sydney System (on a scale of 0-3) (Dixon et al., 1996) with the following specifications 
for each gastritis score: 0 = no infiltration of mononuclear and/or polymorphonuclear cells; 
1 = mild diffuse infiltration of mononuclear and/or polymorphonuclear cells; 2 = moderate 
diffuse infiltration of mononuclear and/or polymorphonuclear cells and/or the presence of one or 
two inflammatory aggregates; 3 = marked diffuse infiltration of mononuclear and/or 
polymorphonuclear cells and/or the presence of at least three inflammatory aggregates. 
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Statistical analysis 
Normality and variance homogeneity of data was analyzed by using D’Agostino-Pearson and 
Shapiro-Wilk normality test. Significant differences in H. suis colonization and mRNA cytokine 
expression among groups were assessed by performing one-way ANOVA analysis. Bonferroni’s 
multiple comparison test was used as post-hoc when equal variances were assessed. Dunnett’s T3 
post-hoc test was used when no equal variances were assessed. OD405nm levels from ELISA and 
histological inflammation scores were compared by Kruskall-Wallis analysis, followed by a 
Mann-Whitney U test. For correlations between different variables, Spearman’s rho coefficient 
(ρ) was calculated. GraphPad Prism5 software (GraphPad Software Inc., San Diego, CA, USA) 
was used for all analyses. Statistically significant differences between groups were considered at 
p < 0.05. 
 
Results 
Immunoproteomics of H. suis 
H. suis proteins were separated on 2D-PAGE (Figure 2a). After 2D-immunoblotting with pooled 
sera from lysate-immunized (Figure 2b) or H. suis-infected animals (Figure 2c), a total of 19 
immunoreactive protein spots were selected. These spots were matched with the protein spots 
that could be seen in the parallel 2D-PAGE (Figure 2a). Little reactivity against H. suis proteins 
was observed in post-infection sera compared to the high reactivity against sera from lysate-
immunized mice. When the blot was probed with a pool of sera obtained from negative control 
mice, no specific immunoreactive protein spots were detected (Additional file 1). Spots of 
interest (n = 19) were cut out of the gel, digested and identified by means of LC-MS/MS analysis. 
The detailed results of these proteins are summarized in Table 1. Spots with the highest reactivity 
(spot 1 to 5) were identified as UreB. H. suis chaperonin GroEL, illustrated as spots 9 and 10 on 
Figure 2a, showed also strong hybridization with sera from lysate-immunized animals. 
Additionally, sera from lysate-immunized mice showed strong reactivity against the urease 
accessory protein (UreH) and the urease subunit A (UreA) (spots 15 to 19), which was less 
pronounced in the infected group. Weak reactivity against the major flagellin FlaA (spots 11 to 
13) was present in both blots. 
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Confirmation of serum reactivity against rUreB 
From the 2D-analysis, UreB showed distinct reactivity with sera from lysate-immunized mice, 
which was not observed in sera from non-immunized but infected mice. In order to confirm these 
data, a 1D-PAGE loaded with rUreB was performed, followed by immunodetection with sera 
from lysate-immunized and H. suis-infected mice. Reactivity was only detected in the immunized 
group and a distinct band was visible at ~ 63 kDa, which corresponds to the molecular weight of 
UreB (Additional file 2). 
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Figure 2. (see legend on next page) 
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Figure 2. H. suis 2D-proteome profile (A) and Western blots of a duplicate 2D-gel reacted with 
pooled sera of lysate-immunized mice (B) or of H. suis-infected mice (C). 100 µg of total protein 
extract of H. suis was separated by 2D-electrophoresis using linear pH3 to10 gradient in the first 
dimension and 10% TrisHCl SDS-PAGE in the second dimension. The separated proteins were detected 
by SYPRO
®
Ruby Protein staining. The boxed areas indicate where immunoreactive antigens were excised 
from the gel and subjected to LC-MS/MS. Identified proteins are indicated by the spot numbers given in 
Table 1. Boxes and numbers in red were identified as UreB. The position of molecular weight (MW) is 
given on the right, and the pH is given at the bottom.  
  
Table 1. Immunoreactive proteins of H. suis identified by LC-MS/MS 
Spot no.
1
 Protein name NCBI ID
2
 Gene pI
3
 MW
3
 
(kDa) 
No. matched 
peptides 
Mascot 
score
4
 
Cov. 
(%)
5
 
1 Urease subunit B  EFX42254 ureB 5.97 62.967 117 1589 72 
2 
 
Urease subunit B  
Threonyl-tRNA synthetase 
EFX42254 
EFX41598 
ureB 
thrS 
5.97 
6.34 
62.967 
69.315 
80 
7 
1042 
186 
58 
60 
3 Urease subunit B EFX42254 ureB 5.97 62.967 80 903 46 
4 Urease subunit B EFX42254 ureB 5.97 62.967 4 103 6 
5 Urease subunit B EFX42254 ureB 5.97 62.967 4 103 6 
6 30S ribosomal protein S1 
Quinone-reactive Ni/Fe hydrogenase, large 
subunit 
Urease of H. heilmannii 
EFX42427 
EFX41851 
 
AAA65722 
rpsA 
hydB 
 
8.29 
8.22 
 
8.86 
64.051 
64.943 
 
25.844 
23 
19 
 
8 
625 
520 
 
258 
28 
28 
 
26 
7 Methyl-accepting chemotaxis protein EFX43528  7.1 48.907 35 905 50 
8 Elongation factor G EFX41637 fusA 5.15 77.242 57 1066 55 
9 Chaperonin GroEL EFX42237 groEL 5.58 58.498 150 3085 78 
10 Chaperonin GroEL 
Urease subunit B 
EFX42237 
EFX42254 
groEL 
ureB 
5.58 
5.97 
58.498 
62.967 
135 
43 
2647 
682 
73 
41 
11 Flagellin A EFX41982 flaA 7.77 54.232 29 756 47 
12 Flagellin A EFX41982 flaA 7.77 54.232 57 1294 62 
13 Flagellin A 
Trigger factor 
EFX41982 
EFX42378 
flaA 
tig 
7.77 
5.13 
54.232 
49.587 
46 
12 
1085 
343 
63 
24 
14 Hydrogenase expression/formation protein 
Nicotinate-nucleotide pyrophosphorylase 
EFX41790 
EFX42191 
hypB 
nadC 
5.59 
6.46 
27.617 
30.591 
15 
11 
314 
219 
35 
25 
  
 
1 
Protein spot corresponding to position on gel and blots (see Figure 2). 
2 
NCBI: National Center for Biotechnology Information. 
3 
Theoretical isoelectric point (pI) and molecular weight (MW).  
4 
For Helicobacter data, Mascot scores greater than 40 are significant (p ≤ 0.05). 
5 
% of the protein sequence covered by the peptides identified. 
 
 7-alpha-hydroxysteroid dehydrogenase 
Conserved hypothetical secreted protein 
Hypothetical protein HSUHS5_0308 
Peroxiredoxin 
EFX41880 
EFX42511 
EFX42276 
EFX42277 
hdhA 6.62 
5.84 
5.47 
5.84 
28.246 
28.011 
29.471 
25.811 
6 
5 
9 
7 
186 
174 
171 
107 
24 
19 
24 
19 
15 Urease accessory protein EFX42255 ureH 6.79 30.447 4 106 13 
16 Urease subunit A EFX42255 ureA 7.79 27.389 24 270 55 
17 Urease subunit A EFX42255 ureA 7.79 27.389 28 112 45 
18 Urease subunit A EFX42255 ureA 7.79 27.389 57 418 69 
19 Urease subunit A EFX42255 ureA 7.79 27.389 75 568 73 
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Protective efficacy of recombinant H. suis proteins in a mouse model 
From the 2D-proteomics approach, H. suis UreB was found to show a high reactivity with sera 
from lysate-immunized mice. Therefore, this protein was selected for further in vivo analyses. In 
addition, the H. suis NapA was tested. NapA has been previously described as a possible 
virulence factor of H. suis (Vermoote et al., 2011a), but was not detected by sera of lysate-
immunized mice. 
During the immunization experiment but before intragastric challenge, one animal from the 
rUreB immunized group and two animals from the group immunized with lysate died. The 
protective efficacy of rUreB, rNapA and lysate is shown in Figure 3 and expressed as the number 
of H. suis copies detected by qPCR in the stomach of challenged mice. High levels of H. suis 
(> 10
5
 copies mg
-1
 stomach) were detected in the stomach of sham-immunized mice. Prophylactic 
immunization with rUreB induced a significant reduction in H. suis colonization compared to 
sham-immunized mice (p < 0.001). In contrast, immunization with rNapA did not induce a 
significant reduction (p = 0.14) in bacterial colonization. Immunization with lysate resulted in a 
significant reduction of the bacterial load (p < 0.001), and in 50% of the animals H. suis DNA 
was not detected by qPCR. A significant lower gastric bacterial load was observed in lysate-
immunized mice compared to rUreB- and rNapA-immunized mice (p < 0.01). 
                                 
                          
Figure 3. Protection against H. suis challenge after prophylactic intranasal immunization. Bacterial load is 
illustrated as log (10) of H. suis copies/mg stomach tissue. Individual mice are illustrated as dots around the mean 
(lines). DL: detection limit of 43.9 copies mg
-1
. Significant differences between immunized (rUreB, rNapA and 
lysate) and sham-immunized, infected animals are noted by *** p < 0.001. Results of negative controls were all 
situated below DL. 
Chapter 2 
111 
Stomach cytokine response 
mRNA expression levels of cytokines (IFN-γ, TNF-α, IL-4, IL-10, IL-17) in gastric tissue are 
illustrated in Figure 4. Expression of IL-17, a marker for a Th17 response, was increased 
(p < 0.05) in all immunized groups compared to sham-immunized mice. The IFN-γ response was 
significantly higher in rUreB- and lysate- immunized groups compared to the sham-immunized 
group (p < 0.05 and p < 0.01 respectively). Immunization with rNapA did not result in increased 
IFN-γ expression levels compared to sham-immunization (p > 0.05). When taking all groups 
inoculated intragastrically with H. suis into account (rNapA, rUreB, lysate and sham), a 
significant inverse correlation was observed between IL-17 and IFN-γ response on the one hand, 
and colonization on the other hand (ρ = -0.388 and ρ = -0.816, respectively, p < 0.05). IL-10 
expression levels in the lysate-immunized group were significantly lower (p < 0.05) compared to 
all other groups (rUreB, rNapA and sham). A significant correlation was observed between IL-10 
response and gastric colonization (p < 0.01, ρ = 0.427). IL-4 expression levels were higher in 
sham- and lysate-immunized groups compared to rNapA- and rUreB- immunized groups. This 
was significantly (p < 0.05) higher in lysate-immunized mice compared to rNapA-immunized 
mice. For TNF-α no significant differences in expression were observed between immunized and 
sham-immunized groups. 
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Figure 4. Fold change in cytokine gene expression level in the stomach relative to negative control 
animals. The stomach mRNA expression levels of cytokines (IL-4, IL-10, IL-17, IFN-γ and TNF-α) at 
final euthanasia were examined by qPCR. Data represent the normalized target gene amount relative to the 
negative control group which is considered 1. Data are shown as means ± standard error of mean. 
Significant differences between immunized (rUreB, rNapA and lysate) and sham-immunized, infected 
animals are noted by * p < 0.05 and ** p < 0.01. Significant differences between immunized groups are 
noted by bars and * p < 0.05. 
 
Specific serum antibody response before and after challenge 
Three weeks after the last immunization and at euthanasia, serum was prepared for analysis of the 
serum-IgG response against rNapA, rUreB, and lysate. Serum levels of anti- rNapA, - rUreB and 
- lysate IgG of mice immunized with respective antigens were significantly elevated compared to 
negative controls at 3 week post-immunization (Additional file 3) and to both negative controls 
and sham-immunized mice at final euthanasia (Figure 5). Mice immunized with lysate showed a 
rUreB-specific serum IgG response but no rNapA-specific response (Figure 5b and c). When 
taking all immunized groups into account (rNapA, rUreB and lysate), a significant inverse 
Chapter 2 
113 
correlation (ρ = -0.783, p < 0.001) between specific IgG and H. suis copies mg-1 stomach was 
observed. 
Figure 5. Serum antibody responses against lysate (A), rUreB (B) or rNapA (C) at euthanasia. The 
levels of specific IgG are shown as the mean OD405 nm + SD. * p < 0.05, *** p < 0.001. 
 
 
Histopathology 
The overall gastric inflammation scores are presented in Table 2. All negative control mice 
showed normal histomorphology with very little inflammatory cell infiltration in the gastric 
mucosa. Sham-immunized mice developed a weak to moderate gastric inflammation. In general, 
higher inflammation scores were observed in the fundus compared to the antrum. Mice 
immunized with lysate showed a weak to moderate gastric inflammation, which was not 
significantly different from that observed in sham-immunized infected mice (p > 0.3). Although 
not significant (p > 0.05), less severe inflammatory infiltration was observed in rNapA and 
rUreB-immunized mice compared to mice immunized with lysate and sham-immunized mice. 
 
  
Table 2. Gastric inflammation scores in mice after immunization and infection 
 
 
1
Shown are the number of animals per group with a specific overall inflammation score in antrum and/or fundus: animals vaccinated with rUreB (n 
= 9), rNapA (n = 10) or lysate (n = 8), sham-immunized and infected controls (n = 10) and negative controls (n = 10). 0, no infiltration of 
mononuclear and/or polymorphonuclear cells; 1, mild diffuse infiltration of mononuclear and/or polymorphonuclear cells; 2, moderate diffuse 
infiltration of mononuclear and/or polymorphonuclear cells and/or the presence of one or two inflammatory aggregates; 3, marked diffuse 
infiltration of mononuclear and/or polymorphonuclear cells and/or the presence of at least three inflammatory aggregates. 
 
 
Group Inflammation score fundus
1
 Inflammation score antrum
1
 Overall mean inflammation score/group 
0 1 2 3 0 1 2 3  
rUreB 
rNapA 
Lysate 
Sham-immunized 
Negative control 
1 
4 
1 
1 
10 
6 
6 
4 
5 
0 
2 
0 
3 
4 
0 
0 
0 
0 
0 
0 
7 
8 
2 
5 
10 
2 
2 
5 
5 
0 
0 
0 
1 
0 
0 
0 
0 
0 
0 
0 
0.66 
0.40 
1.06 
0.90 
0.00 
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Discussion 
We previously demonstrated that immunization with H. suis whole-cell lysate protected mice 
against a subsequent experimental H. suis infection and resulted in high serum anti-H. suis IgG 
titers (Flahou et al., 2009). A H. suis infection, on the other hand, did not result in protective 
immunity, whereby significantly lower serum IgG titers were observed compared to H. suis 
protected animals (Flahou et al., 2009). In order to identify possible vaccine candidates, 2D-gel 
electrophoresis of H. suis proteins was performed followed by immunoblotting with pooled sera 
from H. suis- infected mice or mice immunized with H. suis whole-cell lysate. To our knowledge, 
this is the first study describing the immunoproteome of H. suis. The UreB protein showed a 
pronounced reactivity against sera from immunized mice and was not detected with sera from 
infected mice (Figure 2b and c). This protein was therefore selected for further evaluation of its 
protective efficacy. We found that immunization with rUreB resulted in a significant reduction of 
H. suis colonization in the stomach. The urease protein is known to be crucial for the survival of 
gastric Helicobacter species (Eaton et al., 1991; Haesebrouck et al., 2009) and vaccination with 
its subunit B (either natural or recombinant) also induced partial protection against H. pylori, H. 
felis and H. heilmannii (Ferrero et al., 1994; Michetti et al., 1994; Kleanthous et al., 1998; 
Dieterich et al., 1999; Bégué et al., 2010). 
Vaccination with rUreB did not induce complete protection against an experimental H. suis 
infection. In contrast, a complete clearance was observed in 50% of mice immunized with whole-
cell lysate, which is in line with previously observed results (Flahou et al., 2009). Most probably, 
in order to obtain a degree of protection which is similar to or better than that induced by whole-
cell lysate, additional H. suis antigens will have to be included in subunit vaccines. The H. suis 
chaperonin GroEL (spots 9 and 10) is another protein that showed strong reactivity with sera 
from lysate-immunized mice and might therefore also be a candidate for inclusion in a subunit 
vaccine. Indeed, oral vaccination with H. pylori Hsp60 or E. coli GroEL induced a partial 
protection against H. pylori challenge (Ferrero et al., 1995; Yamaguchi et al., 2003). However, 
vaccination with this protein has also been associated with post-immunization gastritis 
(Yamaguchi et al., 2003). Additionally, it has been demonstrated that antibodies against H. pylori 
Hsp60 may be associated with gastric cancer and - inflammation in humans (Hayashi et al., 1998; 
Ishii et al., 2001; Tanaka et al., 2009). Other immunoreactive protein spots identified in this study 
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include UreA, UreH, FlaA, trigger factor, hydrogenase expression/formation protein, methyl-
accepting chemotaxis protein and elongation factor G. All these proteins have also been 
identified in immunoproteomic studies of H. pylori and seem to be essential for gastric 
colonization of this bacterium (Kimmel et al., 2000). Future research is needed to determine the 
protective efficacy and possible side effects of vaccination with (combinations of) these proteins. 
NapA has been recognized as a key modulator in H. pylori-induced gastritis (Brisslert et al., 
2005) and has been proposed as a protective antigen and promising vaccine candidate against H. 
pylori infections (Satin et al., 2000; Malfertheiner et al., 2008). In the present study, NapA was 
not recognized by the pooled sera from lysate-immunized mice and intranasal immunization with 
rNapA did not result in protection against H. suis challenge, although it induced anti-rNapA IgG. 
The reason for the different outcome in protection studies with this protein in H. suis and H. 
pylori remains unclear. Differences in vaccine preparations, adjuvants and experimental infection 
models used may play a role. Although the H. suis napA gene shows strong homology with its H. 
pylori equivalent (99% of sequence aligned, of which 83% conserved) (Vermoote et al., 2011a), 
the role of NapA in the pathogenesis of H. suis infections has not yet been determined and is not 
necessarily identical to that of H. pylori. 
Different immune mechanisms may be involved in protection induced by the vaccines tested 
here. Serum antibodies against rUreB or antigens present in H. suis lysate were detected in mice 
vaccinated with rUreB or lysate, respectively, while they were absent (rUreB) or remarkably 
lower in non-vaccinated, infected mice. In future studies it may be interesting to also determine 
IgA antibody titers locally produced in the stomach. The role of local and serum antibodies in 
protection against a Helicobacter infection is, however, controversial. Although several authors 
mentioned that they may play a role in protection (Czinn and Nedrud, 1991; Czinn et al., 1993; 
Blanchard et al., 1995; Lee et al., 1995;Ferrero et al., 1997; Jeremy et al., 2006), results of other 
studies indicate that prophylactic immunization against Helicobacter species does not require 
antibodies (Ermak et al., 1998; Blanchard et al., 1999). Whether circulating and/or local 
antibodies play a role in protection against H. suis infections may be determined by using 
antibody-deficient mice or by passive administration of serum antibodies (Czinn et al., 1993; 
Blanchard et al., 1995; Ermak et al., 1998; Blanchard et al., 1999; Keenan et al., 2000). 
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In mice vaccinated with rUreB or lysate, mRNA expression of IFN-γ, a signature Th1 cytokine, 
was significantly higher after challenge with H. suis compared to sham-immunized mice, and this 
was not demonstrated for rNapA-immunized, not protected mice. Moreover, a clear inverse 
correlation was observed between the bacterial load and IFN-γ mRNA expression levels. In non-
vaccinated mice, a H. suis infection does not induce a Th1 response and does not result in 
clearance of the infection (Flahou et al., 2012). This indicates that production of IFN-γ, elicited 
by immunization, could play a role in suppression and clearance of H. suis. 
Expression levels of IL-17 after challenge with H. suis were elevated in mice immunized with 
rUreB, rNapA and lysate, compared to sham-immunized mice and also for this cytokine, an 
inverse correlation with H. suis colonization was observed. In non-vaccinated mice, a H. suis 
infection mainly results in a Th17 response and a secondary Th2 response, which is not able to 
eradicate the infection although the Th17 response inversely correlates with bacterial load 
(Flahou et al., 2012). This might indicate that for a strong suppression or clearance of H. suis, a 
combined Th17 and Th1 response in the stomach is necessary, as was observed in the rUreB- and 
lysate-vaccinated groups. 
We observed that decreased expression levels of IL-10 were correlated with a reduction in gastric 
H. suis colonization. This is not entirely unexpected, since IL-10 is a suppressive cytokine for 
Th17 and Th1. Additionally, it has been shown that IL-10-deficient mice are able to eradicate H. 
pylori infection (Matsumoto et al., 2005). 
After infection with H. suis, expression of IL-4, a marker of a Th2 response, was higher in the 
lysate-immunized group than in groups vaccinated with rUreB and rNapA. Taken all results of 
the present study together, there are indications that in addition to a local Th1 and Th17 response, 
a Th2 response, probably resulting in local production of antibodies, may help to eradicate H. 
suis from the stomach. Indeed, only in the lysate-immunized group, mice were able to clear H. 
suis from the stomach. Further studies are, however, necessary to confirm this hypothesis. 
In lysate-immunized mice, H. suis colonization was significantly lower than in the other 
experimentally infected groups. However, histological examination revealed that the 
inflammatory response in this group was almost similar to that in sham-immunized, H. suis-
infected mice. For H. pylori too, a transient gastritis is often seen after challenge of immunized 
mice (Blanchard and Nedrud, 2010). It remains to be investigated whether gastritis levels of 
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lysate-immunized mice would drop below gastritis levels of sham-immunized animals after a 
longer period post challenge. 
In conclusion, sera from lysate-immunized, protected mice strongly react with H. suis UreB and 
immunization with this antigen induced a significant reduction in gastric H. suis colonization in 
challenged mice. Although rUreB is a promising antigen candidate for the use in vaccines against 
H. suis infections, further studies are necessary to elucidate if inclusion of additional H. suis 
antigens may improve the protective efficacy of subunit vaccines. Also, results obtained in this 
mouse model should be confirmed in pigs, which are the natural host of H. suis. Probably, a 
combination of local Th1 and Th17 responses, complemented by antibody responses play a role 
in the protective immunity against H. suis infections. The exact mechanism by which protection 
against a H. suis infection is mediated remains however to be elucidated. 
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Additional files 
 
Additional file 1. Immunodetection of a 2D-Western blot with a pool of control sera from H. suis-
negative mice. 
                                  
100 µg of H. suis total protein extract was separated by 2D-electrophoresis using linear pH3 to10 gradient 
in the first dimension and 10% SDS-PAGE in the second dimension. After transfer of the proteins onto a 
nitrocellulose membrane, the 2D-immunoblot was analyzed by reacting with a pool of control sera from 
10 H. suis-negative mice. No specific immunoreactive protein spots were detected. 
___________________________________________________________________________________ 
 
Additional file 2. 1D-PAGE immunoblotting of rUreB. 
                                                             
M: Protein marker. Lane 1 and 2: 10 µg rUreB separated on 10% TrisHCl SDS-PAGE and immunoblotted 
with serum of mice 3 weeks after immunization with H. suis whole-cell lysate (1) or with serum of H. 
suis-infected mice at four weeks post-infection (2). Both sera consisted of a pool of 10 animals. Only in 
serum of immunized animals (lane 1) immunoreactivity against rUreB is seen as a ~ 63 kDa band. 
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Additional file 3. Serum antibody responses against lysate, rUreB and rNapA at three weeks post- 
immunization. 
 
Mice were immunized twice with three weeks interval with 100 µg HS5 lysate plus 5 µg CT, 30 µg rUreB 
plus 5 µg CT or 30 µg rNapA plus 5 µg CT, respectively. Three weeks after the last immunization blood 
was collected and serum was prepared from 5 animals of each group. Data are shown as the mean OD405 nm 
+ SD. *** p < 0.001. 
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Abstract 
Helicobacter (H.) suis causes gastric lesions in pigs and humans. This study aimed to evaluate the 
protective efficacy of immunization with combinations of the H. suis urease subunit B (UreB) 
and γ-glutamyl transpeptidase (GGT), both recombinantly expressed in Escherichia coli (rUreB 
and rGGT, respectively). Mice were intranasally immunized with rUreB, rGGT or a combination 
of both proteins, administered simultaneously or sequentially. Control groups consisted of non-
immunized and non-challenged mice (negative controls), sham-immunized and H. suis-
challenged mice (sham-immunized controls), and finally, H. suis whole-cell lysate-immunized 
and H. suis challenged mice. Cholera toxin was used as mucosal adjuvant. All immunizations 
induced a significant reduction of gastric H. suis colonization, which was least pronounced in the 
groups immunized with rGGT and rUreB only. Consecutive immunization with rGGT followed 
by rUreB and immunization with the bivalent vaccine improved the protective efficacy compared 
to immunization with single proteins, with a complete clearance of infection observed in 50% of 
the animals. Immunization with whole-cell lysate induced a similar reduction of gastric bacterial 
colonization compared to rGGT and rUreB in combinations. Gastric lesions, however, were less 
pronounced in mice immunized with combinations of rUreB and rGGT compared to mice 
immunized with whole-cell lysate. In conclusion, vaccination with a combination of rGGT and 
rUreB protected mice against a subsequent H. suis infection and was not associated with severe 
post-vaccination gastric inflammation, indicating that it may be a promising method for control 
of H. suis infections. 
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Introduction 
Helicobacter (H.) suis is a worldwide spread bacterium causing chronic gastritis and reduced 
daily weight gain in pigs (De Bruyne et al., 2012). An infection with H. suis has also been 
associated with erosive and ulcerative lesions in the non-glandular part of the porcine stomach 
(Barbosa et al., 1995; Rossesendaal et al., 2000). Furthermore, this bacterium is the most 
prevalent non-H. pylori Helicobacter species colonizing the stomach of humans suffering from 
gastric disease (Haesebrouck et al., 2009). Previous studies in mice have shown that prophylactic 
intranasal immunization with H. suis whole-cell lysate results in significant protection against H. 
suis infections (Flahou et al., 2009; Vermoote et al., 2012). However, production of sufficient H. 
suis whole-cell lysate may be hindered by the laborious in vitro cultivation of this bacterium. 
Also, whole-cell lysates may contain both protective antigens and antigens suppressing protection 
(Haesebrouck et al., 2004). To overcome these drawbacks, a subunit vaccine, based on the H. suis 
urease subunit B (UreB) has been developed (Vermoote et al., 2012). Immunization with H. suis 
UreB, recombinantly expressed in E. coli (rUreB) only induced a partial protection against H. 
suis challenge in a mouse model and it has been suggested that inclusion of additional antigens 
might improve the protective efficacy of this subunit vaccine (Vermoote et al., 2012). 
In addition, immune modulating factors produced by the bacterium may hamper the development 
of a fully potent immune response against a H. suis infection, and thus may influence the 
effectiveness of certain vaccine formulations. Indeed, H. suis γ-glutamyl transpeptidase (GGT) 
has been shown to modulate the function of lymphocytes in vitro, which may result in host 
immune escape of H. suis leading to a chronic infection and lifelong persistence of H. suis in the 
porcine stomach (Zhang et al., unpublished data). Inhibition of this H. suis virulence factor by 
vaccination, may lead to an abrogation of its immune modulatory effect, enabling the 
development of a fully potent immune response against H. suis infection. 
The aim of the present study was to evaluate the protective efficacy of simultaneous or 
consecutive immunization with recombinant H. suis GGT (rGGT) and rUreB against H. suis 
infections, and to compare it with that of H. suis lysate and univalent vaccination in a 
standardized mouse model. 
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Materials and methods 
Bacterial strain 
H. suis strain 5 was used in all experiments. This strain was isolated from the gastric mucosa of a 
sow, according to the method described by Baele et al. (2008). 
Antigens for immunization 
Recombinantly expressed GGT (rGGT) was prepared as described previously (Flahou et al., 
2011). Briefly, HS5 DNA was used as template to PCR-amplify the ggt gene without predicted 
signal sequence, cloned into the pENTR™/SD/D-TOPO® vector and transferred into the 
pDEST™17 destination vector. Chemically competent E.coli BL21-AI™ cells were transformed 
and protein expression was induced with 0.2% L-arabinose. rGGT was purified by (His)6-tag 
affinity on a Ni-sepharose column (His GraviTrap; GE Healthcare Bio-Sciences AB) following 
manufacturer’s instructions. For further purification, the rGGT was loaded on a Superdex 75 gel 
filtration column (GE Healthcare Bio-sciences AB). Afterwards, rGGT was analyzed using 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and the GGT activity 
assay (Orlowski and Meiser, 1963). 
Recombinantly expressed UreB (rUreB) was prepared as described previously (Vermoote et al., 
2012). Briefly, a fragment encoding the HS5 UreB sequence was amplified by PCR and cloned 
into the protein expression vector pET-24d. The rUreB was expressed in E. coli strain BL21 
(DE3) and E. coli cells were lyzed by sonication in a buffer containing 50mM Na.PO4 pH7, 0.5M 
NaCl, 1M DTT, 1% Triton X-100 and 1mM PMSF. rUreB was purified using Ni-affinity 
chromatography in buffer consisting of 1 M NaCl, 50 mM PBS, 1% Triton X-100, 250 mM 
imidazole and 10% glycerol (His GraviTrap; GE Healthcare Bio-Sciences AB) followed by gel 
filtration on a Superdex™ 200 HR 16/60 column (GE Healthcare Bio-sciences AB). After 
purification, rUreB was analyzed using SDS-PAGE and Western-blot analysis using anti-
hexahistidine-tag mouse monoclonal antibody (Icosagen Cell Factory, Tartu, Estonia). The 
detergent Triton X-100 was removed from the purified rUreB by using Pierce Detergent Removal 
Spin columns (Pierce Biotechnology, Rockford, USA) following manufacturer’s instructions. 
H. suis whole-cell lysate (lysate) was prepared as described by Flahou et al. (2009), but without 
final filtration of the supernatant. The latter was done to prevent potential loss of antigens. 
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Protein concentrations were determined with the RC DC protein Assay (Bio-Rad, Hercules, CA, 
USA). 
Immunization and infection experiments 
One week prior to the initiation of the experiments, 70 five-week-old specific-pathogen-free 
female BALB/c mice were obtained from an authorized breeder (HARLAN, Horst, The 
Netherlands). The animals were housed on autoclaved wood shavings in filter top cages. They 
were fed an autoclaved commercial diet (TEKLAD 2018S, HARLAN) and received autoclaved 
water ad libitum. All experiments involving animals were approved by the Animal Care and 
Ethics Committee of the Faculty of Veterinary Medicine, Ghent University (EC2011/164). 
Immunization and infection experiments were performed as presented in Figure 1. Mice were 
divided over seven groups of 10 animals each. Groups 1, 2, 3, 5, 6 and 7 were intranasally 
inoculated twice with three weeks interval, with a total volume of 17.5 µl/ dose. In groups 1, 2, 3 
and 5, vaccine formulations consisted of Hank’s balanced salt solution (HBSS) with 5 µg cholera 
toxin (CT) (List Biological Laboratories Inc., Madison, NJ, USA), to which 30 µg rUreB, 30 µg 
rGGT, 30 µg rGGT + 30 µg rUreB, and 100 µg lysate had been added, respectively. Groups 6 
(sham-immunized group) and 7 (negative control group) received HBSS only. Mice from group 4 
were first immunized twice (with three weeks interval) with a vaccine consisting of HBSS, 5 µg 
CT and 30 µg rGGT. One week after the second immunization animals were immunized twice 
(with three weeks interval) with a vaccine consisting of HBSS, 5 µg CT and 30 µg rUreB. Three 
weeks after the last immunization, blood was collected by tail bleeding from five animals per 
group and one week later, all animals, except the negative control group, were intragastrically 
inoculated with 200 µL Brucella broth at pH 5 containing 10
8
 viable H. suis bacteria (Flahou et 
al., 2010). The negative control group was intragastrically inoculated with 200 µL Brucella broth 
at pH 5. Four weeks after the challenge with H. suis, mice were euthanized by cervical 
dislocation following isoflurane anaesthesia (IsoFlo; Abbott, IL, USA). Blood was collected by 
sterile cardiac puncture, centrifuged (1000 g, 4°C, 10 min) and serum was frozen at -70°C until 
further use. Stomachs were excised and dissected along the greater curvature. One-half of the 
stomachs, including antrum and fundus, was immediately placed into 1 mL RNA Later (Ambion, 
Austin, TE, USA) and stored at -70°C for further RNA- and DNA-extraction. A longitudinal strip 
of gastric tissue was cut from the oesophagus to the duodenum along the greater curvature for 
histopathological examination. 
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Figure 1. Experimental design of vaccination study. Per group 10 mice were intranasally immunized 
twice with 3 weeks interval, each time with 30 µg rUreB + 5 µg cholera toxin (CT), 30 µg rGGT + 5 µg 
CT, 30 µg rGGT + 30 µg rUreB + 5 µg CT, and 100 µg lysate + 5 µg CT (groups 1, 2, 3 and 5, 
respectively). Groups 6 (sham-immunized group) and 7 (negative control group) were intranasally 
immunized with HBSS. Mice from group 4 (rGGT→rUreB) were first intranasally immunized twice with 
3 weeks interval, each time with 30 µg rGGT and 5 µg CT. One week after the second immunization 
animals were immunized twice with 3 weeks interval with 30 µg rUreB + 5 µg CT. Three weeks after the 
last immunization, blood was collected by tail bleeding from 5 animals per group and one week later, all 
animals, except the negative control group, were intragastrically inoculated 10
8
 viable H. suis bacteria. 
The negative control group was intragastrically inoculated with 200 µL Brucella broth at pH5. Four weeks 
after challenge with H. suis, mice were euthanized. 
a 
I (x): Immunization of (number of group). 
 
Determination of the number of H. suis in the stomach 
After thawing, stomach tissues were homogenized (MagNAlyser, Roche, Mannheim, Germany) 
in 1 mL Tri Reagent
®
 RT (MRC, Brunschwig Chemie, Amsterdam, The Netherlands) and DNA 
was extracted from the inter- and organic phase according to Tri Reagent
®
 RT manufacturer’s 
instructions. The bacterial load in the stomach was determined using a previously described H. 
suis specific quantitative real-time PCR (qPCR) (Vermoote et al., 2011). 
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Stomach cytokine responses 
The mRNA expression levels of IFN-γ, TNF-α, IL-4, IL-10 and IL-17 were assessed by RT-
qPCR using cDNA synthesized from stomach tissue as described previously (Flahou et al., 2012). 
The threshold cycle (Ct) values were normalized to the geometric mean of the Ct-values from the 
reference genes after which normalized mRNA levels were calculated using the 2
-∆ΔCt 
method 
(Livak and Schmittgen, 2001). 
Serum antibody responses 
Anti-rUreB, -rGGT and -lysate serum immunoglobulin G (IgG) responses were assessed by using 
the Protein Detector™ enzyme-linked immunosorbent assay (ELISA) Kit (KPL, Gaithersburg 
MD, USA). Measurement of anti-rUreB and -lysate specific serum IgG was performed as 
previously described (Vermoote et al., 2012). In brief, 96 well flat bottom plates (Nunc 
MaxiSorp, Nalge Nunc Int., Rochester, NY, USA) were coated with 1 µg/well of purified rUreB, 
2 µg/well of purified rGGT, or 1 µg/well of H. suis whole cell proteins diluted in 100 µL coating 
buffer. After blocking with 1% bovine serum albumin in PBS, 100 µL of 1/400 diluted serum 
was added to each well. After further washing, 100 µL of HRP-labeled anti-mouse IgG (H+L) in 
a final concentration of 50 ng per well was added. Absorbance was read at 405nm (OD405nm). 
Histopathological examination 
Longitudinal strips of gastric tissue were fixed in 4% phosphate buffered formaldehyde, 
processed by standard procedures and embedded in paraffin. For evaluation of gastritis, 
haematoxylin - eosin (HE) stained sections of 5 µm were blindly scored based on the degree of 
infiltrating lymphocytes, plasma cells and neutrophils using a visual analog scale similar to the 
Updated Sydney System (on a scale of 0-3) (Dixon et al., 1996) with additional specifications for 
each score. The inflammation scores used in the grading system were as follows: 0, no infiltration 
with mononuclear and/or polymorphonuclear cells; 1, mild diffuse infiltration with mononuclear 
and/or polymorphonuclear cells; 2, moderate diffuse infiltration with mononuclear and/or 
polymorphonuclear cells and/or the presence of one or two inflammatory aggregates; 3, marked 
diffuse infiltration with mononuclear and/or polymorphonuclear cells and/or the presence of at 
least three inflammatory aggregates. 
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Statistical analysis 
Significant differences in H. suis colonization and mRNA cytokine expression among groups 
were assessed by performing one-way ANOVA analysis. Bonferroni’s multiple comparison test 
was used as post-hoc when equal variances were assessed. Dunnett’s T3 post-hoc test was used 
when no equal variances were assessed. OD405nm levels from ELISA were compared by Kruskall-
Wallis analysis, followed by a Dunn’s multiple comparison test. Histological inflammation scores 
were compared using the Mann-Whitney U test. For correlations between different variables, 
Spearman’s rho coefficient (ρ) was calculated. GraphPad Prism5 software (GraphPad Software 
Inc., San Diego, CA) was used for all analyses. Statistically significant differences between 
groups were considered at p < 0.05. 
 
Results 
Protective effect of immunizations against H. suis challenge 
All immunizations induced a significant reduction of gastric bacterial load compared to sham-
immunized infected mice (p < 0.05), albeit significantly less pronounced in the group solely 
immunized with rGGT compared to all other immunizations (p < 0.01) (Figure 2). Highest levels 
of protection were seen in animals immunized with the combination of rGGT+rUreB or with 
lysate, with a 10 000-fold and 1000-fold reduction, respectively, of H. suis numbers (expressed as 
median) in the stomachs, compared to non-immunized infected controls (p < 0.001). Although 
not significant (p > 0.05), an enhanced protective effect was observed in mice immunized with 
combinations of rGGT and rUreB compared to rUreB alone. Immunization with rUreB alone, 
lysate, rGGT+rUreB and the subsequent immunization of rGGT followed by rUreB resulted in 
33%, 50%, 57% and 44% of mice negative for H. suis DNA, respectively. Immunization with 
rGGT alone did not result in mice negative for H. suis DNA in the stomach. During the study 14 
animals died, and the mortality rate per group is shown in Additional file 1. 
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Figure 2. Protection against H. suis challenge after prophylactic immunization. Bacterial load per mg 
stomach tissue was determined for individual mice in each group by qPCR and is illustrated as dots with 
indication of median (horizontal lines) and range (vertical lines). The dotted line (DL) designates the 
detection limit of 41.8 copies/mg stomach tissue.* p < 0.05, *** p < 0.001 compared to non-immunized 
(sham) H. suis-challenged mice. Immunized groups which differed significantly (p < 0.01) are marked 
with different letters. rGGT→rUreB: group of mice which were sequentially immunized with rGGT and 
rUreB. 
 
Stomach cytokine responses 
mRNA cytokine expression levels (IFN-γ, TNF-α, IL-4, IL-10 and IL-17) in gastric tissue are 
presented in Figure 3. Significantly higher levels of IL-17 and INF-γ were observed in animals 
from all immunized groups, except in the group immunized with rGGT only, compared to sham-
immunized mice (p < 0.05). Increased levels of IL-17 and IFN-γ were significantly correlated 
with a decrease in bacterial load (p < 0.05, ρ = -0.513 and ρ = -0.2955, respectively). For IL-4, 
IL-10 and TNF-α no significant differences in mRNA expression levels were seen between 
groups after infection. However, mRNA expression levels of TNF- α were increased in all 
immunized groups, except in the group immunized with rGGT only, compared to non-immunized 
mice. In addition, a mild negative correlation was observed between gastric bacterial load and 
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TNF-α expression levels (p < 0.05, ρ = -0.349). Lower levels of IL-10 were observed in 
immunized animals, compared to sham-immunized mice (p > 0.05) and a mild positive 
correlation was observed between gastric bacterial load and IL-10 expression levels (p < 0.05, ρ = 
0.356). 
Figure 3. Fold change in cytokine gene expression levels in stomach tissue relative to negative 
control animals. * p < 0.05, ** p < 0.01, *** p < 0.001 compared to non-immunized (sham) H. suis-
challenged group. rGGT→rUreB: group of mice which were sequentially immunized with rGGT and 
rUreB. 
 
Humoral immune responses 
Three weeks after the last immunization, 1 week prior to challenge, specific serum anti-rUreB, 
anti-rGGT and anti-lysate IgG antibodies, were significantly increased in animals immunized 
with respective antigens compared to negative control mice (Additional file 2). Serum antibody 
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responses against H. suis lysate, rUreB and rGGT at euthanasia are shown in Figure 4. Negative 
controls and sham-immunized mice showed significantly lower anti-lysate, -rUreB and -rGGT 
serum IgG antibodies at euthanasia compared to groups vaccinated with lysate, -rUreB and/or -
rGGT, respectively. A weak, but significant (p < 0.05, ρ = -0.235) correlation was observed 
between decreased bacterial load and increased specific serum IgG. 
 
Figure 4. Serum antibody responses against H. suis lysate (A), rUreB (B) and rGGT (C) at 
euthanasia. Different groups are indicated by the bars with levels of specific IgG shown as the mean 
OD405nm + SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns: not significant. rGGT→rUreB: group of mice 
which were sequentially immunized with rGGT and rUreB. 
 
Histopathology 
Figure 5 provides the results of histopathological examination of the stomachs. Higher 
inflammation scores were observed in the fundus compared to the antrum (Fig 5A and B). All 
negative controls had a normal gastric histomorphology (score 0) and sham-immunized, infected 
mice showed a weak gastric infiltration of mononuclear and/or polymorphonuclear cells (Fig 5C, 
median score of 0.25). Most pronounced inflammation was observed in mice immunized with H. 
suis lysate (Fig 5C, median score of 1.13), followed by animals immunized with rUreB alone 
(Fig 5C, median score of 1.00), mice immunized with the bivalent vaccine of rGGT and rUreB 
(Fig 5C, median score of 0.75). Immunization with rGGT alone and consecutive immunization of 
rGGT and rUreB resulted in less gastric infiltration of mononuclear and/or polymorphonuclear 
cells compared to all other immunizations, with a median score of 0.50 (Fig 5C). Inflammation in 
the fundic region and the average inflammation score of animals sequentially immunized with 
rGGT and rUreB were significantly lower compared to lysate-immunized mice (p = 0.0033 and p 
= 0.0062, respectively). Lysate-immunized mice also showed significantly higher overall gastric 
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inflammation and more severe inflammation in the fundic region compared to sham-immunized 
mice (p = 0.016 and p = 0.013, respectively). Average gastritis scores of H. suis-challenged 
groups immunized with lysate, rUreB, rGGT and rGGT+rUreB (simultaneously administered) 
differed significantly from that of non-infected negative control mice (p < 0.05). 
  
Figure 5. Gastric inflammation scores per group. Scores in negative controls, immunized and non-immunized (sham) mice 4 weeks after 
challenge were determined in fundus (A) and antrum (B) using haematoxylin-eosin-stained gastric sections. Average of inflammation score 
of fundus and antrum (average inflammation score) were calculated for each animal per group (C). 0, no infiltration with mononuclear and/or 
polymorphonuclear cells; 1, mild diffuse infiltration with mononuclear and/or polymorphonuclear cells; 2, moderate diffuse infiltration with 
mononuclear and/or polymorphonuclear cells and/or the presence of one or two inflammatory aggregates; 3, marked diffuse infiltration with 
mononuclear and/or polymorphonuclear cells and/or the presence of at least three inflammatory aggregates. Gastric scores of individual mice per 
group are illustrated as dots with indication of median (horizontal lines) and range (vertical lines). * p < 0.05, ** p < 0.01, *** p < 0.001 compared 
to non-infected negative control group. a: significant difference in inflammation in fundic region between sham-immunized and lysate-immunized 
mice, p = 0.013. b: significant difference in inflammation in fundic region between lysate-immunized mice and mice sequentially immunized with 
rGGT and rUreB (rGGT→rUreB), p = 0.0033. c: significant difference in average inflammation score between sham-immunized and lysate-
immunized mice, p = 0.016. d: significant difference in average inflammation score between lysate-immunized mice and rGGT→rUreB 
immunized group, p = 0.0062. 
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Discussion 
In a recent study, we demonstrated that intranasal vaccination with rUreB alone resulted in a 
significant reduction of gastric H. suis colonization, although complete protection was not 
achieved (Vermoote et al., 2012). Therefore, the present study aimed to evaluate whether a 
combination of rUreB and rGGT could increase the vaccine efficacy. H. suis GGT is a secreted 
virulence factor that acts in a similar way as the H. pylori GGT. The enzyme causes a glutathione 
degradation-dependent epithelial cell death (Shimayama et al., 2003; Flahou et al., 2011). In 
addition, it inhibits the proliferation of T-cells and thus may prevent the generation of an 
effective host immune response (Schmees et al., 2007; Zhang et al., unpublished data). 
Although immunization with rUreB or rGGT alone induced a significant reduction of gastric H. 
suis colonization, consecutive or simultaneous immunization with both antigens was clearly more 
effective. The improved protective effect of vaccination with combinations of rGGT and rUreB 
compared to immunization with rUreB only, may be related to the consistent anti-GGT response, 
which might overcome immune evasion induced by this enzyme, enhancing clearance of the 
bacteria after challenge. Vaccination with H. suis rGGT alone seems, however, to be less 
effective than vaccination with rUreB alone. 
H. suis colonization in mice generally induces a predominant Th17 response, in combination with 
a less pronounced Th2 response (Flahou et al., 2012). Despite this clear immune response, H. suis 
persists in infected mice. In contrast to H. pylori infection, H. suis infection does not result in 
increased levels of IFN-γ, a signature Th1 cytokine (Flahou et al., 2012). In the present study, 
vaccinated and protected mice showed significantly increased IFN-γ mRNA levels after 
challenge compared to sham-immunized mice and the degree of protection was correlated with 
increased levels of IFN-γ. Increased expression levels of the pro-inflammatory cytokine, TNF-α 
were also correlated with decreased bacterial gastric colonization. This indicates that a Th1 
response may be involved in protective immunity against H. suis infection in mice. Indeed, we 
previously suggested that a combination of local Th17 and Th1 responses, complemented by 
antibody responses are involved in the protective immunity against H. suis infections (Vermoote 
et al., 2012). Also in this study the degree of protection was correlated with increased levels of 
IL-17, a marker of Th17 response, and specific serum IgG responses. 
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A decreased expression level of IL-10 was correlated with a reduction in gastric H. suis 
colonization. IL-10 is an anti-inflammatory cytokine, which is known to down-regulate immunity 
to infection and in this way may help gastric Helicobacter spp. to persist in their host (Matsumoto 
et al., 2005; Couper et al., 2008; Vermoote et al., 2012). 
In addition to IL-10, combined vaccination of rGGT and rUreB depicts reduced levels of IL-4. 
Although increased levels of pro-inflammatory cytokines (IFN-γ, TNF-α and IL-17) and a 
downregulation of IL-10 and IL-4 mRNA were observed in mice immunized with combinations 
of rGGT and rUreB, rather a decrease of the microscopic gastric lesions were observed. The 
reason for this seemingly contradictory result remains to be investigated. 
 
Ideally, an efficacious vaccine should induce protection whilst limiting side-effects. In 
prophylactic H. pylori mouse vaccination experiments, a more pronounced gastritis is often 
observed after challenging of immunized mice. This post-immunization gastritis is an important 
issue in the development of vaccines against H. pylori, especially when using whole-cell lysates 
(Goto et al., 1999; Garhart et al., 2002; Moihara et al., 2007). In the present study, the severity of 
gastric inflammation was higher in mice immunized with whole-cell lysate compared to other 
immunizations and sham-immunized, infected mice. Animals immunized first with rGGT 
followed by rUreB showed remarkably lower gastric inflammation compared to other immunized 
groups. The reason for this reduced inflammation is unclear and requires further studies. For 
example, the role of gastric and systemic cellular immune responses in induction and evolution of 
post-immunization gastritis may be determined by using CD4
+
-, B cell- or neutrophil deficient 
mice (Becher et al., 2010). In addition, it has been shown that post-immunization gastritis 
disappears over time, indicating that it is a transient event (Sutton et al., 2001; Garhart et al., 
2002). A long term study could therefore be interesting to examine the evolution of the 
inflammatory response in all immunized, H. suis-challenged mice. 
 
The results obtained in our mouse model may also be relevant for pigs, which act as the natural 
host of H. suis. Further studies are, however, necessary to confirm this. From an anatomical 
point-of-view, the nasopharynx-associated lymphoid tissue (NALT) of pigs is organized as 
tonsils, and forms the basis of the Waldeyer’s ring (Liebler-Tenorio and Pabst, 2006), while 
NALT in rodents are presented as paired lymphoid aggregates in the floor of the nasal cavity at 
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the entrance to the pharyngeal duct (Kuper et al., 1992). In rodents, lymphocytes from the nose 
preferentially home back to NALT, as well as cervical and mesenteric lymph nodes, but not to 
Peyer’s patches (Koornstra et al., 1992). It is not clear whether this is also true for lymphocytes 
of the porcine NALT. Nevertheless, intranasal vaccination of pigs could be a promising route of 
vaccination for inducing protection not only at the local mucosa, but also at distant mucosal 
surfaces, as has been described for immunization against enteric colibacillosis (Lin et al., 2013). 
 
In this study, an unexpected high mortality was observed in immunized groups that were 
experimentally infected with H. suis, within days after challenge. This was not observed in sham-
immunized and negative control groups, indicating that this most likely relates to the combination 
of immunization and subsequent challenge. The exact cause of death, however, was unclear. An 
extensive local immune response after immunization and subsequent challenge with H. suis 
might be a possible cause of death. Based on autopsy results of some animals, a pronounced local 
immune response related to the administration route (intranasal) and the adjuvant (CT) after 
immunization and subsequent challenge, may lead to excessive swelling of the nasal cavity 
mucosae, resulting in oxygen deficiency. In future H. suis mouse vaccination experiments, it 
should therefore be evaluated whether other mucosal administration routes, such as sublingual or 
oral immunization, could lead to a similar degree of protection without increased mortality. 
 
In conclusion, immunization of mice with the combination of rGGT and rUreB, protected mice 
against a H. suis infection and induced less severe gastric lesions after H. suis challenge than 
immunization with a whole-cell vaccine. Both proteins are potential candidates for inclusion in 
subunit vaccines for control of H. suis infections. However, additional studies are needed to 
confirm the present results. 
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Additional files 
Additional file 1. Mortality rate in different groups during the study. 
 
 
 
 
 
 
 
 
Mice of groups 1, 2, 3 and 5 were intranasally immunized twice with rUreB, rGGT, rGGT+rUreB or 
lysate, respecitively. Groups 6 (sham-immunized group) and 7 (negative control group) were intranasally 
inoculated with HBSS. Mice from group 4 (rGGT→rUreB) were first intranasally immunized twice with 
30 µg rGGT and 5 µg CT. One week after the second immunization animals were intranasally immunized 
twice with 30 µg rUreB and 5 µg CT. Four weeks after the last immunization, all animals, except the 
negative control group, were intragastrically inoculated 10
8
 viable H. suis bacteria. The negative control 
group was intragastrically inoculated with 200 µL Brucella broth at pH5. Four weeks after challenge with 
H. suis, mice were euthanized. 
a
Mice died 2 to 5 days after intragastric challenge with H. suis. 
b
Two mice died before challenge: one 
animal 5 days after the first immunization and one animal 4 days after the second immunization. Two 
animals died 2 and 3 days after intragastric challenge with H. suis. 
c
One mouse was euthanized because of 
a reason unrelated to the study. 
___________________________________________________________________________________ 
 
 
Additional file 2. Serum antibody responses against H. suis lysate (A), rUreB (B) and rGGT (C) at three 
weeks after last immunization. 
Different groups are indicated by the bars with levels of specific IgG shown as the mean OD405nm + SD. * 
p < 0.05, ** p < 0.01, ns: not significant. rGGT→rUreB: group of mice which were sequentially 
immunized with rGGT and rUreB. 
Group Mortality rate (%) 
1. rUreB 40%
a
 
2. rGGT 20%
a
 
3. rGGT+rUreB 30%
a
 
4. rGGT→rUreB 10%
a
 
5. Lysate 40%
b
 
6. Sham-immunized 10%
c
 
7. Negative control 0% 
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Abstract 
Helicobacter suis is a very fastidious porcine gastric pathogen, which is also considered to be of 
zoonotic importance. In vitro antimicrobial susceptibility can not be determined using standard 
assays, as this agent only grows in a biphasic medium with an acidic pH. Therefore, a combined 
agar and broth dilution method was used to analyse the activity of nine antimicrobial agents 
against nine H. suis isolates. After 48h microaerobic incubation, minimal inhibitory 
concentrations (MICs) were determined by software-assisted calculation of bacterial growth. 
Only for enrofloxacin a bimodal distribution of MICs was demonstrated, indicating acquired 
resistance in one strain, which showed an AGT → AGG (Ser → Arg) substitution at codon 99 of 
gyrA. In conclusion, the assay developed here is suitable for determination of the antimicrobial 
susceptibility of H. suis isolates, although activity of acid sensitive antimicrobial agents may be 
higher than predicted from MIC endpoints. 
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Introduction 
Helicobacter suis is a large spiral-shaped bacterium that has been associated with chronic 
gastritis, ulcers of the gastric non-glandular mucosa (Haesebrouck et al., 2009) and decreased 
daily weight gain (Kumar et al., 2010) in pigs. It is also the most prevalent non-Helicobacter 
pylori Helicobacter (NHPH) species in humans suffering from gastric disorders (Van den Bulck 
et al., 2005a; Haesebrouck et al., 2009) and there are strong indications that pigs may act as a 
source of human infections (Meining et al., 1998). H. suis is a very fastidious microorganism 
requiring a highly enriched biphasic medium at pH 5 and a microaerobic atmosphere (Baele et 
al., 2008). Isolation of this agent from the gastric mucosa of pigs is a long and laborious process 
due to its slow growth and the risk of overgrowth with other bacteria which makes frequent 
subculturing necessary in order to obtain pure cultures containing sufficient numbers of H. suis. 
Therefore, it usually takes several weeks to obtain a single H. suis isolate. 
Using a mouse model, it was shown that amoxicillin may be useful for treatment of H. suis 
infected animals (Hellemans et al., 2005). No other antimicrobial susceptibility data of H. suis 
have been published. 
It was the aim of the present study to develop an in vitro assay allowing the determination of the 
antimicrobial susceptibility of H. suis isolates. This method was used to study the presence of 
acquired antimicrobial resistance in H. suis field isolates. 
 
Materials and methods 
Bacterial strains 
Nine H. suis strains, isolated from the gastric mucosa of sows from different herds according to 
the method described by Baele et al. (2008), were included in this study. The microorganisms 
were grown under biphasic and microaerobic culture conditions at 37°C. The biphasic medium 
consisted of a Brucella agar (Oxoid, Basingstoke, England) supplemented with 20% fetal calf 
serum and Vitox supplement (Oxoid), with on top a Brucella broth (Oxoid). The pH of both agar 
and broth was adjusted to 5 by adding HCl. Isolates were passaged twice to ensure reliable 
growth. Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 29213, grown 
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overnight on Columbia agar (Oxoid) supplemented with 5% sheep blood, were included as 
reference strains. 
Antimicrobial susceptibility testing of H. suis 
Susceptibility to ampicillin, ceftiofur, clarithromycin, enrofloxacin, gentamicin, lincomycin, 
metronidazole, tetracycline and tylosin was investigated by a modified agar and broth dilution 
method in 24-well plates (Greiner Bio-On, Frickenhausen, Germany). The composition of the 
agar and broth were the same as described above, both with a pH of 5. All antimicrobials were 
supplied by Sigma (St. Louis, MO) as standard powders with known potencies, except for 
enrofloxacin, purchased from Bayer (Brussels, Belgium). The compounds were dissolved and 
diluted according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI, 
2008). Both agar plates and broth were freshly prepared and contained serial twofold dilutions of 
antimicrobial agents, with final concentrations ranging from 0.03 to 128 µg/ml. The broth 
contained 5×10
7
 bacteria/ml of one of the H. suis strains. MICs for H. suis were determined after 
48h microaerobic incubation by using quantitative real-time PCR (qPCR). 
Suspensions with a density of 0.5 McFarland standard were prepared from overnight-grown 
reference strains E. coli and S. aureus and diluted to a concentration of approximately 5×10
5
 
bacteria/ml. For the reference strains two different MIC assays were performed: i) an assay in the 
biphasic and microaerobic conditions described for H. suis testing, and ii) the broth microdilution 
procedure according to the CLSI (CLSI, 2008). Wells containing agar and broth free of the tested 
antimicrobials served as controls. Plates were examined visually for the presence of bacterial 
growth, as indicated by turbidity after 24h for the reference strains. 
All samples were tested in duplicate. 
Quantitative real-time PCR 
For H. suis quantification by qPCR, 10 fold dilutions ranging from 10
9
 to 10
1
 PCR amplicons of 
an external standard were included. This standard consisted of a 1116 bp segment of the ureA 
gene from H. suis and was constructed using ureaseA sense 5’- CGGGATTGATACCCACATTC 
and antisense 5’- ATGCCGTTTTCATAAGCCAC primers. Amplicons were purified with Spin 
PCRapace (Invitek, Berlin, Germany) and dsDNA amount (ng/µl) was measured using a 
spectrophotometer. The copy number of the amplicon was calculated based on its dsDNA amount 
and length. 
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For enumeration of H. suis in the 24-well plates used for MIC determination, 100 µl aliquots of 
the broth were taken and DNA was isolated by using the PrepMan
®
 Ultra Sample Preparation 
Reagent (Applied Biosystems, CA, USA), following the manufacturer’s recommendations. DNA 
samples (1 µl) were analyzed in 9 µl amplification reactions consisting of 5 pmol of each qPCR 
primer (sense 5’-TTACCAAAAACACCGAAGCC, antisense 5’-CCAAGTGCGGGTAAT 
CACTT), 3.1 µl distilled water and 5 µl iQ™ SYBR® Green Supermix (Bio-Rad, Hercules, CA, 
USA). Thermal cycling (C1000™ Thermal cycler, CFX96™ Real Time system, Bio-Rad) 
consisted of an initial cycle of 95°C for 15min; 47 cycles of 95°C 20s, 60°C 30s, 73°C 30s 
followed by a melting curve analysis. In each qPCR analysis, negative-control reaction mixtures 
containing sterile water instead of DNA were included. 
Both standards and samples were run in duplicate and the average values were used for 
quantification of H. suis. All samples were automatically processed for calculation of threshold 
cycles (Ct)-values and melting curve analysis of amplified DNA using the computer program 
Bio-Rad CFX Manager Version 1.1. (Bio-Rad). The Ct-value stands for the number of PCR 
cycles resulting in a positive quantitative test result. 
The MIC for H. suis isolates in the present study was defined as the lowest concentration of an 
antimicrobial agent for which ΔCt< 50% ΔcCt, with ΔCt = (Ct after incubation – Ct before 
incubation) of antimicrobial-exposed sample, and ΔcCt (Ct after incubation – Ct before 
incubation) of controls. This is the lowest concentration of the antimicrobial agent with at least 
50% less bacterial growth compared to controls without antimicrobials. 
Sequence analysis of the quinolone-resistance determining region of gyrase genes 
The quinolone-resistance determining regions (QRDRs) of gyrA (from codon 59 to 192) and gyrB 
(from codon 250 to 557) from H. suis strains HS1, HS5 and HS6 were amplified using a Pwo 
DNA polymerase (Roche, Mannheim, Germany) and sequenced, based on the conserved regions 
of E. coli (Yoshida et al., 1990; 1991) and H. pylori (Moore et al., 1995). The gyrA primers used 
were sense 5’-CCAGTACACCGGCGTATCCTTTATG and antisense 5’-
CACAGCAATTCCGCTTGAGCCATTG, and the gyrB primers were sense 5’-
TGGCTTTGGCTTATAATGAGG and antisense 5’-GCTATCAATGCCATGCTCAA. The sizes 
of the amplified fragments of gyrA and gyrB were 402 and 926 bp, respectively. Sequence 
analysis and alignments were performed using Vector NTI Software (Invitrogen, Carlsbad, CA, 
USA), and ClustalW. 
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Nucleotide sequences 
Sequences of the gyrA gene in HS1, HS5 and the gyrB gene in HS1, HS5 have been deposited in 
the GenBank database with locus tags HSUHS1_1218, HSUHS5_0002 and HSUHS1_0588, 
HSUHS5_0161, respectively. The sequences of QRDR of gyrA and gyrB of HS6 are presented in 
Additional file 1. 
 
Results 
For the E. coli and S. aureus reference strains MIC endpoints of clarithromycin, gentamicin, 
lincomycin, and tylosin were respectively 10, 10, 14 and 4 times higher than the acceptable 
quality ranges of the CLSI when tested in the H. suis susceptibility assay conditions (CLSI, 
2009). For the other tested antimicrobial agents they fell within acceptable quality ranges. The 
latter was also the case for all antimicrobial agents when tested in CLSI recommended conditions 
(CLSI, 2009). 
MIC results for the H. suis isolates are summarized in Table 1. A monomodal distribution of 
MICs was seen for all antimicrobial agents, except for enrofloxacin for which a clear bimodal 
distribution was observed, indicating acquired resistance in one strain, HS6. An AGT → AGG 
(Ser → Arg) substitution at codon 99 of gyrA in this strain was identified by alignment of its 
gyrA QRDR sequence with the QRDR of strains HS1 and HS5 (MIC≤ 0.06 µg/ml). No mutation 
was found in the gyrB QRDR. 
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Table 1. Distribution of MICs of nine H. suis isolates 
 
Discussion 
The present study is the first to investigate the in vitro susceptibility of H. suis against 
antimicrobial agents. Currently, no standard methods have been described for MIC determination 
for NHPH species. MICs for H. salomonis, H. bizzozeronii and H. felis have been determined by 
using a slightly modified method (that is, horse blood instead of sheep blood) from that 
recommended for H. pylori and Campylobacter jejuni (Van den Bulck et al., 2005b). However, 
H. suis differs from other NHPH in its growth uniqueness. It does not form distinct colonies and 
needs specific biphasic culture conditions with an acidic pH. These growth characteristics impede 
agar dilution testing recommended by the CLSI (CLSI, 2008), leading to the use of a modified 
agar and broth dilution method in the present study. 
Additionally, H. suis growth is not reliably detectable at visual inspection. Therefore, qPCR was 
used in this study as a valuable detection method for growth of these bacteria. qPCR has also 
been described to be a suitable alternative for in vitro susceptibility testing of other fastidious or 
intracellular bacteria, such as Anaplasma phagocytophilum (Hunfeld et al., 2004). 
MICs of gentamicin, clarithromycin, tylosin and lincomycin were higher than the acceptable 
quality ranges for E. coli and S. aureus reference strains when tested in the H. suis susceptibility 
assay conditions. This may be due to the low pH of the media, necessary for H. suis growth, as 
activity of these antibiotics decreases at low pH (CLSI, 2009). Therefore, susceptiblity of H. suis 
Antimicrobial agent No. of strains with a MIC (µg/ml) of: 
≤0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 
Ampicillin     1 2 1 5      
Ceftiofur        1 5  3   
Clarithromycin   1 5 2 1        
Enrofloxacin 4 4     1       
Gentamicin        6 3     
Lincomycin        1 2 5  1  
Metronidazole        2 1 4 2   
Tetracycline    3 3 2 1       
Tylosin        4 5     
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to these antibiotics may be higher than predicted from the MIC endpoints detected here. Indeed, 
for H. suis, MICs of macrolides, lincomycin and gentamicin were higher than those described for 
H. felis, H. bizzozeronii, and H. salomonis (Van den Bulck et al., 2005b). On the other hand, in 
the present study pH conditions were not identical for the reference strains compared to the H. 
suis strains. In the medium of the H. suis strains without antimicrobials, a rapid increase from pH 
5.35 to 7.00 was observed within 24h, which was not the case for the reference strains (data not 
shown). This is most probably due to the strong urease activity of H. suis. 
A clear bimodal distribution of MIC values was demonstrated for enrofloxacin, indicating 
acquired resistance in one strain. In this strain, sequencing of the QRDR of gyrA showed a point 
mutation at position Ser99, which may be responsible for this resistance. In H. pylori, Asn87 and 
Asp91 point mutations in the QRDR have been associated with fluoroquinolone resistance 
(Moore et al., 1995). 
Although the microbiological criterion used here for defining acquired resistance to enrofloxacin 
does not necessarily predict how a patient will respond to the therapy, the MIC value for the 
resistant strain was at least 30 times higher than for the susceptible population. The probability 
that humans or pigs infected with this isolate will respond well to treatment, should be considered 
to be low. The MICs of enrofloxacin for H. suis isolates without acquired resistance are similar to 
those described for H. felis, H. bizzozeronii and H. salomonis (Van den Bulck et al., 2005b). 
For ampicillin, MICs are higher than those described for H. felis, H. bizzozeronii, H. salomonis 
and H. pylori (Loo et al., 1997; Van den Bulck et al., 2005b). This may indicate a reduced 
susceptibility of H. suis to ampicillin, compared with other gastric Helicobacter species. 
In a previous study, H. bizzozeronii and H. felis isolates with MICs of metronidazole of 8-
16µg/ml were considered to be resistant to this antimicrobial agent (Van den Bulck et al., 2005b). 
In the present study, MICs of metronidazole showed a monomodal distribution but mostly fell in 
this higher MIC range. The significance of this finding for treatment of H. suis infections is not 
clear and it remains to be determined how a patient will respond to treatment with this 
antimicrobial agent. 
MICs of tetracycline were in the range as described for H. felis, H. bizzozeronii and H. salomonis 
(Van den Bulck et al., 2005b). To our knowledge, MIC values of ceftiofur have not been 
published for other gastric NHPH species. 
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In conclusion, the assay developed in the present study is suitable for determination of the 
antimicrobial susceptibility of H. suis isolates, although activity of acid sensitive antimicrobial 
agents may be higher than predicted from MIC endpoints. Acquired resistance to 
fluoroquinolones may occur in H. suis field isolates. As the results of this study are based on a 
small number of strains, additional tests are needed to determine if these results reflect the 
susceptibility of the H. suis population. 
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Additional file 
Additional file 1. Helicobacter suis strain 6 quinolone-resistance determining region of gyrA. 
1 CCAGTACACCGGCGTATCCTTTATGCTATGCACGAGTTAGGCTTGGGGG     
50 CACGCGTGCCTTATAAAAAAAGTGCGCGCATTGTAGGCGATGTCATTGG  
99 TAAATACCACCCCCATGGCGATAGGGCAGTCTATGAGGCCTTAGTGCGC    
148 ATGGCACAAGATTTTTCTATGCGTCTGCCTTTAGTAGATGGGCAAGGTAA    
198 TTTTGGCTCTATTGATGGGGATAATGCCGCGGCGATGCGCTATACAGAGG    
248 CACGCATGGCAACTCCAAGTGAGGAACTTTTAAGAGACATTGATAAAGAT    
298 ACAGTAGATTTTAACGACAATTATGACAACACCCTAAAAGAACCCGATGT    
348 CCTGCCTAGCCGTTTGCCTAATTTGCTCATCAATGGCTCAAGCGGAATTG    
398    CTGTG 
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At the time this PhD was started, little was known about pathogenesis of H. suis infections and 
control strategies for this bacterium. This was mainly due to the lack of an in vitro isolation 
protocol for this very fastidious microorganism until 2008 (Baele et al., 2008). Availability of 
pure cultures of H. suis allowed in depth study of its genome and the identification of genes 
involved in bacterium-host interactions. It also facilitated evaluation of the usefulness of new 
control strategies against this microorganism. 
1. New insights into the molecular pathogenesis of H. suis infections 
H. pylori is considered the primary cause of human gastric disorders. However, in gastric 
biopsies of some patients with upper gastrointestinal symptoms, large, spiral-shaped non-H. 
pylori helicobacters (NHPH) are observed (Haesebrouck et al., 2009). In contrast to H. pylori, 
little research has been done on virulence and colonization mechanisms of NHPH in general and 
H. suis in particular. In Chapter 1, we performed a genome-wide analysis of two H. suis strains 
with the aim to obtain better insights into the colonization- and virulence factors of this 
bacterium. 
H. suis is able to persistently colonize the stomach of pigs (Hellemans et al., 2007) and humans 
(Van den Bulck et al., 2005a; Joosten et al., 2013). Therefore, this bacterium needs to survive in 
the acidic environment, and to interact with the host using bacterial surface molecules (OMPs) 
that mediate adherence. Although comparative genome analysis of H. suis with H. pylori resulted 
in the detection of the vast majority of genes known to be essential for colonization of the human 
gastric mucosa, the H. suis genome lacks genes coding for BabA and SabA adhesins, which play 
a major role in H. pylori adhesion to the human gastric mucosa (Yamaoka and Alm, 2008). H. 
suis indeed differs from H. pylori in that it does not bind to the host cell-associated Le
b
 and sLe
x
, 
two blood group antigens mediating the adherence of H. pylori by BabA and SabA, respectively 
(Mahdavi et al., 2002; Yamaoka, 2008). However, recent in vitro experiments demonstrated that 
H. suis could adhere to host mucins (Smet A. and Lindén S., personal communications, 2012), 
which indicates that adherence to host mucins may play a role in the initial colonization and long-
term persistence of H. suis in the stomach, and that it is mediated by adhesins other than BabA 
and SabA. Possible candidate adhesins of H. suis are the HpaA, HorB and Hof proteins. Genes 
encoding these OMPs were detected in the sequenced H. suis genomes and are also present in the 
genomes of other sequenced NHPH (Arnold et al., 2011; Schott et al., 2011; Smet et al., 2013). 
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Future studies, including adhesion experiments with H. suis mutant strains, should elucidate the 
exact role of these OMPs in gastric colonization by these bacteria. 
Before our study, virtually nothing was known about possible H. suis virulence factors involved 
in gastric pathology. As described in the general introduction of this thesis, VacA and CagA play 
a key role in pathogenesis of H. pylori infections (Delahay and Rugge, 2012). VacA induces 
vacuolization and apoptosis in epithelial cells (Cover and Blaser, 1992; Cover et al., 2003), while 
CagA, as a member of the cag pathogenicity island, is responsible for cytoskeletal changes and 
production of pro-inflammatory NF-κB (Mimuro et al., 2002; Brandt et al., 2005). Genes 
encoding a functional VacA and CagA were neither found in H. suis, nor in other gastric 
Helicobacter species (Dailidiene et al., 2004; O’Toole et al., 2010; Arnold et al., 2011; Schott et 
al., 2011; Smet et al., 2013). Despite the absence of these major H. pylori virulence factors, 
infections with NHPH species have been associated with gastric lesions. For instance, H. suis and 
H. felis induce extensive apoptosis and necrosis of parietal cells in experimentally infected mice 
and/or gerbils (De Bock et al., 2006; Flahou et al., 2010), which may have important implications 
for the development of gastric pathologies, such as gastric ulcer formation (Dixon, 2001), gastric 
atrophy and gastric cancer (Shirin and Moss, 1998). Apart from VacA it has been shown that the 
H. pylori γ-glutamyl transpeptidase (GGT) may induce gastric epithelial cell death (Shibayama et 
al., 2003; Gong et al., 2010). In the H. suis genome, we found a homolog of the H. pylori GGT-
coding gene, and proposed it as a potential virulence factor of H. suis. Recent work indeed 
showed that the H. suis GGT is involved in the induction of gastric lesions (Flahou et al., 2011). 
The authors showed that this enzyme is largely responsible for the induction of apoptosis and 
necrosis of AGS cells by H. suis (Flahou et al., 2011). 
Although the incidence of NHPH gastritis is considered lower than that of H. pylori, the risk of 
developing gastric MALT lymphoma is higher in NHPH-infected patients compared to those 
infected with H. pylori. A long-term study of Helicobacter-related gastric pathology indeed 
showed that 1.48% and 0.66% of the patients infected with NHPH and H. pylori, respectively 
developed MALT lymphoma (Stolte et al., 1997; 2002). The development of MALT lymphoma 
has been associated with a Th2 response, rather than with a Th1-predominant response (Knörr et 
al., 1999). In contrast to the predominant Th17/Th1 response evoked by a H. pylori infection 
(Robinson and Atherton, 2010), H. suis infections have been shown to induce a Th17/Th2 
response in mice (Flahou et al., 2012). Interestingly, H. pylori harbors some virulence factors that 
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modulate the host immune response toward a Th1 response, including the cag pathogenicity 
island; the outer inflammatory protein A, OipA; and the neutrophil-activating protein, HP-NAP 
(Amedei et al., 2006; D’Elios et al., 2007; Yamauchi et al., 2008). Except for HP-NAP, H. suis 
lacks homologs of these factors, which could possibly explain the absence of a Th1 response 
associated with a H. suis infection in mice, and the higher incidence to develop MALT 
lymphoma compared to H. pylori infections. In addition, a homolog of the flavodoxin A (FldA)-
coding gene has been found in the H. suis genome. The H. pylori FldA is associated with MALT 
lymphomas in humans (Chang et al., 1999). The exact role of HP-NAP and FldA as putative H. 
suis virulence factors in gastric diseases remains to be elucidated. 
Another point to consider is the role of Helicobacter virulence factors in host immune evasion, 
which may result in a persistent infection. The H. pylori VacA and GGT have been shown to 
inhibit T cell proliferation (Sundrud et al., 2004; Schmees et al., 2007). As discussed above, only 
a homolog for the GGT-coding gene is present in the H. suis genome. Very recently, the H. suis 
GGT has been described to impair proliferation of Jurkat T cells as well as different subsets of 
primary mouse lymphocytes, and both cell death and cell cycle arrest seem to be involved (Zhang 
et al., unpublished data). Experiments using ggt
-
 H. suis-mutants and subsequent evaluation in 
rodent models will clarify the exact mechanism of H. suis GGT-induced immune modulation. 
 
2. New insights into proteins inducing a protective immune response against H. suis 
H. suis infections have been described in more than half of the world’s pig population 
(Haesebrouck et al., 2009). Antimicrobial therapy in pigs is therefore an impractical approach to 
control H. suis infections. In addition, antimicrobial-based therapy in pigs is not recommended 
partly due to increased human health risks associated with antimicrobial use in food producing 
animals, including the spread of antimicrobial resistance in pathogens and in bacteria belonging 
to the normal microbiota (Jensen et al., 2008). Vaccination of pigs may therefore represent a 
valuable alternative to control H. suis infections in pigs and humans. 
Different approaches can be used to select potential candidate vaccine antigens. In Chapter 2, 
the immunoproteomics approach was used to select a first vaccine candidate, the urease subunit B 
(UreB). A second candidate, the H. suis GGT, was selected based on its importance in H. suis-
induced gastric pathology and immunoregulatory capacities (Chapter 3). 
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In addition to insights into genes involved in gastric pathology, genome analysis can be used to 
identify potentially immunogenic proteins by examining their predicted subcellular localization 
(membrane or secreted proteins) or by homology with virulence factors of related pathogens 
(Serruto et al., 2009). In the first study of this thesis, we determined approximately 95 and 208 
open reading frames with a predicted signal peptide cleavage site and transmembrane helix, 
referring to secreted proteins and membrane-associated proteins, respectively. However, to 
reduce this huge haystack of ~ 303 possible antigen candidates, additional tools providing more 
information about host-bacterium relationship and immunogenicity of the proteins were needed. 
Proteomics is particularly useful as it directly reveals actual antigenic properties such as 
abundance, localization and seroreactivity, instead of indirect data as provided by genome-based 
techniques (Bumann et al., 2004). In order to identify potential vaccine candidates, we performed 
two-dimensional gel electrophoresis of H. suis proteins, followed by immunoblotting with sera 
from vaccinated and protected mice on the one hand, and sera from H. suis-infected and non-
protected mice on the other hand. To our knowledge, this is the first study describing the 
immunoproteome of H. suis. This approach has already been used to identify new H. pylori 
antigens of protective value (McAtee et al., 1998, Hocking et al., 1999; Bumann et al., 2002; 
2004). In our experiments, four major proteins of protective interest could be identified with sera 
from H. suis lysate-immunized mice, being UreB, chaperonin GroEL, FlaA and UreA. These 
proteins have also been identified in several H. pylori immunoproteome studies when using sera 
from H. pylori-infected humans (McAtee et al., 1998; Hocking et al., 1999; Kimmel et al., 2000; 
Bumann et al., 2002; Lock et al., 2002), and showed to be of protective value against H. pylori 
infections in mice (Skene et al., 2007; Blanchard and Nedrud, 2010). The abundance of UreB and 
GroEL could possibly obscure the detection of low-abundant proteins. Low-abundant proteins 
may also be poorly recognized by the host immune system as antigen recognition is generally 
dose-dependent. This does, however, not exclude their possible role in protection if included in 
vaccines. Experiments in which H. suis whole-cell proteins are fractionated based on molecular 
weight (size) may allow discovery of these proteins. 
The few vaccination studies that had been carried out for H. suis only focused on the use of 
whole-cell lysates of homologous or heterologous bacteria (Hellemans et al., 2006; Flahou et al., 
2009). Despite positive results obtained during these studies, safety and practical considerations 
related to the large-scale culture of H. suis in vitro are substantial obstacles in developing a H. 
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suis whole-cell vaccine for pigs and/or humans. In Chapters 2 and 3 we evaluated the protective 
efficacy of a limited number of subunit vaccine candidates, and compared it with that of whole-
cell lysate in a mouse model. In a first study, we developed a subunit vaccine based on H. suis 
UreB, recombinantly expressed in E. coli (rUreB) (Chapter 2). Intranasal immunization with 
rUreB and cholera toxin (CT) resulted in a significant decrease of the bacterial load in the gastric 
mucosa, but could not prevent Helicobacter colonization. Immunization with whole-cell lysate, 
however, induced higher levels of protection compared to immunization with rUreB. Therefore, 
in a subsequent study, we investigated the usefulness of rUreB in combination with another H. 
suis protein. Simultaneous and consecutive immunization with the recombinant H. suis GGT 
(rGGT) and rUreB induced better protection against a subsequent H. suis challenge compared to 
immunization with single proteins. A complete clearance was observed in approximately 50% of 
mice which is similar to the protection induced by a whole-cell lysate. This suggests that multiple 
antigens may be necessary for the development of a truly protective vaccine against H. suis. 
Combined vaccination with several protective antigens could result in a synergistic protective 
effect compared to vaccination with the single proteins. It is also possible that effective immunity 
against bacteria is achieved more likely by combining different antigens participating in different 
aspects of the pathogenesis of infection (Ferrero et al., 1995; Rossi et al., 2004). In any case, the 
observation that multiantigen vaccines induce better protection compared to one single antigen 
has been made for H. pylori, and other bacteria as well (Ferrero et al., 1995; Wu et al., 2008; 
Sadilkova et al., 2012). 
An antigen should meet two main requirements to be considered an effective vaccine candidate 
(Blanchard and Nedrud, 2010). First, the protein should be present and conserved in all strains of 
the targeted Helicobacter species. Second, the antigen should induce a strong protective immune 
response when delivered as vaccine antigen with an appropriate adjuvant. To estimate how 
conserved an antigen is among different H. suis strains, proteins derived from many H. suis 
isolates should be tested in the future. In H. pylori, urease is well conserved and abundant, and is 
consequently the most commonly used antigen in H. pylori vaccination studies. Additionally, it 
has been shown that immunoreactivity to UreB is sustained across different H. pylori strains 
(Lock et al., 2002). The H. suis GGT encoding gene has been found in two sequenced H. suis 
strains (Chapter 1). However, it remains to be investigated how conserved this protein is among a 
larger H. suis population. 
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We demonstrated that vaccination with rUreB together with CT induced a strong humoral as well 
as local immune response in mice, which were both correlated with reduction of H. suis 
colonization, suggesting that rUreB is an effective antigen for vaccination against H. suis. 
In contrast to the large number of studies using urease as vaccine candidate, only one study 
evaluated the protective efficacy of vaccination with the H. pylori GGT (Anderl et al., 2010). 
Both H. pylori and H. suis GGT inhibit T cell proliferation and thus interfere with the generation 
of an effective immune response (Schmees et al., 2007; Zhang et al., unpublished data). Mucosal 
immunization with H. pylori GGT in combination with the outer membrane protein, HpaA, 
induced a strong antibody response, and it was suggested that these antibodies block the 
enzymatic activity of GGT and thereby counteract its immunosuppressive effect (Anderl et al., 
2010). Also in our study, we observed significantly higher anti-GGT antibodies in GGT-
immunized and challenged mice compared to all other groups. Notably, immunization with rGGT 
alone did not induce strong gastric T cell responses, as expression level of Th1, Th2 and Th17 
cytokines were not significantly different from that of non-immunized H. suis-infected animals. 
In addition, vaccination with rGGT alone elicited a limited protection against H. suis challenge 
compared to immunization with rUreB alone. Since GGT is a secreted protein, specific immune 
cells induced by the GGT-based subunit vaccine are likely to fail in targeting the pathogen. To 
overcome this, it has been suggested to vaccinate with GGT in combination with an outer 
membrane protein (Anderl et al., 2010). We suggest that rGGT could be a candidate for 
vaccination against H. suis, however most likely as a component of a multiantigenic vaccine, e.g. 
in combination with UreB, HpaA or GroEL. 
One of the most important progresses in vaccine development against H. pylori is the improved 
understanding of mechanisms of protection. Before the start of this PhD research, very little was 
known about the mechanism of vaccine-induced protection against H. suis infections. The studies 
described in Chapters 2 and 3 demonstrated that probably a combination of local Th1 and Th17 
responses, complemented by antibody responses play a role in the protective immunity against H. 
suis infections. We observed that reduction of gastric H. suis colonization was significantly 
correlated with an increase of antigen-specific serum antibodies, indicating that circulating 
antibodies could play a role in protection against H. suis. These findings correspond with some 
H. pylori vaccination experiments where a strong relation between protection and the presence of 
antigen-specific antibodies, both humoral and local, has been described (Czinn et al., 1993; Goto 
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et al., 1999; Jeremy et al., 2006; Nyström et al., 2006; Nyström and Svennerholm, 2007; 
Morihara et al., 2007). Nevertheless, several other authors have been able to induce a similar 
level of protection in antibody-deficient mice compared to wild-type animals, indicating that 
antibodies are not essential for protection against H. pylori (Blanchard et al., 1999; Gottwein et 
al., 2001; Garhart et al., 2003). Future research should elucidate which role humoral and/or local 
antibodies play in vaccine-mediated immunity against H. suis. 
In our studies, an increased gastric response of both Th1 and Th17 (measured by their signature 
cytokines, IFN-γ and IL-17) was significantly correlated with higher levels of protection. Several 
studies showed a positive correlation between IFN-γ production by CD4+ T cells and protection 
in mice after immunization with H. pylori lysate (Akhiani et al., 2002; Rahn et al., 2004; Sayi et 
al., 2009). Also IL-17 has been suggested as a considerable cytokine in vaccine-mediated 
protection against H. pylori (DeLyria et al., 2009; Velin et al., 2009; Flach et al., 2011). 
Experimental infection of mice with pure cultures of H. suis leads to a predominant Th17 
response and a secondary Th2 response (Flahou et al., 2012). Despite this response, H. suis 
persists in the stomach. Our vaccination studies indicate that for a significant protection a 
combination of Th17 and Th1 responses in the stomach is required. 
In addition, we found that reduction of bacterial colonization after vaccination was significantly 
correlated with decreased expression levels of IL-10, an anti-inflammatory cytokine. Regulatory 
T cells (Tregs) are capable of producing large amounts of IL-10 (Roncarolo et al., 2006) and are 
currently considered as a major obstacle for successful vaccination against Helicobacter 
infections. Indeed, Tregs activated in the gastric mucosa have a negative effect on dendritic cells, 
Th1 and Th17 responses (Kao et al., 2010), and thereby hinder the development of an effective 
cell-mediated immune response against H. pylori, and most probably also against H. suis. A 
successful H. suis vaccine must therefore be able to tip the immune system balance in favor of 
Th1 and Th17 responses that will overcome the immunosuppressive properties of Tregs and IL-
10. To limit the negative effect of Tregs, Bayry and coworkers (2008) introduced the use of 
CCR4 antagonists as adjuvants. CCR4 is expressed by Tregs and is the receptor for CCL22 and 
CCL17, two chemotactic cytokines for Tregs in vitro and in vivo (Iellem et al., 2001). Blocking 
CCR4 function and thus inhibiting the immunosuppresive effect of Tregs at the time of 
vaccination has been suggested to enhance vaccine-induced immune responses and could be 
promising for further H. pylori and H. suis vaccine development (Davies et al., 2008). 
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The exact role of T cell subsets and their cytokines in vaccine-induced protection against H. suis, 
however, should be further investigated, possibly by using either CD4
-
 or CD25
-
 mice or animals 
deficient in the cytokine of interest (Matsumoto et al., 2005; Velin et al., 2009). 
An effective vaccine should induce satisfactory protection against infection whilst limiting side-
effects. In our studies, we observed an enhanced gastritis four weeks after H. suis challenge in 
animals vaccinated with whole-cell lysate compared to non-vaccinated H. suis infected mice. 
This effect is an important issue in murine prophylactic H. pylori immunization studies, and has 
been referred to as “post-immunization gastritis” (Goto et al., 1999; Garhart et al., 2002; 
Morihara et al., 2007). A hypothesis for the development of this post-immunization gastritis is 
that in an immunized host, challenge with a gastric Helicobacter will lead to an enhanced gastric 
inflammatory response which could be critical for elimination of the bacteria (Mohammadi et al., 
1996; Blanchard and Nedrud, 2010). Indeed, the severity of this gastritis in H. pylori 
immunized/challenged mice is often inversely correlated with the degree of protection, an 
observation which was also made in our experiments (Chapters 2 and 3). Interestingly, we found 
that post-immunization gastritis was negligible in mice vaccinated with single proteins and mice 
immunized with combinations of rUreB and rGGT, although also in these groups a significant 
reduction and even clearance of H. suis was achieved. The reason for this different inflammatory, 
but similar protective outcome in animals immunized with subunit vaccines compared to lysate-
immunized mice remains to be explored. In addition, post-immunization gastritis has been shown 
to be transient in both H. pylori and H. felis immunization experiments (Sutton et al., 2001; 
Garhart et al., 2002). For H. suis, it still needs to be investigated whether the disparity in gastritis 
between infected animals and immunized/challenged mice will also disappear over time. 
It is clear that not only the antigen, but also the adjuvant, route of administration, vaccination 
protocol and mouse strain influence the outcome of vaccination. The protective efficacy of rUreB 
and rGGT in combination with another adjuvant and/or other administration route could probably 
result in different protective effects. Indeed, Flahou et al. (2009) showed that intranasal (mucosal) 
immunization with H. suis lysate and CT is more effective against a subsequent H. suis infection 
compared to subcutaneous (systemic) vaccination with a saponin-based adjuvant. In contrast, 
more recent work showed that subcutaneous vaccination with H. suis lysate and complete 
Freund’s adjuvant induces a similar reduction of gastric colonization compared to intranasal H. 
suis lysate plus CT immunization (Flahou B., personal communication, 2013). It remains 
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therefore to be elucidated if other delivery routes and/or adjuvants could improve the protective 
effect of vaccination with rUreB and rGGT. 
Following successful vaccination studies in rodent models one could move to the target host, 
humans (in case of H. pylori) and/or pigs (in case of H. suis). It became apparent that H. pylori 
proteins, which were often shown to be highly protective in the H. pylori mouse model (Ermak et 
al., 1998; Corthesy et al., 2005; Harbour et al., 2008; Raghavan et al., 2010; Zhang et al., 2011), 
only conferred modest levels of protection against H. pylori infection in large animal hosts or in 
humans, irrespective of the route of antigen administration used (Dubois et al., 1998; Lee et al., 
1999; Solnick et al., 2000; Kotloff et al., 2001; Aebisher et al., 2008). The cause of differences in 
vaccine efficacy between the models is unclear, but may be related to differences in the host or to 
bacterial differences (e.g. used strain). Host differences could be due to innate immune 
differences or differences in other factors including the age. A comparison of the murine and 
human immunoproteomes of H. pylori, however, revealed that the pattern of H. pylori proteins 
that become exposed to the mouse immune system appears to be similar to that in human H. 
pylori infections, suggesting that the mouse infection model is suitable for preclinical screening 
of antigen candidates (Bumann et al., 2002). In case of H. suis, this still needs to be examined in 
translational studies from mice to pigs. For H. pylori, only two studies have been described in 
gnotobiotic piglets (Eaton and Krakowka, 1992; Eaton et al., 1998). Prophylactic vaccination of 
piglets with H. pylori sonicate did not prevent infection by subsequent challenge but reduced 
bacterial colonization, whereas therapeutic vaccination was unsuccessful. One apparent 
difference between piglets and mice was the neutrophilic gastritis associated with vaccination of 
piglets, in contrast to a more lymphoplasmacytic post-immunization gastritis observed in mice 
(Eaton et al., 1998). Future research will point out whether this post-immunization gastritis and 
the residual bacteria in vaccinated piglets disappear after time, as observed in the mouse model 
(Garhart et al., 2002). 
For the most part, immune cell populations identified in mice are also present in pigs. Globally 
functional orthologs for all cytokines involved in Th1/Th2/Th17/Treg and corresponding cells 
have been described in pigs as well (Murtaugh et al., 2009; Kiros et al., 2011; Käser et al., 2012). 
The results described in Chapters 2 and 3 are therefore promising regarding the development of 
an effective vaccine against H. suis infections in pigs. It remains however to be determined 
whether vaccine-induced protection can really protect against the persistent colonization with H. 
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suis and the subsequent development of gastric lesions. Many antibacterial vaccines, currently 
used in swine, induce only partial protection (Haesebrouck et al., 2004). Nevertheless, even if 
prophylactic vaccination can not prevent a H. suis infection, the decreased colonization due to 
immunization may be economically attractive, as seen for commercial vaccines against 
Mycoplasma hyopneumoniae (Maes et al., 2008) and Actinobacillus pleuropneumoniae 
(Sadilkova et al., 2012). Experimental H. suis infections indeed induce a 10% decrease in daily 
growth rate in pigs over an average period of 5 weeks (De Bruyne et al., 2012). In addition, 
vaccination of pigs against H. suis may help to protect humans against infections with this agent, 
even if there would be no effect on pig performance. Vaccination in production animals to protect 
humans from zoonotic disease, as done already for Salmonella Enteritidis in laying hens, is the 
perfect illustration of the “one health concept” (Cogan and Humphrey, 2003). 
 
3. New insights into the antimicrobial susceptibility of H. suis isolates 
Combination therapy with a proton pump inhibitor and antimicrobial agents (usually 
clarithromycin and amoxicillin and/or metronidazole) is effective to eradicate H. pylori in the 
majority of infected individuals (Collins et al., 2006). However, this multidrug regimen does not 
prevent re-infection and antimicrobial-resistant strains are increasingly common (Mégraud et al., 
2013). In general, human patients suffering from severe gastric pathologies associated with 
NHPH infections are treated with the same therapeutic regimens as used for H. pylori (Morgner 
et al., 2000). Using a mouse model, it has been shown that H. suis infections can be treated with a 
combination of amoxicillin and omeprazole. However, differences in sensitivity were seen 
between different H. suis isolates, which might indicate acquired antimicrobial resistance 
(Hellemans et al., 2005). Since no other data on intrinsic and acquired resistance were available 
for H. suis when we started our studies, in vitro susceptibility of an available collection of H. suis 
isolates was determined (Chapter 4). 
Considering the demanding growth requirements of this Helicobacter species, the agar dilution 
method, recommended by the CLSI to test antimicrobial susceptibility of H. pylori (CLSI, 2010), 
was not suitable for H. suis. We developed a modified agar and broth dilution method consisting 
of a biphasic medium at pH 5. The results from reference strains E. coli and S. aureus, tested in 
H. suis susceptibility assay conditions, indicate that the low pH may influence activity of some 
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antimicrobial agents, including gentamicin, clarithromycin, tylosin and lincomycin. Indeed, it has 
been shown that minimal inhibitory concentrations (MICs) of antimicrobial agents can increase 
in more acid circumstances (Mégraud, 2010), indicating that the acidic pH of the stomach may 
affect the stability and optimal activity of antimicrobials. For this reason, it became mandatory to 
include a drug that diminishes gastric acid secretion, e.g. a proton pump inhibitor (Vergara et al., 
2003). The effect of inclusion of proton pump inhibitors on the suppression of colonization of 
NHPH in the stomach remains to be investigated. 
In vitro susceptibility testing is highly indicative to detect acquired resistance. Acquired 
resistance was only detected to enrofloxacin in one H. suis strain. This antimicrobial agent is 
commercially available for treatment of pigs, and is frequently used to control bacterial intestinal 
disease in piglets in Belgium (Callens et al., 2012). Levofloxacin, the relative of enrofloxacin 
approved for use in humans, is used to treat various bacterial infections, including H. pylori 
infections when a clarithromycin-based therapy fails due to bacterial resistance (Romano et al., 
2010). Worldwide, the application of levofloxacin-containing regimens is limited due to the 
rapidly rising H. pylori levofloxacin resistance rate (Kim et al., 2005; Bogaerts et al., 2006; 
Chang et al., 2009; Mégraud et al., 2013). Quinolone resistance in H. pylori is mainly attributed 
to mutations in the quinolone-resistance determining region (QRDR) of gyrase A (gyrA) (Moore 
et al., 1995; Liou et al., 2011). A point mutation in the QRDR of gyrA was detected in the 
enrofloxacin-resistant strain of H. suis. Further studies are necessary to determine if this point 
mutation is responsible for the observed resistance. Such studies may include introduction of the 
mutation into susceptible strains by natural transformation and subsequent evaluation of their 
altered susceptibility to enrofloxacin (Moore et al., 1995; Pasquali et al., 2007). Alternatively, 
spontaneous enrofloxacin-resistant mutants may be produced by passing susceptible strains on 
media containing enrofloxacin. Less susceptible strains should then be examined for the presence 
of mutations in the gyrA gene (Wang et al., 2001). 
To overcome quinolone resistance, new quinolones such as gemifloxacin have been developed 
recently. It has been shown that gemifloxacin has a 5-times lower MIC against levofloxacin-
resistent H. pylori isolates and could partially overcome quinolone resistance caused by gyrA 
mutation (Chang et al., 2012), making this antibiotic a possible alternative for treatment of 
individuals infected with resistant H. suis and/or H. pylori strains. 
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In our study, MICs of ampicillin and metronidazole showed a monomodal distribution but mostly 
fell in a higher MIC range than described for susceptible strains of other gastric Helicobacter 
species (Loo et al., 1997; Van den Bulck et al., 2005b). This may indicate a reduced susceptibility 
of H. suis to ampicillin and metronidazole, compared to other gastric Helicobacter species. It 
remains to be confirmed if this has practical implications for treatment of H. suis-infected 
patients. 
It should be kept in mind that the results of this study are based on a small number of H. suis 
isolates. Further studies, including more isolates are needed to obtain a representative view on H. 
suis acquired resistance. However, as mentioned before, H. suis is an extremely fastidious 
organism and its isolation is very laborious and time consuming. It indeed requires several weeks 
to obtain a single isolate from porcine stomaches. 
We also need to consider the predictive value of in vitro testing for the clinical outcome of 
infection. Although we may conclude that most antimicrobial agents showed a good in vitro 
activity against H. suis, this does not ensure that H. suis will be eradicated from the stomach of 
patients treated with one of these antimicrobials. With regard to the discrepancy between in vitro 
and in vivo testing, one could refer to the behavior of H. pylori which is highly susceptible to 
antimicrobials in vitro while its eradication in patients requires aggressive triple or quadriple 
therapy (Ecclissato et al., 2002; Mégraud et al., 2013). This indicates that in vitro susceptibility 
testing could give an indication about the susceptibility of a microorganism to an antimicrobial 
agent, but does not guarantee that therapy with that agent will be successful. In general, a 
multidrug therapy including two or three antimicrobial agents and an acid suppressor is necessary 
for eradication of gastric Helicobacter species from the stomach. 
 
4. General conclusions 
The results of this thesis provide new insights into the molecular pathogenesis of H. suis 
infections. The genome annotation of H. suis presented in Chapter 1 shows that this 
microorganism lacks homologs for genes encoding the major H. pylori virulence factors (e.g. 
CagA, VacA, BabA, SabA). Nevertheless, we identified NapA, GGT, HtrA and FldA as potential 
virulence factors of H. suis. Future research, using H. suis mutants should clarify the precise role 
of presented genes in colonization and virulence of H. suis. 
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We provided new insights that may help in the development of an effective vaccine against H. 
suis infections. First, the immunoproteome of H. suis provided a list of candidate antigens which 
can be used in future vaccination experiments against this pathogen. Second, we showed that 
immunization with the H. suis UreB and GGT is a valuable alternative for whole-cell lysate to 
induce a protective immune response against H. suis infections. Future studies in pigs are needed 
to confirm the protective efficacy of these antigens. 
In the present PhD thesis, we developed an in vitro assay to determine the acquired and intrinsic 
resistance of H. suis strains and found that acquired resistance to fluoroquinolones may be 
present in H. suis field isolates. 
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Helicobacter suis is a Gram-negative, spiral-shaped bacterium that colonizes the stomach of the 
majority of slaughter pigs worldwide. An infection with this microorganism has been associated 
with erosive and ulcerative lesions in the non-glandular part of the porcine stomach and with 
chronic gastritis. A reduction in daily weight gain in experimentally infected pigs has been 
described, emphasizing the importance of H. suis infections for the pig industry. Furthermore, it 
is the most prevalent non-H. pylori Helicobacter species colonizing the stomach of humans 
suffering from gastric disease. In humans, H. suis has been associated with gastritis, peptic ulcers 
and mucosa-associated lymphoid tissue lymphomas of the stomach. Pigs are considered to be an 
important source of human infections. Either contact with pigs or the consumption of raw or 
undercooked contaminated pork are proposed as source of infection for humans. 
H. pylori uses a variety of factors to persistently colonize the gastric mucosa and to induce gastric 
pathologies in humans. For a long time, the lack of pure H. suis in vitro isolates hampered the 
progress of research on this bacterium. At the start of this thesis, virtually nothing was known 
about the presence of genes involved in gastric pathogenicity of H. suis and in its specific 
adaptation to the gastric environment. Our research group was the first to successfully isolate H. 
suis in vitro in 2008. This created new opportunities to perform the present PhD studies which 
have the general aim to obtain better insights into the pathogenesis of H. suis infections and to 
develop control strategies against this bacterium. 
Effective measures to control H. suis infections may not only decrease the number of pigs 
suffering from gastric disease, but are also important from a public health point of view. The 
prevalence of H. suis infections in adult pigs is very high, indicating that the immune response 
after natural infection does not result in eradication of the bacterium from the stomach. 
Vaccination with whole-cell lysate was shown to protect against a subsequent H. suis infection in 
a mouse model. However, it was not known which bacterial proteins are important for induction 
of protective immunity against H. suis infections. In addition, at the start of this thesis, no data 
were available on the antimicrobial susceptibility pattern of H. suis. 
In Chapter 1, we describe the genome sequence of two H. suis strains: H. suis strain 1 (type 
strain = LMG 23995
T
) and 5, both isolated from the gastric mucosa of swine. After performing a 
draft pyrosequencing assay and assemblage, the genome was annotated by cross-mapping with 
three well-investigated H. pylori strains. As some virulence factors may differ between both 
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species, ab initio annotations of the H. suis genome were performed as well. Comparison with the 
H. pylori genome revealed that all genes described to be essential for gastric colonization are 
present in the H. suis genome. Homologs of genes encoding the pro-inflammatory H. pylori 
neutrophil-activating protein (NapA), the apoptosis-inducing γ-glutamyl transpeptidase (GGT), 
and some type IV secretion systems were also identified in H. suis. H. suis also possesses several 
presumptive virulence-associated genes, including homologs for mviN, the H. pylori flavodoxin 
gene (fldA) and the H. pylori high-temperature requirement A gene (htrA). Sequences coding for 
outer membrane proteins involved in adhesion to gastric cells, such as H. pylori adhesin A 
(HpaA), HorB and some Hof members were present in H. suis as well. On the other hand, H. suis 
lacks homologs of several other H. pylori adhesion factors, including genes coding for the blood 
group antigen-binding adhesin BabA, the sialic acid-binding adhesin SabA and the adherence-
associated lipoproteins AlpA and AlpB. It was concluded that although genes coding for some 
important virulence factors in H. pylori, such as the cytotoxin-associated protein A (CagA) and 
the vacuolating cytotoxin (VacA), were not detected in the H. suis genome, homologs of other 
genes associated with colonization and virulence of H. pylori and other bacteria were present. 
Previous studies in mice showed that H. suis infection does not result in protective immunity, 
whereas immunization with H. suis whole-cell lysate (lysate) protects against a subsequent 
experimental infection. In Chapter 2, we described for the first time immunoproteomics of H. 
suis. Two-dimensional gel electrophoresis of total H. suis proteins was performed followed by 
immunoblotting with pooled sera from H. suis-infected mice or mice immunized with lysate. 
Little reactivity against H. suis proteins was observed in post-infection sera. Sera from lysate-
immunized mice, however, showed immunoreactivity against a total of 19 protein spots which 
were identified using mass spectrometry (LC-MS/MS). The H. suis urease subunit B (UreB) 
showed most pronounced reactivity against sera from immunized mice and was not detected by 
sera from infected mice. Other identified proteins included H. suis chaperonin GroEL, urease 
subunit A, flagellin A and elongation factor G. Based on this analysis, the immunoreactive UreB 
was selected for further in vivo testing. As a control we included H. suis NapA, which has been 
previously described as a possible virulence factor but was not recognized by sera of mice 
immunized with whole-cell lysate, nor by sera from H. suis-infected mice. In a subsequent study, 
the protective efficacy of intranasal vaccination of BALB/c mice with the H. suis UreB and 
NapA, both recombinantly expressed in E. coli (rUreB and rNapA, respectively), was compared 
Summary 
183 
with that of H. suis lysate. Cholera toxin was used as adjuvant. We found that immunization with 
the rUreB and lysate induced a significant reduction of gastric H. suis colonization compared to 
non-vaccinated and H. suis-infected controls. Immunization with rNapA had no significant 
protective effect. Reduction in gastric bacterial load was correlated with increased mRNA 
expression levels of IL-17, IFN-γ, and antigen specific serum IgG. It was concluded that rUreB 
could be a promising vaccine candidate for the use in vaccines against H. suis infections. Also, 
we suggested that probably a combination of local Th1 and Th17 responses, complemented by 
antibody responses play a role in the protective immunity against H. suis infections. 
In Chapter 3, it was evaluated whether inclusion of an additional antigen could improve the 
protective efficacy of subunit vaccination in a mouse model. Mice were intranasally immunized 
with rUreB, H. suis GGT, recombinantly expressed in E. coli (rGGT) or a combination of both 
proteins, administered simultaneously or sequentially. Control groups consisted of non-
immunized and non-challenged mice (negative controls), sham-immunized and H. suis-
challenged mice (sham-immunized controls), and finally, H. suis lysate-immunized and H. suis 
challenged mice. Cholera toxin was used as mucosal adjuvant. All immunizations induced a 
significant reduction of gastric H. suis colonization, which was least pronounced in the groups 
immunized with rGGT and rUreB alone. Consecutive immunization with rGGT followed by 
rUreB and immunization with the bivalent vaccine improved the protective efficacy compared to 
immunization with single proteins, with a complete clearance of infection observed in 50% of the 
animals. Immunization with whole-cell lysate induced a similar reduction of gastric bacterial 
colonization compared to rGGT and rUreB in combinations. Gastric lesions, however, were less 
pronounced in mice immunized with combinations of rUreB and rGGT compared to mice 
immunized with whole-cell lysate. In conclusion, vaccination with a combination of rGGT and 
rUreB protected mice against a subsequent H. suis infection and was not associated with severe 
post-vaccination gastric inflammation, indicating that it may be a promising method for control 
of H. suis infections. 
In vitro antimicrobial susceptibility of H. suis can not be determined using standard assays, as 
this agent only grows in a biphasic medium with an acidic pH. Therefore, in Chapter 4, we 
developed a combined agar and broth dilution method to analyse the activity of nine 
antimicrobial agents (ampicillin, ceftiofur, clarithromycin, enrofloxacin, gentamicin, lincomycin, 
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metronidazole, tetracycline, and tylosine) against nine H. suis isolates. After 48h microaerobic 
incubation, minimal inhibitory concentrations (MICs) were determined by software-assisted 
calculation of bacterial growth. Only for enrofloxacin a clear bimodal distribution of MICs was 
demonstrated, indicating acquired resistance in one strain, which showed an AGT → AGG (Ser 
→ Arg) substitution at codon 99 of gyrA. For the other antimicrobial agents a monomodal 
distribution of MIC values was observed, indicating absence of acquired resistance. For 
ampicillin, MICs were higher than those described for other gastric Helicobacter species, 
possibly indicating reduced susceptibility of H. suis to this antibiotic. For 7 isolates, MICs of 
metronidazole were also high. The significance of these findings for treatment of H. suis 
infections is not clear. It was concluded that the assay developed in this study is suitable for 
determination of the antimicrobial susceptibility of H. suis isolates, although activity of acid 
sensitive antimicrobial agents may be higher than predicted from MIC endpoints. As the results 
of this study are based on a small number of strains, additional tests are needed to determine if 
these results reflect the susceptibility of the H. suis population. 
 
The present PhD studies confirm that H. suis plays a role in gastric pathology, as its genome 
contains genes known to be essential for gastric colonization as well as genes encoding proteins 
that probably play a role in the induction of gastric lesions. Our results represent the first steps in 
the development of an effective subunit vaccine against H. suis infections. Combined vaccination 
with the H. suis UreB and GGT is suggested as a promising vaccine strategy. Finally, we 
developed an in vitro assay to evaluate the intrinsic and acquired resistance of H. suis isolates, 
and showed that resistance to fluoroquinolones may occur in H. suis field strains. 
  
 
SAMENVATTING 
 
  
Samenvatting 
187 
Helicobacter suis is een Gram-negatieve, spiraalvormige bacterie die wereldwijd frequent 
voorkomt bij varkens. Bij deze diersoort kan een infectie met dit micro-organisme chronische 
gastritis veroorzaken en de kiem wordt ook geassocieerd met erosieve en ulceratieve letsels in de 
pars oesophagea van de maag. Er werd aangetoond dat een experimentele infectie met H. suis bij 
varkens gepaard gaat met een daling in de dagelijkse gewichtsaanzet, wat het economisch belang 
van infecties met deze bacterie bevestigt. H. suis is ook de meest frequent voorkomende niet-H. 
pylori Helicobacter species bij mensen met maagklachten en wordt geassocieerd met chronische 
gastritis, maagulcera en lymfomen van het mucosa-geassocieerd lymfoïd weefsel. Er zijn 
duidelijke aanwijzingen dat varkens een bron van infectie kunnen zijn voor de mens, wat deze 
bacterie een zoönotisch belang geeft. Contact met varkens of de consumptie van rauw of 
onvoldoende verhit varkensvlees zijn een mogelijke besmettingsbron voor de mens. 
Het gebrek aan zuivere in vitro culturen van H. suis belemmerde gedurende lange tijd de 
vooruitgang in het onderzoek op deze bacterie. Bij de aanvang van dit doctoraatsonderzoek was 
er dan ook zo goed als niets geweten over de aanwezigheid van genen die betrokken zijn in de 
pathogeniciteit van H. suis, noch over genen die belangrijk zijn voor de aanpassing van deze 
kiem aan de specifieke omgeving van de maag. H. suis werd in 2008 voor het eerst in vitro 
geïsoleerd, en dit aan onze onderzoeksgroep. Dit creëerde nieuwe mogelijkheden om een beter 
inzicht te verwerven in de pathogenese van H. suis infecties en voor de ontwikkeling van 
strategieën om deze infectie onder controle te krijgen bij de mens en het varken. 
Doeltreffende maatregelen om H. suis infecties bij varkens te bestrijden, zullen niet enkel het 
aantal varkens dat lijdt aan maagpathologieën doen dalen, maar zijn ook van belang voor de 
volksgezondheid. De prevalentie van H. suis infecties bij volwassen varkens is zeer hoog, wat 
erop wijst dat de immuunrespons na een natuurlijke infectie niet voldoende is om de bacterie te 
elimineren uit de maag. In een muismodel werd aangetoond dat vaccinatie met volledig 
kiemlysaat bescherming kan bieden tegen een daaropvolgende infectie met H. suis. Het is echter 
niet gekend welke bacteriële eiwitten van belang zijn voor de inductie van bescherming tegen H. 
suis infecties. Bovendien was er bij de aanvang van dit doctoraatsonderzoek geen informatie 
beschikbaar over de in vitro antimicrobiële gevoeligheid van H. suis. 
In hoofdstuk 1 beschrijven we de genoomsequentie van twee H. suis stammen: H. suis stam 1 
(type stam = LMG 23995
T
) en 5, beide geïsoleerd uit de maagmucosa van varkens. Nadat het 
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genoom werd gesequeneerd en geassembleerd in contigs, werd het geannoteerd door middel van 
vergelijking met drie gekende H. pylori stammen. H. pylori is de frequentst voorkomende 
gastrale Helicobacter species bij de mens. Het is ook de best bestudeerde Helicobacter species. 
Aangezien de genen die een rol spelen in de virulentie niet noodzakelijk identiek zijn voor deze 
beide Helicobacter species, werden er ook ab initio annotaties van het H. suis genoom 
uitgevoerd. De vergelijking met het H. pylori genoom toonde aan dat alle genen die essentieel 
zijn voor de kolonisatie van de maagmucosa ook aanwezig zijn in het H. suis genoom. 
Homologen van genen die coderen voor het pro-inflammatoir H. pylori neutrofiel-activerend 
eiwit (NapA), het apoptosis-inducerend γ-glutamyl transpeptidase (GGT) en enkele type IV 
secretiesystemen werden geïdentificeerd in H. suis. H. suis beschikt bijkomend over een aantal 
genen die vermoedelijk geassocieerd zijn met virulentie, inclusief homologen voor mviN, het H. 
pylori flavodoxine gen (fldA) en het H. pylori “high-temperature requirement A” gen (htrA). 
Sequenties die coderen voor buitenste membraan eiwitten welke betrokken zijn bij de adhesie van 
H. pylori aan maagcellen, waaronder het H. pylori adhesine A (HpaA), HorB en enkele leden van 
de Hof familie eiwitten, werden eveneens in H. suis gedetecteerd. Anderzijds mist H. suis 
homologen van verschillende andere H. pylori adhesines, waaronder genen die coderen voor het 
bloedgroep antigen bindende adhesine BabA, het siaalzuur bindende adhesine SabA, en de met 
adhesie geassocieerde lipoproteïnes AlpA en AlpB. Uit dit onderzoek werd geconcludeerd dat in 
het H. suis genoom genen ontbreken die coderen voor verschillende virulentiefactoren die een 
belangrijke rol spelen in de pathogenese van H. pylori infecties, zoals het cytotoxine 
geassocieerde eiwit A (CagA) en het toxine verantwoordelijk voor celvacuolisatie (VacA). 
Anderzijds werden homologen van een aantal andere genen die geassocieerd worden met 
kolonisatie en virulentie van H. pylori en andere bacteriën wel aangetoond in H. suis. 
Vroeger onderzoek bij muizen toonde aan dat een infectie met H. suis niet leidt tot beschermende 
immuniteit, terwijl vaccinatie met volledig kiemlysaat (lysaat) van H. suis bescherming kan 
geven tegen een daaropvolgende experimentele infectie. In hoofdstuk 2 werd voor het eerst het 
immunoproteoom van H. suis beschreven. Hiervoor werd tweedimensionele gelelektoforese van 
H. suis eiwitten uitgevoerd, gevolgd door Western blot analyse met gepoolde sera van H. suis-
geïnfecteerde muizen of van muizen geïmmuniseerd met lysaat. Sera van geïnfecteerde dieren 
toonden weinig reactiviteit tegenover H. suis eiwitten. Sera van muizen, gevaccineerd met lysaat, 
toonden daarentegen een immunoreactiviteit tegen 19 eiwitspots, die vervolgens werden 
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geïdentificeerd met massaspectrometrie (LC-MS/MS). Sera van met lysaat geïmmuniseerde 
muizen reageerden sterk met het H. suis urease subunit B (UreB) terwijl sera van geïnfecteerde 
dieren dit eiwit niet detecteerden. Andere eiwitten die herkend werden door sera van met lysaat 
geïmmuniseerde muizen waren het H. suis chaperonine GroEL, urease subunit A, flageline A en 
elongatie factor G. Gebaseerd op deze analyses werd het immunoreactieve UreB geselecteerd 
voor verdere in vivo testen. Als controle werd het H. suis NapA opgenomen. H. suis NapA werd 
eerder beschreven als een mogelijke virulentiefactor van H. suis, maar werd noch gedetecteerd 
door sera van met lysaat geïmmuniseerde muizen, noch door sera van H. suis-geïnfecteerde 
muizen. In een daaropvolgende studie werd bij BALB/c muizen het beschermend vermogen 
nagegaan van een tweemalige (3 weken interval) intranasale vaccinatie met het H. suis UreB en 
NapA, beide recombinant tot expressie gebracht in E. coli (respectievelijk rUreB en rNapA). Dit 
werd vergeleken met het beschermend vermogen van H. suis lysaat. Choleratoxine werd aan alle 
vaccins toegevoegd als adjuvans. De dieren werden experimenteel besmet met H. suis op 4 
weken na de laatste vaccinatie. Niet gevaccineerde muizen fungeerden als controledieren. Bij 
muizen die geïmmuniseerd werden met rUreB en lysaat was het aantal H. suis bacteriën in de 
maag significant lager in vergelijking met geïnfecteerde controledieren. Immunisatie met rNapA 
had daarentegen geen significant beschermend effect. De verminderde bacteriële kolonisatie in de 
maag was gecorreleerd met verhoogde mRNA expressie niveaus van IL-17 en IFN-γ in de maag 
en met verhoogde antigen-specifieke serum IgG. Er werd geconcludeerd dat rUreB een 
veelbelovende kandidaat is om in te sluiten in vaccins tegen H. suis infecties. Tevens werd 
gesuggereerd dat een combinatie van lokale Th1 en Th17 reacties, aangevuld met opbouw van 
antistoffen, een rol spelen bij de bescherming tegen H. suis infecties. 
In hoofdstuk 3 werd in het muismodel onderzocht of toevoeging van een extra antigen het 
beschermend vermogen van subunit vaccins kan verbeteren. Muizen werden hiervoor intranasaal 
geïmmuniseerd met rUreB, H. suis GGT dat recombinant tot expressie werd gebracht in E. coli 
(rGGT), of met een combinatie van beide eiwitten, gelijktijdig of achtereenvolgens toegediend. 
De controlegroepen bestonden uit: i) niet-geïmmuniseerde/niet-geïnfecteerde muizen (negatieve 
controles), ii) muizen geïnfecteerd met H. suis na voorafgaande intranasale toediening van een 
steriele fysiologische zoutoplossing (niet-geïmmuniseerde, maar geïnfecteerde controles) en iii) 
muizen geïmmuniseerd met H. suis lysaat en daaropvolgend geïnfecteerd met H. suis. 
Choleratoxine werd opnieuw gebruikt als mucosaal adjuvans. Alle immunisaties zorgden voor 
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een significante daling van het aantal H. suis bacteriën in de maag in vergelijking met de niet-
geïmmuniseerde, maar geïnfecteerde controlegroep. Deze daling was het minst uitgesproken in 
de groepen die enkel geïmmuniseerd werden met rGGT of rUreB. Achtereenvolgende 
immunisatie met rGGT en rUreB en immunisatie met het bivalente vaccin verbeterde het 
beschermend vermogen ten opzichte van immunisatie met één enkel eiwit, waarbij bij 50% van 
de dieren H. suis zelfs niet meer in staat was om de maag te koloniseren (volledige bescherming). 
Immunisatie met volledig kiemlysaat induceerde een vergelijkbare daling van de bacteriële 
kolonisatie in de maag ten opzichte van immunisatie met combinaties van rGGT en rUreB. 
Maagletsels waren echter minder uitgesproken bij muizen geïmmuniseerd met combinaties van 
rGGT en rUreB in vergelijking met dieren geïmmuniseerd met lysaat. Er werd besloten dat 
vaccinatie van muizen met een combinatie van rGGT en rUreB beschermt tegen een 
daaropvolgende H. suis infectie en dat deze immunisatiestrategie niet gepaard gaat met erge post-
vaccinatie gastritis. Dit duidt erop dat het een veelbelovende methode kan zijn voor de bestrijding 
van H. suis infecties. 
Aangezien H. suis enkel groeit in een bifasisch medium met lage pH, kan de in vitro 
antimicrobiële gevoeligheid van deze kiem niet worden bepaald door gebruik te maken van 
standaardmethodes. Daarom werd in hoofdstuk 4 een gecombineerde agar en bouillon dilutie 
methode ontwikkeld. Deze werd gebruikt om de activiteit van 9 antimicrobiële middelen 
(ampicilline, ceftiofur, clarithromycine, enrofloxacine, gentamicine, lincomycine, metronidazole, 
tetracycline en tylosine) tegen negen H. suis isolaten te testen. Na incubatie van deze isolaten met 
tweevoudige verdunningen van de antimicrobiële middelen in een micro-aërobe atmosfeer 
gedurende 48 uur, werden de minimale inhibitorische concentraties (MICs) bepaald. Als MIC 
waarde werd die verdunning van het antimicrobiële middel genomen waarbij de bacteriële groei 
voor 50% geremd was. Dit werd bepaald met behulp van een H. suis-specifieke kwantitieve PCR 
(qPCR). Enkel voor enrofloxacine werd een duidelijke bimodale distributie van de MICs 
aangetoond, wat wijst op verworven resistentie in één stam. Deze stam toonde een AGT → AGG 
(Ser → Arg) substitutie op codon 99 van het gyrase A gen (gyrA). Voor alle andere 
antimicrobiële middelen werd een monomodale distributie van de MICs waargenomen. Dit wijst 
op afwezigheid van verworven resistentie tegenover deze middelen in de hier geteste H. suis 
isolaten. De MICs van ampicilline lagen bij de H. suis isolaten hoger dan wat beschreven werd 
voor andere gastrale Helicobacter species, wat kan duiden op een lagere gevoeligheid van H. suis 
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voor dit antibioticum. Voor 7 H. suis isolaten lag de MIC van metronidazole ook hoog. De 
betekenis van deze bevindingen met betrekking tot behandeling van H. suis infecties, is 
onduidelijk. De methode die in deze studie werd ontwikkeld is bruikbaar voor de bepaling van de 
antimicrobiële gevoeligheid van H. suis isolaten, hoewel de activiteit van zuurgevoelige 
antimicrobiële middelen hoger kan liggen dan voorspeld op basis van de MIC eindpunten. 
Aangezien de resultaten van deze studie gebaseerd zijn op een klein aantal stammen, is 
aanvullend onderzoek nodig om te bepalen of deze resultaten de gevoeligheid van de H. suis 
populatie bij varkens weerspiegelen. 
De resultaten van dit doctoraatsonderzoek toonden aan dat meerdere genen die essentieel zijn 
voor kolonisatie van de maag, aanwezig zijn in H. suis, evenals genen die coderen voor eiwitten 
die waarschijnlijk een rol spelen in de inductie van maagletsels. Onze resultaten vormen ook de 
eerste stap in de ontwikkeling van een effectief subunit vaccin tegen H. suis infecties, waarbij een 
veelbelovende kandidaat een combinatie van het H. suis UreB en GGT is. Verder onderzoek is 
evenwel noodzakelijk om dit te bevestigen, onder andere door het uitvoeren van experimentele 
infecties bij gevaccineerde varkens. Tot slot werd een in vitro test op punt gesteld die toelaat om 
de intrinsieke en verworven antimicrobiële resistentie van H. suis isolaten in vitro te bepalen. Met 
deze test werd aangetoond dat verworven resistentie tegen fluoroquinolones kan voorkomen bij 
H. suis isolaten van varkens. 
  
  
 
CURRICULUM VITAE 
 
 
 
 
 
 
 
  
Curriculum Vitae 
195 
Miet Vermoote werd geboren op 1 augustus 1984 in Oostende. Na het beëindigen van haar 
middelbare studies Wetenschappen-Wiskunde aan de Katholieke Centrumscholen te Sint-
Truiden, startte ze in 2002 de studies Diergeneeskunde aan de Universiteit Gent. In 2008 
behaalde ze met grote onderscheiding het diploma van Dierenarts, optie onderzoek. Onmiddellijk 
daarna startte zij aan diezelfde universiteit een doctoraatsonderzoek aan de vakgroep Pathologie, 
Bacteriologie en Pluimveeziekten, waarbij ze in het kader van een Geconcerteerde 
Onderzoeksactie (GOA) voornamelijk onderzoek verrichtte naar de aanwezigheid van 
virulentiegenen in Helicobacter suis. In 2009 behaalde zij een specialisatiebeurs toegekend door 
het Agentschap voor Innovatie door Wetenschap en Technologie van Vlaanderen (IWT). Dit liet 
haar toe om gedurende vier jaar onderzoek uit te voeren naar beschermende antigenen en 
antimicrobiële gevoeligheid van Helicobacter suis. Dit onderzoek resulteerde in het huidige 
proefschrift. 
 
Gedurende deze periode heeft zij ook gewerkt aan de doctoraatsopleiding in Life Sciences and 
Medicine van de Universiteit Gent, waarvan zij het getuigschrift behaalde in 2013. 
 
Miet Vermoote is auteur en medeauteur van meerdere wetenschappelijke publicaties in 
internationale en nationale tijdschriften. Zij nam actief deel aan internationale congressen en was 
daar meermaals spreker. 
  
  
 
BIBLIOGRAPHY 
 
 
 
 
 
 
 
 
  
  
 
Bibliography 
199 
Publications in national and international journals 
Vermoote M, Flahou B, Pasmans F, Ducatelle R, Haesebrouck F: Protective efficacy of vaccines 
based on the Helicobacter suis urease subunit B and γ–glutamyl transpeptidase. Vaccine, 
provisionally accepted. 
Vermoote M, Van Steendam K, Flahou B, Pasmans F, Glibert P, Ducatelle R, Deforce D, 
Haesebrouck F: Immunization with the immunodominant Helicobacter suis urease subunit B 
induces partial protection against H. suis infection in a mouse model. Vet Res 2012, 43:72. 
De Bruyne E, Flahou B, Chiers K, Meyns T, Kumar S, Vermoote M, Pasmans F, Millet S, 
Dewulf J, Haesebrouck F, Ducatelle R: An experimental Helicobacter suis infection causes 
gastritis and reduced daily weight gain in pigs. Vet Microbiol 2012, 160:449-54. 
Vermoote M, Pasmans F, Flahou B, Van Deun K, Ducatelle R, Haesebrouck F: Antimicrobial 
susceptibility pattern of Helicobacter suis strains. Vet Microbiol 2011, 153:339-342. 
Vermoote M, Vandekerckhove TM, Flahou B, Pasmans F, Smet A, De Groote D, Van Criekinge 
W, Ducatelle R, Haesebrouck F: Genome sequence of Helicobacter suis supports its role in 
gastric pathology. Vet Res 2011, 42:51.  
Haesebrouck F, Pasmans F, Flahou B, Meyns T, Vermoote M, Kumar S, Chiers K, Decostere A, 
Ducatelle R: Bacteriën van huisdieren als oorzaak van maagklachten bij de mens. Vlaams 
Diergeneeskundig tijdschrift 2009, 78:295-301. 
 
Abstracts presented on national and international meetings 
Vermoote M, Bram Flahou B, Frank Pasmans F, Ducatelle R, Haesebrouck F: Protective 
efficacy of recombinant Helicobacter suis proteins against Helicobacter suis challenge in a 
mouse model. Poster presentation Studienamiddag International Pig Veterinary Society 
(IPVS) Belgian Branch. 2012, November 23, Merelbeke, Belgium. 
Vermoote M, Van Steendam K, Flahou
 
B, Pasmans F,
 
Ducatelle R, Deforce D, Haesebrouck F: 
Immunoproteomics of Helicobacter suis and protective efficacy of a subunit vaccine in a 
mouse model. Oral presentation at the 2
nd
 Prato conference on the Pathogenesis of Bacterial 
Diseases of Animals (VetPath 2012). 2012, October 9-12, Prato, Italy. MSD Animal Health 
Student Scholarship Award. 
Vermoote M, Flahou B, Pasmans F, Ducatelle R, Haesebrouck F: Protective efficacy of 
recombinant Helicobacter suis proteins against Helicobacter suis challenge in a mouse 
model. Oral presentation at the 10
th
 International workshop on Pathogenesis and Host 
Response in Helicobacter infections. 2012, July 4-7, HelsingØr, Denmark. Young Scientist 
Award for Best Oral Presentation. 
Flahou B, Smet A, Meyns T, Liang J, Vermoote M, De Cooman L, Pasmans, Ducatelle R, 
Haesebrouck F: Helicobacter suis infection in a pig veterinarian. 10
th
 International workshop 
on Pathogenesis and Host Response in Helicobacter infections. 2012, July 4-7, HelsingØr, 
Denmark. 
Bibliography 
200 
Vermoote M, Pasmans F, Flahou B, Van Deun K, Ducatelle R, Haesebrouck F: Antimicrobial 
susceptibility pattern of Helicobacter suis strains. Poster presentation at the 24
th
 International 
workshop on Helicobacter and Related Bacteria in Chronic Digestive Inflammation and 
Gastric Cancer. 2011, September 11-13, Dublin, Ireland. 
Flahou B, Ducatelle R, Pasmans F, Chiers K, Smet A, Vermoote M, De Cooman L, Zhang G, 
Liang J, Haesebrouck F: Gastric non-Helicobacter pylori Helicobacter infections: origin and 
significance for human health. 16th International workshop on Campylobacter, Helicobacter 
and Related Organisms. 2011, August 28-September 1, Vancouver, Canada.  
Vermoote M, Vandekerckhove T, Flahou B, Pasmans F, Smet
 
A, De Groote D, Van Criekinge 
W, Ducatelle R, and Haesebrouck F: Genome Sequence of Helicobacter suis supports its role 
in gastric pathology. Poster presentation at the 3
rd
 European symposium on Porcine Health 
Management (ESPHM 2011). 2011, May 25-27, Espoo, Finland. 
Kumar S, Smet A, Flahou B, Vermoote M, Van Deun K, Pasmans F, Chiers K, Ducatelle R, 
Haesebrouck F: Multilocus sequence typing (MLST) of Helicobacter suis. 23
th
 International 
Workshop on Helicobacter and Related Bacteria in Chronic Digestive Inflammation and 
Gastric Cancer. 2010, September 16-18, Rotterdam, The Netherlands. 
Vermoote M, Vandekerckhove T, Flahou B, Pasmans F, Annemieke Smet
 
A, De Groote D, Van 
Criekinge W, Ducatelle R, and Haesebrouck F: Genome Sequence of Helicobacter suis 
supports its role in gastric pathology. Oral presentation at the 9
th
 International workshop on 
Pathogenesis and Host Response in Helicobacter infections. 2010, July 7-10, HelsingØr, 
Denmark. 
Vermoote M, Pasmans F, Flahou B, Van Deun K, Ducatelle R, Haesebrouck F: In vitro 
antimicrobial susceptibility of Helicobacter suis. Poster presentation at the 9
th
 International 
workshop on Pathogenesis and Host Response in Helicobacter infections. 2010, July 7-10, 
HelsingØr, Denmark. 
Flahou B, Kumar S, Van Deun K, Vermoote M, K. Chiers K, Pasmans F, Haesebrouck F, 
Ducatelle R: Pathogenesis of chronic gastritis in an animal model of Helicobacter infection. 
27th Meeting of the European Society of Veterinary Pathology and the European College of 
Veterinary Pathologists (ESVP-ECVP). 2009, September 9-13, Kraków, Poland. 
Haesebrouck F, Pasmans F, Flahou B, Vermoote M, Kumar S, Chiers K, Ducatelle R: Human 
gastric non-Helicobacter pylori infections: “H. heilmannii” comprises several Helicobacter 
species, naturally occurring in animals. 3
rd
 Congress of European Microbiologists. 2009, June 
28-July 2, Gotenburg, Sweden. 
Van Deun K, Pasmans F, Flahou B, Vermoote M, Kumar S, Chiers K, Ducatelle R, Haesebrouck 
F: Human gastric non-Helicobacter pylori infections : 'heilmannii' comprises several 
Helicobacter species, naturally occurring in animals. 5th Annual scientific meeting on 
Zoonoses Research in Europe (Med-Vet-Net meeting). 2009, June 3-6, Madrid, Spain. 
  
 
DANKWOORD 
 
 
 
 
 
 
 
 
  
  
 
Dankwoord 
203 
Doctoreren doe je niet alleen. Ik werd omringd door mensen die één voor één een rol spelen in dit 
werk. Graag wil ik deze personen dan ook bijzonder bedanken voor hun steun, hulp, raad en 
zoveel meer. 
In de eerste plaats heb ik een bijzonder woord van dank voor mijn promotoren. 
Prof. Haesebrouck, bijzonder bedankt voor uw uitstekende begeleiding gedurende mijn 
doctoraat! Uw oprechte toewijding, inzichten en kritische aanpak maakten dit werk “af”. 
Daarnaast wil ik u bedanken voor het vertrouwen dat u in mij had, de mogelijkheden die u me gaf 
en de kennis die u me bijleerde. Prof. Pasmans, Frank, bij jou kon ik ook steeds terecht met 
vragen of problemen. Bedankt voor de leuke manier waarop je me steeds ten rade stond, op elk 
moment en met om het even welke vraag. Prof. Ducatelle, uw interesse, optimisme en klare kijk 
op mijn onderzoek gaven me steeds een duwtje in de rug, bedankt. 
Mijn oprechte dank gaat uit naar de leden van mijn begeleiding- en/of examencommissie: Prof. 
dr. P. Vandamme, prof. dr. L. De Zutter, prof. dr. D. Maes, prof. dr. P. Deprez en prof. dr. S. 
Lindén. Bedankt voor de opbouwende raad en het grondig nalezen van deze thesis. Prof. Lindén, 
Sara, I’m honored to have you in my exam committee. Many thanks for flying from Sweden to 
attend my public defense. 
Ik wil ook graag de Universiteit Gent bedanken voor het toekennen van de GOA 
onderzoeksbeurs, welke mij financiële steun bood tijdens het eerste jaar van mijn doctoraat. 
Verder wil ik het Agentschap voor Innovatie door Wetenschap en Technologie in Vlaanderen 
(IWT) bedanken voor hun vertrouwen in mij als persoon en in dit project, en voor het toekennen 
van een beurs en aldus de financiële steun van mijn doctoraatsonderzoek. 
dr. Dominic De Groote en prof. dr. K. Chiers wil ik danken voor hun inbreng bij de 
voorbereidingen van de aanvraag van mijn IWT beurs. Prof. dr. Hermans, Katleen, bedankt voor 
uw nuttige tips tijdens mijn dierexperimenten. 
Dit doctoraat kwam tot stand door een nauwe samenwerking met mensen buiten de faculteit. 
Dankzij prof. dr. W. Van Criekinge en dr. Tom Vandekerckhove van de Faculteit Bio-
ingenieurswetenschappen werd ik op korte tijd wegwijs in de wereld van de bio-informatica. 
Daarnaast heb ik mooie herinneringen aan de Faculteit Farmaceutische Wetenschappen, waar de 
gedrevenheid en humor op het laboratorium van farmaceutische biotechnologie je meteen thuis 
doen voelen. Prof. dr. D. Deforce, bedankt voor je interesse in mijn immunoproteomics 
Dankwoord 
204 
onderzoek. Katleen (Van Steendam), bedankt om me te begeleiden tijdens dit onderzoek, voor je 
adviezen, maar ook voor de leerrijke discussies en leuke babbels. Ook Pieter en Liesbeth, een 
welverdiende merci voor de leuke samenwerking! 
Ondertussen is het Helicobacter-team uitgegroeid tot het grootste van ons laboratorium. En daar 
mogen onze postdocs Bram en Annemieke fier op zijn. Bram, bedankt voor de tijd die je in mij 
investeerde, je advies, maar ook voor de persoonlijke touch waarmee je ons allemaal probeert te 
begeleiden. Veel succes in je verdere carrière, je bouwplannen en zoveel meer! Annemieke, 
bedankt voor je advies bij de genoomannotatie, maar ook voor je directe manier van aanpak. Ik 
wens je het allerbeste op het werk en met de komst van je tweede spruit! Lien, bedankt om er 
steeds voor me te zijn (als collega, maar vooral ook als vriendin), voor alle leuke momenten en 
gezellige babbels. Ik wil je super veel succes wensen in het verder verloop van je onderzoek. Je 
bent goed bezig, go for it! 
Anderhalf jaar geleden, ongeveer, werd onze groep vergezeld door twee jonge en dynamische 
onderzoeksters, Ellen en Myrthe. Bedankt om de sfeer op de bureau zo aangenaam te maken, 
voor de kleine attenties en de hilarische momenten. Jullie hebben me alle ruimte gegeven om 
mijn doctoraat te schrijven, bedankt. Eerlijk toegegeven, ik zal jullie missen. 
Guangzhi, you are a smart person with sense of humor. Ideal partner to join our office ;) Thank 
you for always turning off the heather when I was pregnant, for your attentions and helpfulness! I 
wish you and your family a lovely future. Iris, jou wens ik veel succes met het vervolg van de 
vaccinatiestudies. Wie weet komt er nog een patent uit . Caroline, met jou gedrevenheid en 
toewijding zul je vast en zeker een mooi doctoraat maken. Succes ermee. Jungang and Cheng, I 
wish you both good luck with the progress of your research. 
Sofie DB, jij weet van aanpakken! Je oog voor details en accuraatheid zorgden ervoor dat 
experimenten vlekkeloos verliepen. Bedankt voor de leuke samenwerking! Nathalie, bedankt 
voor je hulp tijdens mijn laatste in vivo proef! Sophie, bedankt voor je preciesheid in de analyses 
en de manier waarop je omging met de dieren. Ook een dikke merci voor de leuke babbels, en 
vooral om me op te beuren wanneer het gemis naar Afrika te groot werd ;). Kim, jou kende ik als 
dé specialist in statistiek en qPCR. Bedankt voor je raad hierin. Ook Tom Meyns en Smitha, 
bedankt om er te zijn als goede collega’s! 
En of we een team zijn… Ellen & Myrthe (the leading women), Iris, Caroline, Lien, Guangzhi 
(en mijn Bert natuurlijk), een dikke merci om mijn receptie te verzorgen. Jullie motivatie om er 
Dankwoord 
205 
iets moois & gezelligs van te maken zullen me steeds bijblijven. Jullie hebben dit nog van mij 
tegoed! 
Venessa, jou enthousiasme in het onderzoek en daarbuiten maakte je een ideale bureaugenote. 
Het waren leuke jaren met jou op de bureau, bedankt voor je tips en raad! Ook Rebecca en 
Rosalie, bedankt voor de mooie bureaumomenten. Rosalie, veel plezier in je nieuwe huis & 
succes in je mooie job. 
Filip B., bedankt om me de kans te geven om mee de practica bacteriologie te verzorgen. Ook 
een dikke merci voor de nuttige informatie tijdens de diagnostiek en tips “als het over 
antimicrobiële resistentie ging”. 
Pascale, de laatste loodjes van ons doctoraat vielen samen. Het was leuk om dit met jou te 
beleven. Mij heb je sowieso aan je been voor de komende jaren, maar dan als knutsel- en kook 
maatje! Anja R., bedankt om er niet enkel te zijn als fantastische collega, maar ook als vriendin! 
Bedankt voor de momenten van ontlading (lachen maar), de leerrijke discussies over qPCR en 
dergelijke en voor zoveel buiten het werk! David, bedankt voor de leuke & ontspannende 
babbels. Veel geluk met jullie eerste kindje! 
Marleen, jij bent één uit de duizenden. Bedankt voor alle vriendschap en bezorgdheid! Je stond 
steeds paraat om me te helpen, wat je siert. Elin, je bent een super leuke onderzoekster. Bedankt 
om me te ontzien tijdens de varkensproef. Veel succes met je postdoc en natuurlijk ook veel 
geluk buiten het werk! 
De humor die ik afgelopen jaren te verwerken kreeg steeg boven mijn verwachtingen. Daarom, 
dikke merci Serge, Alexander, Jo, Koen P., Gunter M., Bregje, Gunther A., An G., Hanne, 
Melanie, Marc V., Lieven, Urszula, Connie en Ilse om de vrolijke noot erin te houden. Arlette & 
Serge, bedankt voor de mooie momenten tijdens de routine! Voor de hulp, tips en jullie 
enthousiasme. Koen P., Jo en Gunter wil ik extra bedanken voor hun snelle hulp als ik technische 
of administratieve vragen had. 
Aan de nieuwe garde (waarvan de meeste al een jaartje ons labo vergezellen): Nele, Maxime en 
Lien VdM, Roel, Gunther A, Shaoji en Lieze, veel succes in jullie doctoraat. 
Ook de collega’s van Pathologie, bedankt voor de leuke momenten in het labo! Ruth, jou wens ik 
heel veel succes met het beëindigen van je doctoraat en je toekomstplannen (het hondenpension 
bijvoorbeeld, ik zie het al volledig bij jou!). Evy, je spoedcursus fotografie werpt nog steeds zijn 
Dankwoord 
206 
vruchten af. Bedankt voor de grappige en gezellige babbels. Dorien, jij zal wellicht de eerste 
geweest zijn die wist dat ik zwanger was (Miet die prosecco laat staan, dat is niet normaal). Wat 
ik je nog wou zeggen: ga eens de Italiaanse natuur verkennen met Christof . Leen, Marjan, 
Celine, Wolf, Sofie K, Karen, Stefanie en Sofie G., bedankt voor de leuke tijd. 
Christian, Delphine en Sarah, mijn oprechte dank voor de snelle verwerking van mijn stalen, en 
dit steeds met een glimlach! 
Daarnaast wil ik vrienden en familie bedanken voor hun interesse in mijn doctoraat, hun steun en 
voor het zorgen van de meest fantastische & gezellige momenten. Stijn & Lien, bedankt om er 
steeds voor me te zijn als broer en zus. Mema, bedankt voor alle steun en genegenheid. 
 
Bert, jij maakt mijn verhaal compleet, en bent er dan ook het begin en het einde van. Met jou 
optimisme, humor en oneindige liefde kon ik dit werk volledig optimaliseren. Je brengt het 
allerbeste in mij naar boven en geeft me veel meer dan vleugels alleen. Bedankt voor de mooiste 
en meest intense momenten van mijn leven, samen met jou. 
…om dan nog even te zwijgen over het mooiste geschenk dat we binnenkort verwachten… 
 
  
  
 
